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Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting reproductive aged 
women, as well as being the leading cause of anovulatory infertility. The syndrome is characterised by 
hyperandrogenism, anovulation, an overabundance of preovulatory follicles within the ovary and 
insulin resistance. Sufferers also have an increased risk of developing type 2 diabetes, obesity, 
endometrial cancer, and mental health sequalae.  
It is well understood that PCOS has a genetic component with a heterogeneous mode of inheritance, 
as is evident from familial and population studies. However, despite the discovery of a number of risk 
alleles via genome wide association studies (GWAS), the genetic aetiology of the syndrome remains 
largely unknown. An alternative approach to GWAS for identifying mutations involved in genetic 
diseases is via whole exome sequencing. This method detects functional variants (i.e. mutations 
occurring in protein coding genes) that are present within the exome and are segregating within 
affected families. Therefore, undertaking exome sequencing on PCOS patients has the potential to 
identify genetic lesions involved in the aetiology of the syndrome. 
The overarching aim for this project was to increase understanding of the aetiology of PCOS by 
identifying functional variants within families afflicted with PCOS using exome sequencing. To 
achieve this, bioinformatic analysis was performed on exome sequencing data files collected before 
the commencement of this project by the Keogh Institute. The functional variant rs143321413 within 
the eukaryotic elongation factor kinase 2 (EEF2K) gene was identified within one of the exome 
sequenced families affected by PCOS. The possible functional role of the rs143321413 variant was 
then investigated using an in vitro model system. This was done by producing mammalian expression 
vectors containing wildtype and mutant EEF2K sequences. These vectors were then transfected into a 
human embryonic kidney cell line containing the SV40 large T antigen (HEK293FT cells). Protein 
was extracted and a co-immunoprecipitation was performed to determine whether rs143321413 
impacts the ability of EEF2K to bind to its substrate. Lastly, exome sequencing was also carried out 
on additional women affected by PCOS who were newly recruited throughout this project to identify 
new functional variants for future study.  
The main finding from this thesis was the discovery of the novel rs143321413 variant, which has the 
potential to be involved with PCOS. Mammalian expression vectors containing both wildtype EEF2K 
and mutant EEF2K sequences were successfully created. Additionally, optimisation of the protocol 
was accomplished for transfection reactions to induce expression of these vectors within HEK293FT 
cells.Both of these experimental achievements will aid in the future research of rs143321413 and by 
extension PCOS. Finally, two additional variants were identified within the data from the newly 




Table of Contents 
 
1 Introduction ..................................................................................................................................... 1 
1.1 Polycystic Ovary Syndrome.................................................................................................... 1 
1.1.1 History of PCOS ............................................................................................................. 1 
1.2 Clinical Signs and Symptoms ................................................................................................. 1 
1.2.1 Hyperandrogenism .......................................................................................................... 1 
1.2.2 Ovulatory Dysfunction .................................................................................................... 4 
1.2.3 Polycystic Ovary Morphology ........................................................................................ 6 
1.3 Secondary Increased Health Risks .......................................................................................... 7 
1.3.1 Insulin resistance ............................................................................................................. 7 
1.3.2 Obesity ............................................................................................................................ 8 
1.3.3 Type 2 Diabetes and Gestational Diabetes ...................................................................... 9 
1.3.4 Endometrial Cancer....................................................................................................... 10 
1.3.5 Other Cancers ................................................................................................................ 11 
1.3.6 Metabolic Syndrome and Cardiovascular Disease ........................................................ 12 
1.3.7 Imbalances of Hormones other than Androgens ........................................................... 13 
1.3.8 Psychological Sequalae ................................................................................................. 14 
1.4 Diagnosis............................................................................................................................... 15 
1.4.1 Establishment of PCOS Diagnostic Criteria ................................................................. 15 
1.4.2 Issues with PCOS Diagnosis ......................................................................................... 15 
1.4.3 Lean and Obese PCOS Subtypes .................................................................................. 17 
1.5 Potential Contributing Risk Factors ...................................................................................... 17 
1.5.1 Lifestyle Factors ............................................................................................................ 17 
1.5.2 Environmental Factors .................................................................................................. 18 
1.5.3 Genetic Factors ............................................................................................................. 19 
1.6 Treatment .............................................................................................................................. 19 
1.6.1 Non-Pharmacological Treatment .................................................................................. 19 
1.6.2 Pharmacological Treatment .......................................................................................... 21 
1.6.3 Ovulation Induction ...................................................................................................... 24 
1.7 Genetic Tools for the Study of PCOS ................................................................................... 24 
1.7.1 Candidate Gene Studies ................................................................................................ 24 
1.7.2 Genome Wide Association (GWAS) Gene Discovery ................................................. 25 
1.7.3 Next Generation Sequencing ........................................................................................ 25 
1.7.4 Functional Genomics .................................................................................................... 26 




2 General Materials and Methods .................................................................................................... 28 
2.1 Materials and Reagents ......................................................................................................... 28 
2.2 DNA Extraction from Whole Blood ..................................................................................... 34 
2.3 Polymerase Chain Reaction .................................................................................................. 34 
2.3.1 Routine PCR ................................................................................................................. 34 
2.3.2 High Fidelity PCR ......................................................................................................... 35 
2.3.3 Colony PCR .................................................................................................................. 37 
2.4 Isolation of cDNA ................................................................................................................. 38 
2.4.1 Reverse Transcription ................................................................................................... 38 
2.5 Cloning .................................................................................................................................. 38 
2.5.1 Production of XL2-Blue Competent Cells .................................................................... 38 
2.5.2 Ligation of cDNA into pDrive and pcDNA3.1 Plasmids.............................................. 38 
2.5.3 Transformation .............................................................................................................. 39 
2.5.4 DNA Extraction from Broth Cultures ........................................................................... 39 
2.5.5 Sanger Sequencing ........................................................................................................ 40 
2.6 Cell Culture ........................................................................................................................... 40 
2.6.1 Thawing of Frozen Mammalian Cell Stocks ................................................................ 40 
2.6.2 Passaging of mammalian cell lines ............................................................................... 40 
2.6.3 Maintenance of Mammalian Cell Lines ........................................................................ 40 
2.6.4 Freezing Mammalian Cell Lines ................................................................................... 41 
2.6.5 Transfection of Mammalian Cells ................................................................................. 41 
2.7 Functional Genomics ............................................................................................................ 41 
2.7.1 Western Blot ................................................................................................................. 41 
2.7.2 Immunoprecipitation ..................................................................................................... 44 
3 Identification of putative causal mutations in the exome sequence of individuals with PCOS. ... 45 
3.1 Introduction ........................................................................................................................... 45 
3.2 Materials and Methods .......................................................................................................... 46 
3.2.1 Sample Preparation and Exome Sequencing by Australian Genome Research Facility 
(AGRF) 46 
3.2.2 Bioinformatics analyses ................................................................................................ 46 
3.3 Results ................................................................................................................................... 48 
3.4 Discussion ............................................................................................................................. 49 
3.4.1 SNVs that are least likely to play a role in PCOS ......................................................... 49 
3.4.2 Variants that may play a role in PCOS ......................................................................... 50 
3.4.3 Variants most likely to play a role in PCOS ................................................................. 52 
3.5 Conclusion ............................................................................................................................ 53 
4 Effect of rs143321413 on EEF2K and EEF2 protein-protein interaction ..................................... 54 




4.2 Materials and Methods .......................................................................................................... 56 
4.2.1 Confirming the presence of rs143321413 in Q1857 and Q1895 .................................. 56 
4.2.2 Cloning of the EEF2K ORF into the pcDNA3.1(+) mammalian expression vector ..... 57 
4.2.3 Transfection optimisation of wildtype and mutant EEF2K .......................................... 61 
4.2.4 Co-immunoprecipitation ............................................................................................... 62 
4.3 Results ................................................................................................................................... 65 
4.3.1 Isolation of EEF2K cDNA ............................................................................................ 65 
4.3.2 Presence of rs143321413 in Q1857 and Q1895 ............................................................ 65 
4.3.3 Cloning .......................................................................................................................... 66 
4.3.4 Transfection optimisation of wildtype and mutant EEF2K in mammalian cell lines ... 67 
4.3.5 Co-immunoprecipitation ............................................................................................... 69 
4.4 Discussion ............................................................................................................................. 73 
4.4.1 Isolation of EEF2K cDNA ............................................................................................ 73 
4.4.2 Cloning .......................................................................................................................... 73 
4.4.3 Determination of optimal cell line for co-immunoprecipitation ................................... 73 
4.4.4 Presence of endogenous EEF2 ...................................................................................... 74 
4.4.5 Transfection for equivalent expression ......................................................................... 74 
4.4.6 Co-immunoprecipitation ............................................................................................... 74 
4.5 Conclusion ............................................................................................................................ 77 
5 Clinical recruitment and identification of putative exonic causal mutations in Western Australian 
women with PCOS ................................................................................................................................ 78 
5.1 Introduction ........................................................................................................................... 78 
5.2 Materials and Methods .......................................................................................................... 78 
5.2.1 Clinical recruitment....................................................................................................... 78 
5.2.2 Exome sequencing ........................................................................................................ 79 
5.2.3 Bioinformatic Analysis ................................................................................................. 79 
5.3 Results ................................................................................................................................... 80 
5.3.1 Clinical Recruitment and exome sequencing ................................................................ 80 
5.3.2 Identified mutations ...................................................................................................... 80 
5.4 Discussion ............................................................................................................................. 81 
5.4.1 Neuregulin 1 (NRG1).................................................................................................... 82 
5.4.2 Protein Tyrosine Phosphatase, Receptor Type N2 (PTPRN2) ...................................... 82 
5.4.3 Eukaryotic Elongation Factor 2 (EEF2K) ..................................................................... 83 
5.5 Conclusion ............................................................................................................................ 83 
6 General discussion and Conclusion .............................................................................................. 84 
6.1 Bioinformatic analysis of old exome sequencing data files .................................................. 84 
6.2 Functional genomics on the rs143321413 mutation ............................................................. 85 




6.4 Future directions ................................................................................................................... 86 
6.5 General conclusion ................................................................................................................ 86 
7 References ..................................................................................................................................... 88 
8 Appendix ..................................................................................................................................... 109 
8.1 Recipes ................................................................................................................................ 109 
8.2 Clinical Recruitment Forms ................................................................................................ 114 
































Firstly, I would like to give a huge thank you to A/Prof Robert Mead. Thank you for encouraging me 
to have the courage to pursue an external honours project. Having social anxiety, I would have 
struggled not only to begin my honours project, but to complete my undergraduate degree without 
you. I owe so much of my success and enjoyment throughout university to you. 
To A/Prof Scott Wilson, thank you for giving me the opportunity to undertake this project and for 
your help, support, and understanding. There were times when I was convinced I wouldn’t be able to 
complete this thesis, but you went above and beyond to help me overcome any problems. 
Thank you to Professor Bronwyn Stuckey for sharing your immense knowledge of PCOS and taking 
the time out of your very busy schedule to assist me. Your patience and willingness to help were very 
encouraging throughout my project. 
I am overwhelmingly grateful to Bryan Ward. I don’t know where you find the time to conduct your 
own research while helping the students in the lab. Your immense patience and kindness was a large 
part of what got me through my lab work. 
To Purdey Campbell and Alexia Weeks, thank you for not only helping me out with my project and 
my lab work, but for becoming good friends of mine. I don’t know how I would have coped if I didn’t 
have the two of you around to help me work out problems in my experiments, send science memes to 
each other, and vent about our projects. 
Ben Mullin, Shelby Mullin, and Kharis Burns thank you for always making time to help me and for 
making my transition into honours so friendly. 
Thank you so much to Anna Cole and Loky Blanch. I don’t know how you two were able to put up 
with me while I was so stressed and worrying about honours. Without your support and love I 
wouldn’t have been able to stay sane outside of honours. 
Last but not least: thank you to my mum Vicki Smith. Thank you for supporting and encouraging me 









List of Abbreviations 
 
Abbreviation Definition 
17G Androstane-3alpha,17beta-diol-17 glucuronide 
AGEs Advanced glycated end products 
AMH Anti mullerian hormone 
BMI Body mass index 
BPA Bisphenol A 
cDNA Complementary DNA 
CNS Central nervous system 
CVD Cardiovascular disease 
CYP11A1 Cytochrome p450 11A1 
CYP17A1 Cytochrome P450 17A1 
CYP19A1  Cytochrome p450 19A1 
CYP2C11/6 Cytochrome p450 2C11/6  
CYP3A2/1 Cytochrome p450 3A2/1 
DENND1A  
DENND1AV2  
DHEAS Dehydroepiandrosterone sulphate 
DNA Deoxyribonucleic acid 
gDNA Genomic DNA 
GnRH Gonadotropin releasing hormone  
FAI Free androgen index 
FG score Ferriman-Gallwey score 
FSH Follicle stimulating hormone 
FSHβ  Follicle stimulating hormone beta 
FSHR Follicle stimulating hormone receptor 
FST Follistatin 
GABA(A) γ-aminobutyric acid type A receptor 
GWAS Genome wide association study 
HA Hyperandrogenaemia/hyperandrogenism 
hCG Human chorionic gonadotrophin 
HDL-C High density lipoprotein cholesterol 
HSD3B2 Hydroxy-Delta-5-Steroid Dehydrogenase, 3 
Beta- And Steroid Delta-Isomerase 2 
IR Insulin resistance 
INSR Insulin receptor 
LD Linkage disequilibrium  
NGS Next generation sequencing 
LH Luteinising hormone 
LHCGR Luteinizing Hormone/Choriogonadotropin 
Receptor 
NIH National Institute of Health 
OC Oral contraceptive pill 
PCOS Polycystic ovary syndrome 
PCOM Polycystic ovary morphology 
SHBG Sex hormone binding globulin 
T2AH Testosterone 2α-hydroxylase  
T2D Type II diabetes 
THADA THADA, Armadillo Repeat Containing 




Index of Figures 
 
Figure name Page 
number 
Figure 1: Common locations and range of intensity of hair growth in PCOS women 
with hirsutism.  
3 
Figure 2: Phases of follicular growth and degradation along with patterns of hormone 
secretion throughout the ovarian cycle.  
4 
Figure 3: Image adapted from Norman et al. 2007 showing the difference in follicle 
number between a normal ovary (left) and a polycystic ovary (right). Follicles are 
shown with red arrows. 
6 
Figure 4: Illustration of the methodology of next generation sequencing used in 
Illumina technology platforms. 
26 
Figure 5: Set up of the western blotting apparatus. 42 
Figure 6: Nitrocellulose membrane post Ponceau staining with protein stained red. 43 
Figure 7: Examples of the pathogenicity predictions for an example pathogenic single 
nucleotide variant (SNV) from (a) PolyPhen-2 and (b) SIFT. 
47 
Figure 8: Sequence data for rs71745629 in individual Q1959 visualised with IGV 
software. 13 reads of the mutant deletion and 11 reads of the wildtype T allele are 
evident, confirming the presence of the heterozygous variant.  
48 
Figure 9: Illustration showing how phosphorylation of eEF2 by EEF2K inhibits its 
protein synthesis activity. (https://www.fredhutch.org/en/news/spotlight/imports/novel-
phosphorylation-of-eef2-inhibits-its-protein-synthesis-act.html) 
55 
Figure 10: 1% Agarose Gel showing the EEF2K cDNA band just before the 2kb 
marker.  
65 
Figure 11: Chromatogram showing heterozygous adenine and guanine bases in Q1857 
(left) and Q1895 (right). 
65 
Figure 12: Chromatograms of EEF2K cDNA in pDrive showing the correctly 
incorporated a) FLAG-tag sequence, b) EcoRV sequence, and c) XhoI sequence. 
66 
Figure 13: Chromatogram showing the rs143321413 mutation in one of the colonies 
resulting from site directed mutagenesis. 
67 
Figure 14: Expression of wildtype and mutant in HEK293 and HEK293FT cells 67 
Figure 15: Expression of endogenous EEF2 in HEK293 and HEK293FT cells. 68 
Figure 16: Comparisons of different ratios of wildtype and mutant for equivalent 





Figure 17: Co-immunoprecipitation membrane 1 probed with rabbit polyclonal 
antibody to eEF2. 
69 
Figure 18: Co-immunoprecipitation membrane 2 probed with rabbit polyclonal 
antibody to phosphorylated eEF2 (Thr56). 
69 
Figure 19:  Co-immunoprecipitation membrane 2 probed with anti-FLAG M2 
monoclonal antibody to visualise pulled down EEF2K. 
70 
Figure 20: Co-immunoprecipitation lysate membrane 1 probed with rabbit polyclonal 
antibody to eEF2.  
70 
Figure 21: Co-immunoprecipitation lysate membrane 1 probed with anti-FLAG M2 
monoclonal antibody and mouse monoclonal anti-α-tubulin antibody. 
71 
Figure 22: white ‘ghost bands’ with partial probing at 82kDa on lysate membrane 1. 71 
Figure 23: Co-immunoprecipitation lysate membrane 2 probed with rabbit polyclonal 
antibody to phosphorylated eEF2 (Thr56). 
72 
Figure 24: Co-immunoprecipitation lysate membrane 2 probed with anti-FLAG M2 















Index of Tables 
Table name Page 
number 
Table 1: Table from Essah and Nelson 2006 listing three different methods of 
diagnosis for the metabolic syndrome. 
13 
Table 2: General reagents 28 
Table 3: General Equipment 28 
Table 4: Peripheral Blood Sample Collection 29 
Table 5: DNA Extraction from Peripheral Blood Samples 
 
30 
Table 6: Polymerase Chain Reaction (PCR) 
 
30 
Table 7: Agarose Gel Electrophoresis  
 
31 
Table 8: Reverse Transcription 
 
31 
Table 9: DNA extraction from bacterial samples 
 
31 
Table 10: Cloning 
 
32 
Table 11: Cell culture 
 
32 
Table 12: Functional Genomics 
 
33 
Table 13: Statistical and Other Software Packages 
 
34 
Table 14: Components of routine PCR reactions 
 
35 
Table 15: Cycling conditions for routine PCR 
 
35 
Table 16: Step 1 of making up AmpliTaq Gold® 360 reactions 
 
36 
Table 17: Step 2 of making up AmpliTaq Gold® 360 reactions 
 
36 
Table 18: Cycling conditions for AmpliTaq Gold® 360 PCR 
 
36 
Table 19: Components of colony PCR reactions 37 
Table 20: Cycling conditions for colony PCR 
 
37 
Table 21: Details of potentially pathogenic variants were identified from 5 PCOS 
affected families through exome sequencing. 
48 
Table 22: Characteristics of primers the amplification of the sequence containing 
rs143321413 
56 




Table 24: Characteristics of internal primers 59 
Table 25: Characteristics of the site-directed mutagenesis primers 60 
Table 26: Transfections carried out in both HEK293 and HEK293FT cell lines using 
Lipofectamine 2000. 
61 
Table 27: Transfections for equivalent expression of wildtype and mutant in 
HEK293FT cells. 
62 
Table 28: Composition of transfection reactions for co-immunoprecipitation 63 
Table 29: Number of coding variants identified via exome sequencing in each 
individual. 
80 
Table 30: Details of potentially pathogenic variants were identified from 2 PCOS 







1.1 Polycystic Ovary Syndrome  
 
1.1.1 History of PCOS 
Polycystic ovary syndrome (PCOS) was first identified as a syndrome of amenorrhea and polycystic 
ovaries by two American gynaecologists in 1935: Irving F. Stein and Michael L. Leventhal (Stein and 
Leventhal 1935). Over time, the then called Stein-Leventhal syndrome evolved to be characterised by 
secondary amenorrhoea, infertility, and bilateral polycystic ovaries, with hirsutism being common but 
not always present (Leventhal 1941, Chamberlain and Wood 1964). 
PCOS is now known to be a common endocrinopathy, affecting 5-10% of women of reproductive age 
worldwide (Glueck et al. 2002, Wild et al. 2000, Morin-Papunen et al. 2012) and a common cause of 
anovulatory infertility (Schmid et al. 2004, Balen et al. 2016). Today, the main symptoms of PCOS 
are recognised as hyperandrogenism, oligo/amenorrhoea, and polycystic ovary morphology (PCOM) 
These symptoms confer an increased risk of developing a variety of chronic endocrine, reproductive 
and metabolic complications (e.g. insulin resistance, obesity, type 2 diabetes (T2D), metabolic 
syndrome and cardiovascular disease). Some association with cancer and mental health sequalae (e.g. 
depression) have also been reported (Chittenden et al. 2009, Thomson et al. 2010). However, 
controversy still remains, on the most accurate method of clinical diagnosis for the disorder and there 
is little consensus with physicians using the National Institute of Health (NIH) diagnostic criteria of 
PCOS, Rotterdam criteria or Androgen Excess Society criteria (Azziz et al. 2009).  
1.2 Clinical Signs and Symptoms 
1.2.1 Hyperandrogenism 
Increased androgen levels are arguably the most important characteristic of PCOS. According to the 
NIH diagnostic criteria, the presence of hyperandrogenism (HA) is the most crucial feature needed in 
order to reach a diagnosis of PCOS (Zawadski and Dunaif 1992). The Androgen Excess Society has 
also defined PCOS as being ‘above all a disorder of androgen excess in women’ (Azziz et al. 2006). 
The mechanism of HA in women with PCOS is due to aberrantly increased androgen production, 
insufficient conversion of androgens to oestrogen, or both. Theca cells of women with PCOS have 
been reported to show increased activity of steroidogenic enzymes CYP17A1 and HSD3B2, as well as 
increased androgen production in both basal and gonadotropin stimulated states (Nelson et al. 1999). 
Furthermore, the DENND1A version 2 transcript produced by the DENND1A gene (DENND1AV2) 




normal theca cells to DENND1AV2 causes a PCOS phenotype with increased CYP17A activity and 
increased androgen production (McAllister et al. 2014); suggesting the ovary may be a primary site of 
HA in PCOS. The adrenal glands may also be implicated in PCOS as dehydroepiandrosterone 
sulphate (DHEAS), an androgen produced exclusively by the adrenal gland, has been noted at higher 
concentrations in PCOS women (Kumar et al. 2005). These are all possible mechanisms whereby HA 
occurs due to excess androgen production.  Another possible cause of HA, is from the androgens, 
testosterone and androstenedione which are normally converted to oestrogens (oestrone and 
oestradiol) in the theca cells of the ovaries by aromatase. Aromatase is produced in the ovarian 
granulosa cells. There is evidence of decreased aromatase efficiency in PCOS women regardless of 
BMI (Chen et al. 2015). Impaired aromatase action can result in a ‘back up’ of androgens as they are 
not sufficiently being converted to oestrogens. Therefore, this may be another mechanism of HA in 
PCOS women.   
HA can be described by clinical and biochemical means. Clinical HA is characterised by the physical 
symptoms of HA which are hirsutism, acne, and androgenic alopecia. Biochemical HA is determined 
by increased levels of androgens in the blood. Elevated free testosterone levels are generally used to 
diagnose biochemical HA, but androstenedione and DHEAS levels can also be relevant. Sex hormone 
binding globulin (SHBG) is also often decreased in PCOS women. Typically, testosterone exists in 
the circulation bound to SHBG. Decreased SHBG and increased androgens in women with PCOS 
leads to an increase of free circulating androgens in the blood unbound to SHBG. An estimate of the 
amount of free circulating androgens, known as the free androgen index (FAI), is another tool used 
for diagnosing HA. HA is the cause of the hirsutism, acne, and androgenic alopecia seen in many 
women with PCOS and is likely implicated in other clinical consequences of PCOS e.g. anovulation 
and insulin resistance (Burgers et al. 2010, Abbott et al. 2005, Manneras et al. 2007).   
Hirsutism refers to the growth of terminal (coarse) hair in a typically male pattern (Figure 1). 
Androgens affect the follicular-mesenchymal interactions within the skin which alters the activity of 
papilla cells, keratinocytes and melanocytes, as well as hair growth rate and dermal papilla size 
(Randall 2007). Androgens being present in women at levels comparable to those seen in men, cause 
small, unpigmented vellus hairs to become long, coarse, terminal hairs (Randall 2008). Thus, 
androgen excess in PCOS women is a cause of hirsutism. Indeed, 70-80% of women with HA display 
hirsutism (Azziz 2003). The presence of this stereotypically masculine characteristic is a source of 





Figure 1: Common locations and range of intensity of hair growth in PCOS women with hirsutism.  
Acne is present in many women with HA (Hasinski et al. 1997, Slayden et al. 2001, Lai et al. 2012). 
A recent study found that 72% of 207 acneic women had hyperandrogenism, and the most common 
cause was PCOS (Uysal et al. 2017). The cause of acne is largely unknown but it involves increased 
sebum production, follicular dermal hyperplasia, the presence and increased activity of 
propionibacterium acne, inflammation, and keratinisation (Lai et al. 2012, Uysal et al. 2017). 
Androgens are able to alter the activity of sebaceous glands through their action on pilosebaceous 
follicles (Hasinski et al. 1997). As increased sebum production is involved in the formation of acne, 
this may be a mechanism by which androgens contribute to acne production. However, the exact 
aetiology of acne production due to androgen excess is unknown (Lai et al. 2012). Acne is a further 
factor that contributes to decreased quality of life in many women with PCOS.  
Although androgens cause the growth of terminal hair in many locations, they can also paradoxically 
cause balding on the scalp (androgenic alopecia). The mechanism of this paradoxical androgenic 
balding is not well understood. However, it is characterised by follicular miniaturisation, increased 
ratio of telogen to anagen hairs, and the production of light, vellus hairs from coarse, terminal hairs 
(Trueb 2002). The importance of androgens in this type of alopecia is known from experiments in 
castrated men. Castrated men do not exhibit balding but, when exposed to testosterone, balding in the 
typical male-pattern alopecia fashion occurs (Hamilton 1942). Androgenic alopecia has been reported 
in women with PCOS at rates of 3.2% -34.8% (Quinn et al. 2014) and has a negative psychological 
impact on PCOS women affected by it (Tabolli et al. 2013).  
HA also impacts ovulatory function, follicle number and insulin resistance in PCOS women. 
Androgen levels are positively correlated with more severe ovulatory dysfunction, increased follicle 




al. 2007). The mechanism of HA on the development of these symptoms will be discussed in more 
detail in later sections.  
1.2.2 Ovulatory Dysfunction 
The ovarian cycle follows a pattern of folliculogenesis, followed by ovulation, followed by the 
degradation of the leftover follicle (corpus luteum) (Figure 2). The second most important 
characteristic symptom required for a PCOS diagnosis via NIH criteria is a decreased occurrence/lack 
of ovulation (oligoovulation and anovulation respectively). As a result of anovulation, PCOS 
commonly causes irregular menstrual bleeding (oligomenorrhoea) or the cessation of menstrual 
bleeding for extensive periods (amenorrhoea). Anovulation also results in infertility as no ovum is 
released from either ovary to undergo fertilisation. Indeed, PCOS is the most common cause of 
anovulatory infertility in reproductive aged women (Sirmans and Pate 2013). Difficulty falling 
pregnant has a significant impact on women with PCOS as well as their partners (Klemetti et al. 2010, 
Ezzell 2016). Furthermore, women with PCOS who do manage to fall pregnant have a higher rate of 
complications and miscarriage (Boomsma et al. 2006, Boomsma, Fauser, and Macklon 2008).  
Anovulation also results in decreased secretion of progesterone. As women with PCOS have reduced 
ability of passing the ovulation phase of the ovarian cycle, they rarely reach the luteal stage where 
progesterone is released by the corpus luteum. The menstrual cycle remains halted in the follicular 
phase where higher oestrogen secretion occurs. Therefore, the preovulatory secretion of oestrogen 
aberrantly continues unopposed by progesterone. Oestrogen secretion unopposed by progesterone can 
cause hyperplasia of the endometrium and therefore increase risk of developing endometrial cancer. 
Endometrial hyperplasia as a result of unopposed oestrogen secretion is also likely a cause of heavy 
menstrual bleeding known as anovulatory menorrhagia. Research regarding the relationship between 
PCOS and menorrhagia is lacking, but it is a known source of complaint in adolescents with PCOS 
(Maslyanskaya et al. 2016). Furthermore, PCOS women have a higher rate of admission to hospital 
due to menorrhagia (Hart and Doherty 2015). Menorrhagia can disrupt the normal lifestyle of those 
women suffering from it and cause distress due to increased rate of changing hygiene products, 
disruptions to work and sexual activity, painful cramping (dysmenorrhoea), mood swings, and 
hospitalisation (Apgar et al. 2007, Hart and Doherty 2015). Overall, anovulation disrupts the lifestyle 
of PCOS women and has the potential to decrease quality of life due to infertility, pregnancy 






Figure 2: Phases of follicular growth and degradation along with patterns of hormone secretion 
throughout the ovarian cycle.  
The development and severity of ovulatory dysfunction in PCOS women is associated with HA. 
Testosterone and androstenedione are increased, while SHBG is decreased in anovulatory women 
compared with oligoovulatory women (Burgers et al. 2010). Normo-ovulatory women have a lower 
FAI than anovulatory and oligoovulatory PCOS women (Amato et al. 2011). Furthermore, 
anovulation and/or irregular ovarian cycles have been induced in rats by treating them with 
testosterone and aromatase inhibitors (Barraclough 1961, Manneras et al. 2007). Androgens are 
important in primate folliculogenesis as they promote proliferation of thecal and granulosa cells, as 
well as promoting preantral/antral follicle growth (Vendola et al. 1998). However, increased androgen 
concentration can impact late stage follicular development by causing apoptosis of granulosa cells and 
hypertrophy of theca cells in rats, leading to follicle atresia (Honnma et al. 2006, Kim et al. 2013). 
This is hypothesised to be a mechanism behind hyperandrogenic anovulation.  
Insulin resistance may also be implicated in ovulatory dysfunction. Insulin sensitivity is lower in 
anovulatory PCOS women compared with normo-ovulatory women (Guastella, Longo, and Carmina 
2010). Folliculogenesis is also regulated by the action of insulin on the oocyte (Kezele, Nilsson, and 
Skinner 2002, Zhang et al. 2010) as insulin is involved in causing the progression of primordial 
follicles to primary follicles (Kezele, Nilsson, and Skinner 2002). Additionally, exposure of mouse 
ovaries to 5µg/mL insulin leads to retarded oogenesis and decreased proportion of secondary follicles 




cycle and possibly contribute to oligo/anovulation. Furthermore, as discussed in section 3.1, insulin 
and HA seem to exacerbate each other. Therefore, insulin resistance could increase the negative 
effects of increased androgens on anovulation and vice versa. 
1.2.3 Polycystic Ovary Morphology 
Ovaries with the appearance of multiple ‘cysts’ was one of the first symptoms that PCOS was 
characterised by (Stein and Leventhal 1935). In more recent times, it has been discovered that the 
polycystic appearance is due to the presence of multiple preovulatory follicles in the ovary (Figure 3). 
Ovaries are considered to possess the polycystic ovary morphology phenotype (PCOM) when they 
contain ≥12 preovulatory follicles measuring from 2mm to 9mm in diameter and/or if they have an 
ovarian volume exceeding 10mL (Rotterdam 2004). Typically, in a normal ovarian cycle, a number of 
follicles will be produced initially from which a dominant follicle is selected. The dominant follicle 
undergoes ovulation while the other follicles become atretic. In anovulatory women, folliculogenesis 
halts before the follicles reach 10mm, which is just prior to selection of a dominant follicle (Webber 
et al. 2003). This may responsible for an accumulation of preovulatory follicles.    
 
Figure 3: Image adapted from Norman et al. 2007 showing the difference in follicle number between a 
normal ovary (left) and a polycystic ovary (right). Follicles are shown with red arrows. 
PCOM is highly associated with HA. Serum androgen levels and high follicle number are tightly 
correlated. Furthermore, the injection of testosterone into rhesus monkeys and rodents causes PCOM 
(Abbott et al. 2005, Beloosesky et al. 2004). It has been determined that women with PCOS have a 
reduced amount of primordial follicles and an increased amount of early preantral follicles (Webber et 
al. 2003). This could be due to an increased rate of primordial follicle conversion to primary follicles 
and a reduction and/or slowing of atresia of developing early antral follicles. A proposed mechanism 
for this is via the action of androgens on early follicular development. Androgens have the ability to 
speed up the rate of early folliculogenesis by increasing the follicle’s sensitivity to follicle stimulating 
hormone (FSH) (Hillier and Tetsuka 1997, Weil et al. 1999). The resulting increase in primary 
follicles causes an increase in anti mullerian hormone (AMH) secretion, which has an inhibitory effect 




primary follicles leads to a slowing of the next stage of follicular development. Follicles that are not 
selected as the dominant follicle consequently undergo atresia more slowly, leading to an 
accumulation of follicles. Furthermore, insulin resistance (IR) may be implicated for a role in altering 
ovarian morphology as insulin has anti-apoptotic abilities in a variety of tissues (Maeda et al. 2004, 
Aikawa et al. 2000) including ovary (Bertrand et al. 1999), adding to the decreased rate of atresia of 
early antral follicles. Therefore, PCOM is likely a result of HA and exacerbated by IR. 
1.3 Secondary Increased Health Risks 
1.3.1 Insulin resistance  
IR with or without obesity is a common finding in PCOS women, with 64% of patients displaying IR 
(DeUgarte, Bartolucci, and Azziz 2005). IR refers to an impairment of body cells (notably 
hepatocytes, adipocytes, and skeletal muscle cells) to respond to insulin and facilitate glucose uptake 
(Ekim Ustunel et al. 2016). In healthy individuals, the presence of glucose from carbohydrate intake 
triggers the release of insulin from the beta cells of the pancreas. Insulin then stimulates the uptake of 
glucose from the circulatory system. In patients with IR, the response of the body’s cells to the 
presence of insulin is dampened. This results in hyperglycaemia and hyperinsulinaemia (Shanik et al. 
2008). Hyperinsulinaemia resulting from insulin resistance has been implicated in symptoms such as 
fatigue and increased hunger. Furthermore, IR increases the chances of developing clinical 
consequences such as type 2 diabetes, cardiovascular disease, metabolic syndrome, and hypertension. 
IR also likely exacerbates the main clinical symptoms of PCOS. HA and menstrual cycle irregularities 
are often more severe in in PCOS women with IR (Huang et al. 2015, Strowitzki, Capp, and von Eye 
Corleta 2010, DeUgarte, Bartolucci, and Azziz 2005). Furthermore, treatment with insulin sensitising 
drugs such as metformin, improves HA and oligo/amenorrhoea, as well as increasing live-birth rate in 
women with PCOS (Velazquez et al. 1994, Morin-Papunen et al. 2012, Brettenthaler et al. 2004). 
There is a complex relationship between insulin resistance and HA in PCOS women. The presence of 
insulin resistance could be caused by HA. Rats with induced HA have been observed to develop IR 
and increased body fat (Manneras et al. 2007). Hyperandrogenic individuals also display decreased 
insulin activity, and treatment with some antiandrogens can increase insulin sensitivity in patients 
with both IR and HA (Moghetti et al. 1996, Dahlgren et al. 1998). Conversely, there is evidence to 
suggest that insulin resistance leads to HA. Insulin stimulates secretion of testosterone by human 
thecal cells (Nestler, Jakubowicz, de Vargas, et al. 1998). Furthermore, insulin lowers circulating 
levels of SHBG (Plymate et al. 1988). Treatment of IR with insulin-sensitising agents has also been 
observed to improve hyperandrogenic and reproductive symptoms in women with PCOS (Nestler, 
Jakubowicz, Evans, et al. 1998, Velazquez et al. 1994, Moghetti et al. 2000, Azziz et al. 2001). 





Evidently, HA and IR are linked. However, it has been suggested that high body fat may play more of 
a role in the development and aetiology of IR in women with PCOS than HA. Adipose tissue is a 
major regulator of the action of insulin throughout the whole body and aberrant function of adipocytes 
has been observed to cause systemic insulin resistance. Aberrant function, along with altered 
morphology, of adipose tissue has been observed in women with PCOS. Furthermore, it is well 
documented that IR can be induced by obesity (Olefsky and Glass 2010, Rabe et al. 2008, Sinaiko and 
Caprio 2012). A large number of PCOS women are obese, which is a likely cause of the high 
percentage of PCOS women with IR. IR has been shown to be most highly correlated with adipocyte 
size, circulating adiponectin, and waist circumference in PCOS women (Manneras-Holm et al. 2011). 
There have been instances in which anti-androgen treatment only statistically increased insulin 
sensitivity in lean PCOS women (Moghetti et al. 1996). Furthermore, not all anti-androgen 
medications have an insulin sensitising effect. Therefore, increased body fat may play a more 
substantial role in the development and progression of IR compared with HA. However, increased 
body fat cannot be the only important contributor to the development of IR in PCOS women because 
many lean PCOS women display IR. In summary, there is a complex relationship between androgens, 
body fat, and insulin activity occurring in PCOS women. To add to the complexity, the causes of the 
underlying HA, IR, and adipose abnormalities may differ slightly from patient to patient. These 
interrelationships contribute to, and exacerbate, the symptoms of hyperandrogenaemia, obesity, and 
IR in women with PCOS.  
1.3.2 Obesity  
In the developed countries of the world, approximately 50% of women with PCOS are overweight or 
obese (Balen et al. 1995). The pattern of obesity in PCOS women is a central adiposity distribution. 
Lean PCOS women also have a more central pattern of adiposity compared with controls (Yildirim, 
Sabir, and Kaleli 2003, Svendsen et al. 2008). This may imply that there is a predisposing factor of 
PCOS towards weight gain and/or a central pattern of adiposity. Although there are no differences in 
weight loss between PCOS patients and controls undergoing the same weight loss program 
(Jakubowicz and Nestler 1997, Toscani et al. 2011, Spanos et al. 2012), there is evidence to suggest 
that PCOS women may be subject to aberrant energy expenditure, appetite regulation, basal metabolic 
rates, and caloric utilisation (Robinson et al. 1992, Georgopoulos et al. 2009, Moran et al. 2004). All 
of these factors could potentially play a role in predisposing PCOS women to weight gain. 
Furthermore, both obese and lean women with PCOS have been shown to possess a higher total fat 
mass and increased visceral/central deposition of adipose tissue compared with healthy controls of a 
similar BMI (Borruel et al. 2013). Interestingly, these patterns of fat mass and visceral adipose tissue 
depots are similar to men. Borruel et al. tentatively hypothesised that this could be evidence of an 
implication of androgen levels in the patterns of fat distribution in PCOS women. Obesity is 




2007) which may lend further weight to this hypothesis of HA playing a role in weight gain and the 
development of visceral fat distributions. However, more research is needed to prove this. 
Additionally, PCOS patients display decreased adiponectin levels regardless of BMI. Lastly, zonulin, 
a biomarker of gut permeability in humans, is increased in women with PCOS. This may be another 
mechanism by which PCOS could predispose to weight gain, as increased gut permeability is a 
characteristic of obesity (Zhang, Zhang, et al. 2015). Although a predisposing role of PCOS towards 
obesity has not been proven, it is evident that PCOS patients possess aberrations in multiple body 
systems that can affect fat accumulation and deposition.  
 It is not entirely clear how much of the obesity seen in PCOS patients is due to a predisposing factor 
of PCOS to obesity, or whether it is simply a reflection of the prevalence of obesity in the patient’s 
country. The prevalence of obesity in a country has a direct relationship with the prevalence of PCOS. 
(Balen et al. 1995, Taponen et al. 2004, Hahn, Tan, et al. 2005, Carmina et al. 2005). Furthermore, 
there is little difference in the number of lean PCOS patients and obese PCOS patients in the US 
(Yildiz, Knochenhauer, and Azziz 2008), which may discount a predisposing role of PCOS to obesity. 
However, conflicting studies exist that do demonstrate an increased rate of PCOS in obese compared 
with lean individuals (Laitinen et al. 2003). It seems likely that there is a role of lifestyle and genetics 
in the development of obesity in PCOS due to the differing percentages of obesity in PCOS patients in 
different countries. However, these percentages are likely impacted by differing diagnostic techniques 
utilised in different countries so the possibility of a predisposing role of PCOS on obesity cannot be 
ignored. Lifestyle, genetics, and PCOS aetiology are likely all connected in the development of 
obesity.  
Regardless of whether or not PCOS causes predisposition to obesity, it is evident that obesity 
exacerbates the reproductive and metabolic symptoms of PCOS. Serum testosterone levels are often 
higher in overweight PCOS women, and the clinical signs of HA i.e. hirsutism, acne, and androgenic 
alopecia are more severe. Insulin resistance is also often more severe in obese PCOS women and the 
likelihood of developing T2D and cardiovascular disease is increased. Additionally, amenorrhoea 
tends to be more prolonged and infertility is worsened in obese individuals. Weight loss of only 5% in 
PCOS patients improves testosterone, SHBG, and insulin levels, while often also leading to the 
resumption of menstruation and the return of fertility (Crosignani et al. 2003, Stamets et al. 2004, 
Moran et al. 2003, Gower et al. 2013, Thomson et al. 2010). Therefore, although the cause of the 
prevalence of obesity in PCOS women is unknown, weight gain has significant negative effects on 
PCOS symptoms. 
1.3.3 Type 2 Diabetes and Gestational Diabetes 
T2D is a metabolic disorder characterised by long term hyperglycaemia due to IR and aberrant insulin 




insulin resistance, and a family history of T2D. However, not all obese, insulin resistant individuals 
develop T2D. In order for T2D to occur, the beta cells of the islets of Langerhans in the pancreas must 
display impaired efficiency in compensating for the decreased insulin sensitivity (Kahn 2001). The 
insulin resistance and obesity seen in many women with PCOS results in an increased risk of 
developing T2D. As PCOS women are commonly insulin resistant and obese, it is not surprising that 
a high prevalence of T2D in PCOS patients has been observed in many studies (Dahlgren et al. 1992, 
Ehrmann et al. 1999). Furthermore, the rate of conversion from impaired glucose tolerance to full-
blown T2D is accelerated in women with PCOS (Ehrmann et al. 1999, Norman et al. 2001). Women 
with PCOS also show an earlier age of onset of T2D than the general population (Norman et al. 
2001). T2D causes a decrease in life expectancy (Mulnier et al. 2006) and increased risk of 
developing cardiovascular disease (Barnett et al. 2010) in PCOS women.  
PCOS may also increase the risk of developing gestational diabetes. Decreased insulin sensitivity 
occurs naturally during pregnancy. However, it has been theorised that if decreased insulin sensitivity 
or IR already existed before pregnancy, the pregnant state could exacerbate this aberrant insulin 
metabolism, leading to increased incidence of gestational diabetes. A meta-analysis of pregnancy 
outcomes in women with PCOS discovered a significant association between PCOS and gestational 
diabetes. However, the chosen studies had a high degree of heterogeneity which was not accounted 
for (Boomsma et al. 2006). A further meta-analysis concluded that a correlation between PCOS and 
gestational diabetes cannot be deduced as the result is dependent on study-level characteristics (Toulis 
et al. 2009). Therefore, a conclusion cannot be drawn concerning increased rates of gestational 
diabetes in PCOS women. However, Toulis et al. suggested that the varying results could be 
explained if gestational diabetes was associated with some subtypes of PCOS and not others.    
1.3.4 Endometrial Cancer 
A possible link between PCOS and endometrial cancer has been suspected since 1949 (Speert 1949). 
Many studies have identified endometrial cancer in PCOS patients (Jafari, Javaheri, and Ruiz 1978, 
Colafranceschi et al. 1989, Honore and Davey 1989, Brinton et al. 2010). Furthermore, PCOS women 
have been classified as being ~3x more likely to develop endometrial cancer than the rest of the 
population (Chittenden et al. 2009, Haoula, Salman, and Atiomo 2012). The mechanism/s by which 
PCOS increases the risk of developing endometrial cancer are not understood, however theories 
involve imbalanced oestrogen and progesterone levels, increased amount of luteinising hormone 
receptors, and the presence of IR, obesity, and HA. 
The unopposed oestrogen hypothesis proposes that increased oestrogen concentration coupled with 
decreased progesterone concentration heightens the risk of endometrial cancer. Oestrogen increases 
the rate of mitosis (Biggers and Claringbold 1955, Kaye, Sheratzky, and Lindner 1971) which is a risk 




concentration through a variety of mechanisms. One such mechanism involves the agonist-bound 
progesterone receptor-A inhibition of transcription of the oestrogen receptor (Giangrande and 
McDonnell 1999). In the pre-ovulatory stage of the menstrual cycle, oestrogen is secreted by the 
ovaries, but very little progesterone is released (Rose, Lubin, and Connolly 1997, Shaikh 1971, 
Hashimoto et al. 1968). Therefore, the chronic anovulatory state seen in many women with PCOS 
results in prolonged production of oestrogen with a lack of progesterone, which is a likely mechanism 
by which endometrial cancer risk is increased in PCOS patients. 
 An increase in the receptors for luteinising hormone (LH) and human chorionic gonadotrophin (hCG) 
has been observed in cases of endometrial cancer (Konishi et al. 1997). Therefore, an increase in LH 
concentration could be implicated in the aetiology of endometrial cancer. As some women with PCOS 
display increased serum LH, this could be a mechanism for increased predisposition to endometrial 
cancer in PCOS women.  
IR, obesity, and T2D have been implicated in endometrial cancer. IR is present in many women with 
endometrial cancer (Burzawa et al. 2011), and blood insulin concentration is higher in women with 
endometrial cancer than healthy controls (Bershtein et al. 2000, Gamayunova et al. 1997). Insulin is 
further implicated in endometrial cancer by the effect of metformin in decreasing proliferation in 
endometrial cancer cell lines (Cantrell et al. 2010). Furthermore, insulin enhances aromatase activity 
in endometrial cancer tissue (Randolph et al. 1987). Therefore, hyperinsulinaemia and IR may 
increase endometrial cancer risk by upregulating oestrogen production by aromatase. Many studies 
have demonstrated a significantly higher risk of endometrial cancer with increasing BMI and/or 
weight (MacDonald et al. 1978, Burzawa et al. 2011). Obesity also confers increased risk of death in 
endometrial cancer patients compared with non-obese patients (Reeves et al. 2007). Aromatase is 
active in adipose tissue (Longcope et al. 1978) and aromatase levels increase with obesity, which 
results in higher circulating oestrogen (MacDonald et al. 1978, Grodin, Siiteri, and MacDonald 1973). 
Therefore, as IR, obesity, and T2D are present in many women with PCOS, these may be factors 
predisposing PCOS women to endometrial cancer. 
1.3.5 Other Cancers 
A link between PCOS and breast cancer has long been suspected because there is a lot of overlap 
between risk factors for developing breast cancer and PCOS characteristics. These consist of early 
menarche, late menopause, obesity, fewer births, nulliparity, and increased age of first birth (Kim et 
al. 2016, Papaioannou and Tzafettas 2010). Increased ovarian testosterone production, and the oral 
contraceptive pill use (a common therapy for PCOS) have also been associated with breast cancer 
(Gordon et al. 1990, Secreto et al. 1989, Cogliano et al. 2005). Furthermore, it has been suggested that 
the unopposed oestrogen hypothesis explained previously, could be implicated for a role in breast 




the association of breast cancer with PCOS. Some studies report an association between the two (Kim 
et al. 2016, Coulam, Annegers, and Kranz 1983), many studies indicate no association (Chittenden et 
al. 2009, Wild et al. 2000), and some even discovered a reverse correlation (Gammon and Thompson 
1991, Anderson et al. 1997). The degree of conflicting results may be explained by the fact that many 
of the studies were subject to aberrant ratios of PCOS cases and controls, differing methods of PCOS 
diagnosis, self-reporting of PCOS, and failure to control for BMI in some cases (Jakimiuk and Issat 
2009, Papaioannou and Tzafettas 2010). Therefore, presently, it is not possible to draw a conclusion 
on whether PCOS increases the risk towards developing breast cancer.  
It has also been proposed that PCOS increases the risk of developing ovarian cancer. As with breast 
cancer, the evidence for an association between PCOS and ovarian cancers is inconsistent (Barry, 
Azizia, and Hardiman 2014, Bodmer et al. 2011, Olsen et al. 2008). One explanation for this 
inconsistency could be the fact that histological subtypes are not always accounted for. It has been 
suggested that PCOS may be associated with some histological subtypes of ovarian cancer, but not 
others (Harris et al. 2017). However, more research on this topic is needed. There is less research on 
the relation of PCOS with ovarian cancer compared with breast and endometrial cancer research. 
Furthermore, many of the studies are subject to different methods of PCOS diagnosis, and self-
reporting of PCOS. At this time, it seems impossible to draw a conclusion on any association of 
ovarian cancer with PCOS.  
As endometrial, breast, and ovarian cancer have shown possible associations with PCOS in some 
studies, an interest in investigating an increased risk of developing other gynaecological cancers in 
PCOS women has been expressed. These cancers include cervical, vaginal, and vulval cancer. 
However, next to no research has been performed on the relation of these cancers to PCOS 
(Chittenden et al. 2009). Therefore, no conclusion can be drawn concerning an increased risk of 
developing these gynaecological cancers in PCOS women.  
1.3.6 Metabolic Syndrome and Cardiovascular Disease 
Metabolic syndrome is a disorder consisting of at least three of the following: insulin resistance, 
obesity, dyslipidaemia, hypertension, and decreased high density lipoprotein cholesterol (HDL-C) 
(Essah, Wickham, and Nestler 2007). There are three different methods of diagnosis (Table 1), but in 
general, insulin resistance/type 2 diabetes/impaired glucose metabolism are the most important 
symptoms (Essah, Wickham, and Nestler 2007). Insulin resistance, obesity, and T2D are common in 
those with PCOS (DeUgarte, Bartolucci, and Azziz 2005, Balen et al. 1995, Ehrmann et al. 1999), and 
dyslipidaemia and low HDL-C have also been reported (Rocha et al. 2011). Therefore, it is not 
surprising that there is a high prevalence of metabolic syndrome present in women with PCOS. 
Studies have reported that approximately 43% – 47% of PCOS women have metabolic syndrome, 




syndrome coincides with, or increases the risk of developing T2D (Stern et al. 2004). Furthermore, 
metabolic syndrome incurs a substantial increased risk of developing cardiovascular disease (Mottillo 
et al. 2010).  
HA may be implicated in the development of metabolic syndrome. The possible causative role of HA 
on IR - and consequently obesity and T2D - has been discussed. However, HA may also be involved 
in decreased HDL-C. Low HDL-C has been associated with decreased SHBG and increased free 
circulating testosterone (Chen et al. 2006, Korytkowski et al. 2005). Heightened testosterone and 
decreased SHBG are negatively correlated with lipoprotein lipase activity (Desmeules et al. 2003, 
Korytkowski et al. 2005). Therefore, increased free circulating testosterone could accelerate the 
activity of lipoprotein lipase, leading to a deficit in HDL-C. This may be a mechanism behind PCOS 
increasing the risk of developing metabolic syndrome.  
Table 1: Table from Essah and Nelson 2006 listing three different methods of diagnosis for the 
metabolic syndrome. 
 
The prevalence of metabolic syndrome in PCOS women heightens their risk of developing 
cardiovascular disease (CVD) (Essah, Wickham, and Nestler 2007). Patients with metabolic 
syndrome have a 2-fold increased risk for developing CVD. Furthermore, metabolic syndrome incurs 
an increase in CVD-related mortality, all-cause mortality, myocardial infarction, and stroke (Mottillo 
et al. 2010). Risk of developing CVD may also be increased in PCOS women by actions of HA, as 
decreased SHBG has been directly associated with increased CVD risk (Bataille et al. 2005, Joffe et 
al. 2006). Metabolic syndrome and CVD are serious health risks in PCOS women that decrease their 
overall quality of life and increase risk of mortality (Wild et al. 2010). 
1.3.7 Imbalances of Hormones other than Androgens 
Many women with PCOS display hypersecretion of LH, resulting in a higher LH/FSH ratio. In fact, a 




since been determined that not all women with PCOS exhibit this increased LH/FSH ratio, with only 
approximately 50% of PCOS women displaying the symptom (Banaszewska et al. 2003). Therefore, 
elevated LH/FSH ratio was removed as a standard in the diagnosis of PCOS (Banaszewska et al. 
2003). However, elevated LH secretion is still a characteristic of a sizable amount of PCOS patients 
so it is worthy of discussion. 
In those women who do have a high LH/FSH ratio, the elevated LH likely contributes to HA due to 
increased ovarian androgen secretion. This is because LH enhances ovarian steroidogenesis through 
the action of protein kinase A (Nelson-Degrave et al. 2005). IR may also be implicated in LH-induced 
steroidogenesis as theca cells obtained from PCOS women exhibit an increase in LH-induced 
androstenedione production after being exposed to insulin (Poretsky et al. 1984). Therefore, in some 
PCOS women, LH secretion, HA, and IR may be interrelated.  
Elevated LH levels are also likely implicated in infertility and anovulation. Hypersecretion of LH is 
associated with reduced chance of conception and an increased chance of miscarriage (Tarlatzis et al. 
1995, Kousta, White, and Franks 1997). The mechanism by which LH exerts this negative effect on 
fertility is unknown. However, it is suggested that increased LH concentration impacts follicular 
growth. In a normal ovulatory cycle, LH is thought to cause mitotic arrest in follicles at the start of the 
LH surge. Therefore, an elevated LH concentration may cause mitotic arrest of follicles at an earlier 
stage and prevent them from developing to undergo ovulation (Hillier 1994, Willis et al. 1996).  
1.3.8 Psychological Sequalae 
Many women report mental stress and decreased quality of life as a result of the symptoms of PCOS. 
The physical manifestations of PCOS such as hirsutism, acne, alopecia, and obesity negatively impact 
the self-esteem of patients (Hahn, Janssen, et al. 2005, Tabolli et al. 2013). Furthermore, infertility 
and menstrual irregularity are very distressing for many women, particularly adults who want to have 
children (Klemetti et al. 2010, Ezzell 2016). These distressing factors impact the mental health and 
quality of life of many PCOS women, and may exacerbate or fuel the development of mood disorders. 
Some aspects of PCOS may also play a part in the aetiology and development of mental health 
disorders such as depression and anxiety. Insulin resistant patients are reported to have higher rates of 
anxiety and depression (Rasgon et al. 2003, Klimczak, Szlendak-Sauer, and Radowicki 2015, Pearson 
et al. 2010, Shomaker et al. 2010). This may be due to the role of insulin in the central nervous system 
(CNS). Insulin alters the expression of noradrenaline and dopamine transporters as well as γ-
aminobutyric acid type A receptors (GABA(A)), and increases translocation of GABA(A) to the 
plasma membrane (Figlewicz 1999, Gerozissis 2003). Additionally, insulin increases serotonin levels 
as well as neuronal plasticity (Orosco, Rouch, and Gerozissis 2000, Orosco and Gerozissis 2001, 




that insulin sensitisers can improve the symptoms of depression (Rasgon et al. 2002, Guo et al. 2014). 
Consequently, there may be a physiological link between IR and the development of mood disorders.  
It has also been suggested that androgens may be involved in the aetiology of mood disorders, 
possibly through effects on the HPA axis, corticotrophin releasing factor expression, and/or the action 
of the androgen receptor in the amygdala (Hermans et al. 2007, Costine et al. 2010, Hu et al. 2015). A 
number of studies have found a correlation between increased serum androgens levels and depression 
(Weber et al. 2000, Kurita et al. 2013), and chronic exposure to testosterone induces symptoms of 
anxiety in female rats (Costine et al. 2010), as well as their offspring (Hu et al. 2015). Furthermore, 
psychiatric side effects are evident in athletes who illicitly abuse anabolic androgenic steroids 
(Pagonis et al. 2006). However, conflicting studies also exist in which no relationship or an inverse 
correlation between androgens and mood disorders is shown (Rasgon et al. 2003, Adali et al. 2008). 
Additionally, many papers display an anxiolytic effect of testosterone (Hermans et al. 2007). 
Therefore, the relationship between mood disorders and androgens, and by extension PCOS, remains 
elusive.  
1.4 Diagnosis 
1.4.1 Establishment of PCOS Diagnostic Criteria 
As mentioned, there is controversy on the diagnosis of PCOS. The first attempt at establishing a set of 
diagnostic criteria for PCOS occurred at a conference by the National Institute of Health in 1990. This 
conference concluded that a diagnosis of PCOS could be reached if the patient displayed clinical or 
biochemical hyperandrogenism as well as oligo/anovulation in the absence of other causes for 
androgen excess and anovulation. Hyperandrogenism was considered the most important symptom. In 
the following years, concerns arose that the symptoms of PCOS were more variable than those that 
were put forward by the NIH. Therefore in 2003, a second conference discussing the diagnosis of 
PCOS was held by The European Society for Human Reproduction and Embryology and the 
American Society for Reproductive Medicine. This conference put forward the Rotterdam diagnostic 
criteria which stated that PCOS can be diagnosed if any two of the following three symptoms are 
present: hyperandrogenism, oligo/anovulation, and polycystic ovary morphology. Other disorders that 
cause hyperandrogenism and/or oligo/anovulation also need to be excluded. Finally, in 2006, the 
Androgen Excess Society put forward a diagnosis criterion in which clinical or biochemical 
hyperandrogenism is essential along with either oligo/anovulation or polycystic ovary morphology.  
1.4.2 Issues with PCOS Diagnosis 
There are a number of diagnostic issues concerning hyperandrogenism, oligo/anovulation, and 
PCOM. Firstly, the diagnosis of hirsutism is somewhat subjective. The severity of hirsutism is 




anatomic areas on a scale of 0 – 4. These scores are then pooled for an overall FG score. There is no 
consensus for what constitutes as an FG score denoting abnormal hair growth with scores of >3, >5, 
and >8 all being suggested (Ferriman and Gallwey 1961, Ferriman and Purdie 1983, DeUgarte et al. 
2006). Furthermore, it has been observed that there is a significant amount of variability in the FG 
scores assigned by different clinicians to the same women (Wild et al. 2005). Secondly, it is unclear 
whether acne occurs more often in PCOS patients compared with the general public as acne is 
prevalent in many adolescents and adults (Perkins et al. 2012). Alopecia can also occur for reasons 
other than androgen excess (St Pierre et al. 2010). Furthermore, both acne and hair loss scores are 
rarely recorded for PCOS women, making it hard to compare these symptoms between patients 
(Lujan, Chizen, and Pierson 2008). The diagnosis of biochemical hyperandrogenism is also subject to 
some level of inaccuracy as there are no universal agreements on the androgens that should be 
screened for (i.e. free serum testosterone, FAI, bioavailable testosterone, and SHBG), the time during 
the menstrual cycle at which androgens should be measured, the normal level of androgens in women, 
and the analytical techniques that should be used to measure androgens (Lujan, Chizen, and Pierson 
2008, Barth, Yasmin, and Balen 2007).  
Oligomenorrhoea is diagnosed when fewer than 8 menses occur per year and/or when menstrual 
cycles occur at intervals over 35 days. Amenorrhoea is diagnosed when 3 months have passed without 
the occurrence of menses or pregnancy. However, women who report normal menstrual cycling may 
still have ovulatory dysfunction (Norman et al. 2007). Therefore, ovulation must be confirmed by 
measuring progesterone levels during the luteal and visualising corpus lutea via ultrasonography. 
Inaccuracy can occur by measuring progesterone levels at incorrect times, and due to infrequent 
ultrasonography for the observation of corpus lutea (Lujan, Chizen, and Pierson 2008).  
PCOM is diagnosed when ovaries contain ≥12 preovulatory follicles measuring from 2mm to 9mm in 
diameter and/or if they have an ovarian volume exceeding 10mL (Rotterdam 2004). The identification 
of PCOM via ultrasonography is subjective and clinicians often do not agree on diagnoses of PCOM 
(Amer et al. 2002). Furthermore, PCOM is evident in many phenotypically normal women, which 
calls into question whether PCOM should be used as a diagnostic characteristic of PCOS (Polson et 
al. 1988, Clayton et al. 1992). 
There is no consensus on which method of diagnosis should be used in scientific research with most 
papers either using the NIH or Rotterdam criteria. The NIH diagnostic criteria may have limitations 
because it doesn’t account for the phenotypic variability of PCOS. The Rotterdam diagnostic criteria 
are limited by the fact that they result in a variety of subtypes of PCOS, one of which is 
oligo/anovulation coupled with PCOM and normal androgen levels. As PCOM occurs in many 
phenotypically normal women and HA is considered to be the most important feature of PCOS by 




The use of differing diagnostic criteria, and different PCOS subtypes as a result of the Rotterdam 
criteria, makes many scientific findings incomparable, and likely results in inaccurate conclusions in 
the literature. 
1.4.3 Lean and Obese PCOS Subtypes 
Obesity, IR, and abnormal LH levels are characteristics that occur in numerous PCOS women but not 
all. It has been observed that many obese PCOS women have IR with normal LH levels. Conversely, 
lean PCOS women tend to have better insulin sensitivity and elevated LH levels (Banaszewska et al. 
2003). This has led to the theory that there are multiple subtypes of PCOS, two examples being an 
obese, insulin resistant subtype and a lean subtype with increased LH levels. It has been proposed that 
the clinical features of PCOS come about via different mechanisms in these subtypes. In the lean 
subtype, HA and subsequent ovulatory dysfunction and PCOM come about due to an increase in LH-
induced steroidogenesis. In the obese phenotype, the clinical signs are due to increased androgen 
production by the action of insulin (Banaszewska et al. 2003). If it is true that different PCOS 
subtypes exist, the grouping of these subtypes in one overarching disorder likely confounds the results 
of scientific research. Therefore, a concerted effort made by the research community to standardise 
the PCOS diagnostic criteria is critical, and specification of formal PCOS subtypes may aid in this 
respect. 
1.5 Potential Contributing Risk Factors 
1.5.1 Lifestyle Factors 
Lifestyle factors that lead to weight gain such as high fat diets and physical inactivity increase the risk 
of exacerbating the hormonal and metabolic symptoms of PCOS. Furthermore, obesity in pre and 
peripubertal girls who are predisposed to PCOS may increase their risk of developing PCOS 
(Littlejohn et al. 2007). This concept is supported by studies showing that obese girls possess higher 
androgen levels compared with lean age matched girls (Reinehr et al. 2005, McCartney et al. 2007). 
Furthermore, HA in these obese girls decreased to normal levels following weight loss (Reinehr et al. 
2005).  
Diet quality may also have an impact on the development of PCOS and the severity of symptoms. 
Advanced glycated end products (AGEs), which are oxidative molecules prevalent in western food, 
have been observed at increased levels in lean, non-diabetic PCOS women (Diamanti-Kandarakis et 
al. 2005, Diamanti-Kandarakis et al. 2008). AGEs positively correlate with androgen and AMH 
levels, and have been shown to accumulate in the ovaries of rats (Diamanti-Kandarakis et al. 2005, 
Diamanti-Kandarakis et al. 2007, Diamanti-Kandarakis et al. 2009). Therefore, AGEs may have a 
direct effect on ovarian functioning in a manner that could increase the risk of developing PCOS 




inflammatory and pro-atherogenic cascades (Vlassara et al. 2002, Vlassara 2005, Uribarri et al. 2007). 
Therefore, elevated AGEs in PCOS women may increase their risk of developing secondary 
cardiometabolic symptoms. 
1.5.2 Environmental Factors 
1.5.2.1 Chemical Exposure 
There is some concern that the industrialism of modern society is resulting in increased exposure to 
harmful pollutants which could have an effect on fertility. One such compound is bisphenol A (BPA) 
which is utilised in the production of plastics and epoxy resins. BPA decreases activity of cytochrome 
p450 isoforms testosterone 2α-hydroxylase (T2AH) and testosterone 6α-hydroxylase, along with 
decreasing protein levels of cytochrome CYP2C11/6 and CYP3A2/1. This indicates that BPA may 
impact testosterone hydroxylation (Hanioka et al. 1998). BPA is also a SHBG ligand and has been 
shown to outcompete androgens for SHBG binding and increase FAI (Dechaud et al. 1999). BPA 
contamination has been detected in follicular fluid of women, and the concentration of BPA is 
significantly higher in phenotypically normal men and PCOS women (both obese and non-obese) 
compared with control women. BPA levels are also significantly higher in normal obese women 
compared with normal lean women. Furthermore, significantly positive correlations exist between 
serum BPA and free testosterone, total testosterone, androstenedione, and DHEAS (Takeuchi and 
Tsutsumi 2002, Takeuchi et al. 2004). These results could imply an increased risk of developing 
PCOS due to exposure to contaminants such as BPA, however, more research is needed. 
1.5.2.2 Foetal Exposure to Androgens 
Exposure to elevated levels of androgens in the womb may increase the chance of the offspring 
developing PCOS. The prenatal introduction of androgens in a range of animals results in a PCOS-
like phenotype in the offspring. Such offspring develop HA, hypersecretion of LH, oligoanovulation, 
PCOM, and impaired insulin sensitivity/IR. (Clarke, Scaramuzzi, and Short 1977, Robinson, 
Forsdike, and Taylor 1999, West et al. 2001, Recabarren et al. 2005, Eisner et al. 2002, Abbott, 
Tarantal, and Dumesic 2009, Foecking et al. 2005, Demissie et al. 2008, Wu et al. 2010). 
Additionally, prenatally androgenised (PA) sheep and monkeys show altered beta cell (Recabarren et 
al. 2005). PA monkeys and rats also display increased body weight (Demissie et al. 2008, Abbott, 
Tarantal, and Dumesic 2009).  PCOS women have significantly higher serum androgen levels 
compared with pregnant controls (Sir-Petermann et al. 2002, Falbo et al. 2010). Furthermore, 
daughters of women with PCOS are more likely to develop PCOS themselves (Kahsar-Miller et al. 
2001, Battaglia et al. 2002). Therefore, daughters of PCOS women could be at more risk of 
developing PCOS due to increased prenatal androgen exposure, although it is difficult to determine 




1.5.3 Genetic Factors 
There is strong evidence for a genetic component of PCOS as demonstrated by familial studies 
identifying the manifestation of PCOS in families (Legro et al. 1998, Kahsar-Miller et al. 2001). The 
mode of inheritance is complex. Initially an autosomal dominant pattern of inheritance was suggested, 
but it is now generally accepted that PCOS is a polygenic disorder (McAllister et al. 2015). Due to its 
genetic complexity, PCOS is likely caused by multiple genetic lesions complementing each other to 
produce an overall PCOS phenotype. It is also probable that different combinations of genetic lesions 
end up causing the PCOS phenotype in different families. 
Progress on the study of genetics in PCOS has been slow. This may be due to the fact that PCOS is 
considered by many in the genetics community to be a rather benign disorder when compared with the 
large number of seriously debilitating monogenic disorders; a situation which has substantially 
impacted on funding for PCOS genetics research. Furthermore, the differing methods of diagnosis, the 
probable existence of multiple PCOS subtypes, and the complexity of the PCOS mode of inheritance 
likely confound the results of some of the past genetic studies, hindering the successful identification 
of genetic lesions associated with PCOS. The fact that PCOS is a fertility disorder also decreases the 
effectiveness of traditional genetic studies, as the size of affected families is generally small. 
Therefore, the large extended multigenerational pedigrees that are needed to perform valid genetic 
linkage studies are not available. It is very likely that genetic makeup increases the risk of developing 
PCOS, but more research is vital; this topic and recent progress in the field of genetics of PCOS is 
discussed in detail in section 7. 
1.6 Treatment 
1.6.1 Non-Pharmacological Treatment 
Non-Pharmacological treatment of PCOS refers to treatment strategies that do not involve the 
administration of medicinal drug regimes. The first line of PCOS treatment is usually lifestyle 
modification in an effort to reduce body weight. This lifestyle modification involves dietary changes 
and/or exercise programs. Other non-pharmacological techniques such as acupuncture have been 
sought out for infertility treatment by PCOS patients, but more research is needed to confirm a 
beneficial role of these techniques. 
1.6.1.1 Dietary Modification 
The recommended diet for weight loss in women with PCOS is a hypocaloric, low saturated fat, 
increased mono- and polyunsaturated fat diet in which there is a 500-1000kcal/day reduction, 
consisting of less than 30% fats and less than 10% saturated fats, with increased consumption of fiber, 
whole-grain breads, cereals, fruits, and vegetables (Wild et al. 2010). When hypocaloric diets are 




circulating androgens, decreased basal β-cell response, decreased insulin levels (both basal and post 
glucose challenge), increased SHBG, an improved lipid profile, and alleviation of depression have 
been observed (Crosignani et al. 2003, Stamets et al. 2004, Moran et al. 2003, Gower et al. 2013, 
Thomson et al. 2010). Comparisons of hypocaloric regimes with either a high protein or high 
carbohydrate diet composition generally found negligible differences in the resulting alleviation of 
symptoms (Stamets et al. 2004, Moran et al. 2003). Therefore, it has been concluded that the most 
important dietary aspect of PCOS treatment is decreased caloric intake regardless of the dietary 
composition (Ravn, Haugen, and Glintborg 2013). However, hypocaloric, low glycaemic index diets 
have been observed to further improve insulin resistance and menstrual cycling compared with 
normoglycaemic diets (Marsh et al. 2010). Furthermore, consumption of walnuts has been shown to 
increase adiponectin and SHBG as well as increasing the insulin response during OGTT in PCOS 
patients (Kalgaonkar et al. 2011). However, more research is needed to determine whether certain diet 
compositions such as nuts and low glycaemic foods should be added to the hypocaloric dietary 
treatment of PCOS.  
1.6.1.2 Exercise 
PCOS patients undergoing exercise training have exhibited a decrease in visceral fat, decreased 
triglycerides, the return of normal menstrual cycling, improved cardiopulmonary functional capacity, 
improved autonomic function, improved inflammatory pattern, and improved serum testosterone and 
SHBG levels. (Giallauria et al. 2008, Hutchison et al. 2011, Roessler et al. 2013, Vigorito et al. 2007). 
Notably, decreased visceral fat and triglycerides only occurred in PCOS patients and not in 
phenotypically normal obese women undergoing the same exercise training  (Giallauria et al. 2008). 
The type of exercise does not seem to significantly impact the extent of symptom relief, with high 
intensity, moderate intensity, aerobic only, and aerobic combined with resistance training showing 
negligible differences in efficacy (Ravn, Haugen, and Glintborg 2013, Thomson et al. 2008). Exercise 
alone commonly did not affect hormone levels; only one study was found in which serum testosterone 
and SHBG levels improved with exercise-only treatment (Giallauria et al. 2008, Vigorito et al. 2007, 
Palomba et al. 2008). However, the use of diet and exercise together did result in hormonal benefits, 
along with improvements in body composition that were beyond that of diet alone (Thomson et al. 
2008, Thomson et al. 2010). Therefore, it is recommended that lifestyle management includes both a 
hypocaloric diet and exercise.  
1.6.1.3 Acupuncture   
The use of acupuncture in medicine is controversial because it is traditionally based on an ancient 
Chinese philosophy involving a type of energy flow (Qi) within the body. So called ‘disruption’ of 
this energy flow is said to lead to the manifestation of diseases, and the correction of this disruption 
through treatments such as acupuncture can supposedly treat these diseases. The ancient Chinese 




resulting from the use of acupuncture such as analgesic effects and increased β-endorphin levels 
(Mayer, Price, and Rafii 1977, Petti et al. 1998). Acupuncture is commonly sought out by PCOS 
patients for infertility treatment so investigation of this treatment is worthwhile. The effectiveness of 
acupuncture regarding the treatment of medical conditions is a source of debate in the scientific and 
medical communities. Nevertheless, some studies have observed PCOS women undergoing 
acupuncture treatment developing increased menstrual frequency, and decreased levels of total 
testosterone, free testosterone, and the glucuronidated androgen metabolite androstane-3alpha,17beta-
diol-17 glucuronide (17G) (Stener-Victorin et al. 2000, Jedel et al. 2011). Additionally, rats with 
PCOS induced by dihydrotestosterone, showed an increase in insulin sensitivity and improved ovarian 
morphology following acupuncture (Manneras et al. 2008, Manneras et al. 2009). It is hypothesised 
that acupuncture improves menstrual function by inducing an increase in β-endorphin, which affects 
the release of gonadotropin releasing hormone (GnRH) from the hypothalamus along with 
gonadotrophin from the pituitary. The decrease in plasma androgen levels seen in some PCOS women 
undertaking acupuncture is hypothesised to be the result of decreased sympathetic nerve activity 
induced by the placement of needles into areas that somatically innervate the ovaries and uterus 
(Chang, Chung, and Rosenwaks 2002, Stener-Victorin, Jedel, and Manneras 2008). More research 
needs to be undertaken to determine whether acupuncture does indeed improve some PCOS 
symptoms, and by what mechanisms. If acupuncture does incur some beneficial effects in PCOS 
patients, it could broaden treatment options in a number of ways. For example, acupuncture could be 
used in women unable to undertake pharmacological treatment due to side effects or drug resistance. 
Furthermore, acupuncture may be a more convenient option in PCOS women who find it difficult to 
adhere to a diet or exercise program. However, as of now, acupuncture remains too controversial and 
understudied to recommend in a clinical context. 
1.6.2 Pharmacological Treatment 
Although non-pharmacological treatment is effective, many PCOS women struggle with non-
compliance and those who do successfully complete a diet/exercise program tend to regain weight 
over time. Additionally, some patients do not respond to the treatment, or do not improve as much as 
desired (Rotterdam 2004, Poppitt et al. 2002, Thomson et al. 2010, Thomson et al. 2008). In these 
cases, pharmacological treatment can be utilised. Pharmacological treatment of PCOS refers to 
treatment options that involve the use of medicinal drugs. The most commonly used drugs for the 
treatment of PCOS are antiandrogens to combat the symptoms of hyperandrogenemia, the oral 
contraceptive pill for hormonal and menstrual normalisation, insulin-sensitisers to improve insulin 
sensitivity, and ovulation inducing medications to increase the chance of conceiving. 
1.6.2.1 Anti-androgens  
Anti-androgens are drugs that reduce the effect of androgens in the body by blocking the androgen 




HA i.e. hirsutism, acne, and androgenic alopecia. The most common antiandrogen used in PCOS 
treatment is Spironolactone. The mechanism of Spironolactone’s antiandrogenic effect involves 
antagonism at the androgen receptor, decreasing 5α reductase activity, and decreasing microsomal 
cytochrome p450 activity (Armanini et al. 1985, Menard, Stripp, and Gillette 1974, Adams et al. 
1985, Diamanti-Kandarakis, Tolis, and Duleba 1995). Spironolactone is effective at improving 
hirsutism and acne in PCOS women with varying success at treating androgenic alopecia (Zulian et al. 
2005, Sinclair, Wewerinke, and Jolley 2005). However, there are conflicting results on the capability 
of Spironolactone to improve circulating androgen levels, LH levels, and insulin sensitivity (Ganie et 
al. 2004, Armanini et al. 2007, Spritzer et al. 2000). Oligo/amenorrhoea can be treated using 
Spironolactone, but this often results in irregular bleeding between menstrual periods (metrorrhagia) 
(Zulian et al. 2005). Spironolactone also increases HDL-C and decreases blood pressure in some 
women, which could beneficial for PCOS women suffering from metabolic syndrome (Zulian et al. 
2005, Chapman et al. 2007). However, due to the variability of Spironolactone in treating a variety of 
PCOS symptoms, as well as the common side effect of metrorrhagia, medications such as the oral 
contraceptive pill and insulin sensitisers are usually utilised instead.  
Another known antiandrogen is cyproterone acetate. However, as well as being an anti-androgen, 
cyproterone acetate is also a progestogen (Diamanti-Kandarakis, Tolis, and Duleba 1995). Therefore, 
cyproterone acetate is almost always used in conjunction with oestradiol as an oral contraceptive. 
1.6.2.2 Oral contraceptive pill 
The oral contraceptive pill (OC) is the first line of pharmacological treatment in PCOS women who 
aren’t interested in becoming pregnant. OCs are generally composed of an oestrogen and a 
progestogen. Many different OCs exist with different types of oestrogens and progestogens at 
differing concentrations (Stewart and Black 2015). OCs alter the functioning of the hypothalamic-
pituitary-gonadal axis by suppressing the release of luteinising hormone and follicle stimulating 
hormone through the action of progestogen and oestrogen respectively. These effects result in the 
cessation of ovulation and therefore prevent conception (Crosignani et al. 1996). 
Apart from being a contraceptive, OCs also induce more predictable and less painful menstrual 
cyclicity, with a decreased volume and duration of bleeding (Dragoman 2014). These effects are 
evident in PCOS women, as increased regularity of menstrual cycles is exhibited after taking OCs. 
OCs are also beneficial in the treatment of HA as the oestrogen component of the drug increases the 
amount of SHBG in the circulation, resulting in a lower FAI (Wiegratz et al. 2003). However, the 
effect of OCs on HA is highly dependent on the type of progestogen used. Some older OCs utilise a 
progestogen derived from testosterone which can exacerbate androgenic symptoms such as hirsutism 
and acne (Dragoman 2014). Conversely, the progestogens drospirenone and cyproterone acetate have 
antiandrogenic properties. Treatment of PCOS utilising OCs containing drospirenone or cyproterone 




lipid and hormone profiles (Kriplani et al. 2010, Morin-Papunen et al. 2012, Gode et al. 2011). 
Drospirenone OCs can also decrease BMI and acne, improve blood pressure, and may also have 
insulin sensitising effects (Kriplani et al. 2010). 
1.6.2.3 Insulin sensitisers 
Insulin sensitisers refer to drugs that act on glucose metabolism pathways to increase sensitivity to 
insulin. Insulin sensitisers that have been shown to alleviate PCOS symptoms include Metformin, 
Thiazolidinediones, and d-chiroinositol, each of which increases insulin sensitivity via different 
mechanisms.   
Thiazolidinediones are agonists of the PPARγ receptor, the binding of which induces expression of 
multiple lipogenic genes. This leads to an insulin sensitising effect by improving fat metabolism, 
decreasing hepatic gluconeogenesis, and increasing glucose uptake (Phielix, Szendroedi, and Roden 
2011). Treatment of PCOS with Thiazolidinediones has been observed to improve insulin sensitivity, 
decrease LH levels and androgen levels, improve ovulatory function, increase pregnancy rate, 
decrease blood pressure, and normalise cholesterol levels (Cataldo et al. 2006, Li et al. 2011). 
However, Thiazolidinediones can be prone to side effects. Indeed, one brand of Thiazolidinediones 
(Troglitazone) was removed from the market due to increased incidence of hepatitis. Apart from liver 
toxicity, Thiazolidinediones can also increase cardiovascular and osteoporosis risk, induce weight 
gain, and possibly impact foetal growth (Grover and Yialamas 2011). Therefore, Metformin is 
commonly prescribed instead of Thiazolidinediones for the treatment of PCOS. 
Metformin exerts its insulin sensitising effect by inhibiting gluconeogenic enzymes, activating 
glycolytic enzymes, reducing the uptake of gluconeogenic substrates, and increasing phosphorylation 
of the insulin receptor and insulin receptor substrates (Ashokkumar and Pari 2005, Yuan, Ziegler, and 
Hamann 2003). Metformin also seems to decrease LH-induced steroidogenesis independent of its 
insulin sensitising actions (Kurzthaler et al. 2014). Treatment of PCOS women with metformin 
increases insulin sensitivity, decreases androgen levels, restores ovulatory function, and has 
favourable outcomes on the symptoms of metabolic syndrome and cardiovascular disease (Diamanti-
Kandarakis et al. 2010). However, live birth rate generally isn’t significantly improved by the use of 
metformin alone, and neither are the incidents of miscarriage (Balen et al. 2016). Initial 
gastrointestinal side effects are common with metformin use but usually disappear with time 
(Diamanti-Kandarakis et al. 2010). Additionally, unlike other insulin sensitisers, metformin may aid 
in the endeavour of weight loss (Naderpoor et al. 2015). Therefore, metformin is commonly the 
preferred insulin sensitising medication for PCOS treatment, but other methods such as clomiphene 
citrate may need to be considered for fertility treatment.   
The mechanism of insulin sensitisation by d-chiroinositol is not completely understood, but it acts on 




GLUT4 transporters to the cell surface (Ortmeyer et al. 1995, Brautigan et al. 2005, Yap et al. 2007). 
Therefore, d-chiroinositol has the potential to alter insulin metabolism in a variety of ways. Moreover, 
d-chiroinositol reduces the expression of steroidogenic enzyme genes CYP19A1 and CYP11A1, which 
has positive implications for treating HA (Sacchi et al. 2016). Indeed, treatment of PCOS women with 
d-chiroinositol results in decreased testosterone levels, along with decreased blood pressure, improved 
glucose metabolism, and increased frequency of ovulation (Nestler et al. 1999, Iuorno et al. 2002). 
Side effects are uncommon with d-chiroinositol treatment (Nestler et al. 1999, Iuorno et al. 2002). 
Therefore, d-chiroinositol may be a useful medication for insulin sensitisation in PCOS women who 
experience side effects from other insulin sensitising agents.  
1.6.3 Ovulation Induction 
The most commonly used medication for ovulation induction in PCOS women is clomiphene citrate. 
Clomiphene citrate is an anti-oestrogen which refers to a class of drugs that block or minimise 
oestrogen action in the body (Begum et al. 2013). Specifically, clomiphene citrate is a selective 
oestrogen receptor modulator, meaning that it exerts its antioestrogen effect via action on the 
oestrogen receptor. By binding to oestradiol receptors in the hypothalamus, clomiphene citrate alters 
the pulse frequency of GnRH and increases the release of FSH which results in enhanced follicular 
development (Balen et al. 2016). The use of clomiphene citrate restores ovulation in 50-80% of PCOS 
women and results in pregnancy in 40-50% of women (Begum et al. 2013). 20% of PCOS patients 
display clomiphene citrate resistance, but this resistance can be counteracted in many women by 
combining clomiphene treatment with metformin (Vandermolen et al. 2001, Begum et al. 2013).   
1.7 Genetic Tools for the Study of PCOS  
1.7.1 Candidate Gene Studies 
Until 2011, research into the genetics of PCOS was dominated by candidate gene studies. The first 
step in a candidate gene study is the identification of genes that could be involved in the aetiology of a 
disorder, usually based on existing knowledge of biochemical pathways that are relevant to clinical 
symptoms of the disorder. Following this, variants are identified in or near the gene that could alter 
the encoded protein or are in linkage disequilibrium (LD) with a variant that does. Finally, statistics 
are utilised to discover a difference in allele frequency between cases and controls or any correlations 
between the variants and the phenotype variation in the disorder (Tabor, Risch, and Myers 2002). 
Genes that are commonly focused on in candidate gene studies relating to PCOS are FSHβ, FSHR, 
LHCGR, FST, and INSR (Tong et al. 2000, Conway et al. 1999, Capalbo et al. 2012, Urbanek et al. 
1999, Du et al. 2014) due to their known roles in the female reproductive system and insulin 
biochemistry. The success of candidate gene analyses depends on the accuracy of the prior hypothesis 
identifying the genes to be studied. As the selection of candidate genes is determined through 




biased. Additionally, due to the complexity of PCOS, accurately selecting genes that are implicated in 
PCOS is likely a subject of error. Despite the publication of a substantial number of candidate gene 
studies in relation to PCOS, little genuine progress was made in the field; primarily due to a lack of 
statistical power, poor study design and failure to provide replication of findings.  
1.7.2 Genome Wide Association (GWAS) Gene Discovery 
A powerful method of identifying variants associated with genetic disease is the genome wide 
association study (GWAS). When carried out correctly, GWAS is free of bias and returns large 
amounts of data concerning variants that are prevalent in patients with genetic syndromes. GWAS 
involves genotyping common variants across the whole genome of a large number of cases and 
controls to identify SNPs associated with a specific trait (NIH 2007). Unlike many earlier 
methodologies such as candidate gene studies, GWAS is not limited to one or a few genes; 
conceptually all genes in the genome are surveyed. Likewise, GWAS is not limited to known genes 
and regulatory regions. However, a sufficient number of SNPs need to be genotyped so that the 
majority of common variants in the genome are captured. It has only been within the past six years 
that GWAS for PCOS have started to appear in the literature, the first relatively small study (n < 
10,000 individuals), being published in 2011 (Chen et al. 2011). Since then, four more GWAS, along 
with numerous replication studies, have been published identifying genes such as FSHR, LHCGR, 
THADA, DENND1A, YAP1 and INSR as containing variants with a statistically significant association 
with PCOS (Shi et al. 2012, Day et al. 2015, Hayes et al. 2015, Lee et al. 2015, Goodarzi et al. 2011, 
Goodarzi et al. 2012). This approach has provided valuable information on some of the genes and 
pathways involved in PCOS, however, the genes and variants reported to date explain only a small 
proportion of the heritability of PCOS. Nevertheless, larger studies are expected to be performed and 
these will almost certainly lead to improved knowledge on the aetiology of the disease. 
1.7.3 Next Generation Sequencing 
Next generation sequencing (NGS) is the most current method of DNA sequencing that can determine 
the sequence of a genome in a far more cost and time efficient manner compared to the previous 
methodology of Sanger sequencing. However, NGS is potentially more error prone, so findings made 
via NGS are usually confirmed using Sanger sequencing. For examples in Illumina-based technology 
platforms, the first step of NGS is the preparation of a DNA library from supplied genomic DNA 
(gDNA). gDNA is fragmented, and specialised adaptors are added to the fragment ends via ligation. 
The fragments are then loaded into a flow cell where they hybridise to the flow cell surface. Each 
fragment is amplified into clonal clusters in preparation for sequencing. Fluorescently labelled 
nucleotides are commonly utilised for sequencing, and every time a base is incorporated, the 
fluorescence from each cluster is measured and recorded. Once sequencing is complete, reads are 
aligned with a reference genome and loci where variation occurs are recorded (Figure 4). This process 




genome of an individual. Variants that are potentially associated with disease can be identified by 
sequencing the genome of many individuals with a shared disorder and looking for variants that are 
common between them.  
 
Figure 4: Illustration of the methodology of next generation sequencing used in Illumina technology 
platforms. 
An alternative and more cost effective NGS method is exome sequencing. Using this method, NGS 
sequencing is carried out on the exome of individuals rather than the whole genome. The exome 
consists of less than 2% of the genome and targets only the DNA sequence of genes that code for 
proteins; and generally captures and sequences the coding regions of the genes. Functional variants 
i.e. variants that result in changes to the resulting protein are present in this region of the genome. 
Therefore, exome sequencing can be used to identify possibly pathogenic functional variants in 
individuals with lessened time and money constraints compared with whole genome sequencing.  
1.7.4 Functional Genomics 
Functional genomics describes a variety of methodologies that seek to determine the relationship 
between genotype and phenotype. Variants discovered via GWAS or NGS that are hypothesised to be 
associated with disease are subjected to functional genomics to glean the phenotypic effects of the 
variants. Generally, functional genomics involves the study of transcription, translation, regulation of 
gene expression, and protein-protein interaction within cell lines to determine whether variants 




PCOS exist but are limited compared to the number of genetic studies that exist (McAllister et al. 
2014, Anjali et al. 2015, Xu et al. 2015, Zhao et al. 2015).  
 
1.7.5 Conclusions and Hypotheses 
Despite evidence for PCOS having a strong genetic component, genetic research has been slow to 
progress and this has hindered the understanding of PCOS aetiology. Exome sequencing and 
functional genomics are effective, modern methodologies for discovering disease-associated 
pathological variants and determining their effects on cell function. However, the use of these 
techniques in the study of PCOS has been sparse to date. Due to the tendency for PCOS to run in 
families, it is hypothesised that pathological variants involved with PCOS can be identified by exome 
sequencing affected family members in the WA PCOS cohort, and singling out those variants that are 
1) shared between affected family members, 2) are not present in unaffected family members and are 
rare in the general population, and 3) are predicted from bioinformatics modelling to be potentially 
pathogenic. Following this, the pathogenicity and mode of action of these variants could be confirmed 
via functional genomic techniques. With this hypothesis in mind, three aims were constructed for this 
thesis: 
1. Perform bioinformatics on new and previously exome sequenced PCOS families to identify 
variant/s that could be involved in PCOS which would be ideal for functional genomics 
investigation. 
2. Produce wildtype and mutant sequences in mammalian expression vectors and investigate the 
effects of the selected variant on substrate binding, as well as expression of intermediates in 
relevant biochemical pathways. 
3. Recruit approximately 6 PCOS women in familial pairs to add to the WA PCOS cohort and 
submit genomic DNA samples from those individuals for exome sequencing in order to 











2  GENERAL MATERIALS AND METHODS 
2.1 Materials and Reagents 
 
Table 2: General reagents 
Item Supplier 
Sodium Chloride (NaCl)  Bio-Strategy Laboratory Products, Australia 
Potassium Chloride (KCl) Bio-Strategy Laboratory Products, Australia 
Di-Sodium Hydrogen Orthophosphate, 
Anhydrous (Na2HPO4) 
VWR, Australia 
Potassium Phosphate Monobasic, Minimum 
99.0% (KH2PO4) 
Sigma-Aldrich, USA 
HEPES Sigma-Aldrich, USA 
Sodium Bicarbonate NaHCO3 Thermo Fisher Scientific, USA 
BactoTM Tryptone Pancreatic Digest of Casein  VWR, Australia 
BactoTM Yeast Extract VWR, Australia 
BactoTM Agar VWR, Australia 
Trizma® base Sigma-Aldrich, USA 
Tween® 20 Sigma-Aldrich, USA 
Glycine, Electrophoresis Grade MP Biomedicals, USA 
Sodium dodecyl sulfate (SDS) MP Biomedicals, USA 
Methanol Thermo Fisher, USA 
Absolute Ethanol Rowe Scientific Pty Ltd, Australia 
30% Acrylamide/Bis Solution 29:1 Bio-Rad, USA 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, USA 
Sodium deoxycholate Sigma-Aldrich 
 
Table 3: General Equipment 
Item Supplier 
0.3mL PCR tubes Axygen, USA 
1.7mL eppendorf tubes Axygen, USA 
Autoclave Atherton, Australia 
Compact Microwave Oven R20A0W Sharp, Japan 




Greiner 15mL centrifuge tube Sigma-Aldrich, USA 
Harvard Trip Mechanical Single Beam Balance 
Scale 2kg – 5lb 
Ohaus, USA 
Hoshizaki Ice Maker (Model FM-150KE) Hoshizaki, Japan 
Nanodrop One Thermo Fisher Scientific, USA 
Non-Sterile, Latex Gloves Ansell, USA 
Orbital 420 Centrifuge Clements Medical Equipment, Australia 
Parafilm Pechiney Plastic Packaging, USA 
PIPETMAN Neo Single Channel Pipettes (P2, 
P20, P200, P1000) 
Gilson Inc., USA 
Pipette tips (P2, P20/P200 & P1000) Bio-Rad, Australia 
Power PacTM 1000/500 Bio-Rad, USA 
Sartorius 1216MP Scientific Balance Sartorius, Germany 
Storage Freezer VIP Series (Model: MDF-
U76VC) 
Sanyo, Japan 
SW22 Shaking Water Bath Julabo Labortechnik, Germany 
Ultraviolet Transilluminator (UVT) 100 International Biotechnologies Inc., USA 
ChemiDoc XRS+ Bio-Rad, USA 
TGA-6 Centrifuge Kontron, Germany 
Roller Mixer Ratek Instruments, Australia 
Wide Mini-Sub Cell GT Bio-Rad, USA 
Mini SubTM DNA Cell Bio-Rad, USA 
VM1 Personal Vortex Mixer Ratek Instruments, Australia 
Rocker Unit RR9 Chiltern, USA 
labCHEM-pH Benchtop pH - mV - Temperature 
Meter 
TPS Instruments, Australia 
IKAMAG REO Stirrer Mixer Stirring Plate Drehzahl Electronic, Germany 
220/240V.AC. 50/60Hz. 4Amp Hot Pate Industrial Equipment & Control Pty Ltd, 
Australia 
Mini-PROTEAN Tetra System Bio-Rad, USA 
Certomat® R Benchtop Shaker B. Braun Melsungen, Germany 
 
Table 4: Peripheral Blood Sample Collection  
Item Supplier 




K2E (EDTA) Blood Collection Tube (10mL) Vacutainer, UK 
Medi-SwabsTM Smith and Nephew, Australia 




Table 5: DNA Extraction from Peripheral Blood Samples 
Item Supplier 
Mo Bio Ultraclean DNA Blood Isolation Non-
Spin Kit 
Mo Bio Laboratories, USA 
• Solution G1  
• Solution G2  
• RNase A  
• Solution G3  
• 100% Isopropanol  
• 70% Ethanol  
• Solution G4  
• 2.0ml Collection Tube  
 
Table 6: Polymerase Chain Reaction (PCR) 
Item Supplier 
HotStarTaq Plus DNA Polymerase Kit Qiagen, USA 
• 10X PCR Buffer  
• 25 mM Magnesium Chloride  
• 5X Q-Solution  
• dNTP mix (10mM)  
• HotStarTaq Plus DNA Polymerase  
AmpliTaq Gold® 360 DNA Polymerase kit ThermoFisher Scientific, USA 
• 10X AmpliTaq Gold 360 Buffer  
• 25mM MgCl2  
• AmpliTaq Gold 360 DNA Polymerase  
• 360 GC Enhancer  






Oligonucleotide Primers (EEF2K_ORF forward 
and reverse) 
Sigma-Aldrich, USA 
Oligonucleotide Primers (EEF2K internal 
reverse, EEF2K internal forward 1, EEF2K 
internal forward 2) 
Sigma-Aldrich, USA 




Table 7: Agarose Gel Electrophoresis  
Item Supplier 
6X Loading Dye Qiagen, USA 
1% Agarose Gel See appendix 
Ethidium Bromide Sigma-Aldrich, USA 
GelPilot 1Kb Plus Ladder Qiagen, USA 
1 Kb Plus Ladder ThermoFisher Scientific, USA 
 
Table 8: Reverse Transcription 
Item Supplier 
QuantiTect® Reverse Transcription Kit Qiagen, USA 
• gDNA Wipeout Buffer  
• Quantiscript® Reverse Transcriptase  
• Quantiscript RT Buffer  
• RT Primer Mix  
• RNase-free water  
 
Table 9: DNA extraction from bacterial samples 
Item Supplier 
Wizard® Plus SV Minipreps DNA Purification 
System 
Promega, USA 
• Cell Resuspension Solution  
• Cell Lysis Solution  
• Neutralization Solution  




• Wizard® SV Minicolumns  
• 2ml Collection Tubes  
• Alkaline Protease Solution  
• Nuclease-Free Water  
PureYield™ Plasmid Miniprep System Promega, USA 
• Cell Lysis Buffer  
• Neutralization Solution  
• Endotoxin Removal Wash  
• Elution Buffer  
• PureYield™ Minicolumns  
• PureYield™ Collection Tubes  
 
Table 10 Cloning 
Item Supplier 
PCR Cloning Kit Qiagen, USA 
• Ligation Master Mix, 2x  
• pDrive Cloning Vector  
• Distilled Water  
T4 DNA Ligase New England Bio Labs, USA 
T4 DNA Ligase Reaction Buffer New England Bio Labs, USA 
2xYT Media See appendix 
QIAEX II Agarose Gel Extraction Kit Qiagen, USA 
• Buffer QX1  
• QIAEX II  
• Buffer PE  
EcoRV Restriction Endonuclease Promega, USA 
XhoI Restriction Endonuclease Promega, USA 
Buffer D Promega, USA 
 
Table 11: Cell culture 
Item Supplier 
Dulbecco’s Modified Eagles Medium without 
L-glutamine (Liquid) 
Sigma Aldrich, USA 




Dimethyl Sulfoxide (DMSO)  
Foetal Bovine Serum (FBS) Invitrogen, USA 
Penicillin-Streptomycin Sigma Aldrich, USA 
GlutaMAXTM Thermo Fisher Scientific, USA 
Trypsin Sigma Aldrich, USA 
Phosphate Buffered Saline (PBS) See appendix 
Opti-MEM Thermo Fisher Scientific, USA 
LipofectamineTM 2000 Thermo Fisher Scientific, USA 
 
Table 12 Functional Genomics 
Item Supplier 
RIPA Buffer See appendix 
Protease Inhibitor Cocktail  
Pierce™ BCA Protein Assay Kit ThermoFisher Scientific, USA 
• BCA Reagent A  
• BCA Reagent B  
• Albumin Standard Ampules, 2mg/mL  
6x Loading Buffer  See appendix 
10% SDS-PAGE Separating Gel See appendix 
10% SDS-PAGE Stacking Gel See appendix 
Precision Plus ProteinTM Dual Color Standards Bio-Rad, USA 
Transfer Buffer See appendix 
Ponceau Stain  
Instant Skim Milk Powder Coles, Australia 
Anti-FLAG M2 Monoclonal Antibody  
Rabbit Polyclonal Antibody to eEF2 Cell Signaling Technology, USA 
Rabbit Polyclonal Antibody to Phosphorylated 
eEF2 (Thr56) 
Cell Signaling Technology, USA 
Anti-tubulin  
Tris Buffered Saline (TBS) See appendix 
Tris Buffered Saline Tween (TBST) See appendix 
Goat Anti-Mouse Horseradish Peroxidase 
Conjugated Antibody 
 






Western Lightning® ECL Pro Enhanced 
Chemiluminescence Substrate 
PerkinElmer, USA 
• Reagent A  
• Reagent B  
GammaBind G sepharose beads GE Healthcare Life Sciences, USA 
 
Table 13: Statistical and Other Software Packages 
Item Supplier 
Ensembl Genome Viewer Ensembl, UK 
University of California Santa Cruz (UCSC) 
Genome Browser 
UCSC, USA 
dbSNP Short Genetic Variations NCBI, USA 
R The R Foundation for Statistical Computing 
2.2 DNA Extraction from Whole Blood 
DNA was extracted from patient blood samples using the UltraClean® Blood DNA Isolation (Non-
Spin) Kit (Mo Bio Laboratories, USA) according to the manufacturer’s instructions. Following 
extraction, DNA was quantitated using a Nanodrop One (ThermoFisher Scientific, USA) via 
measurement of UV absorbance at 260nm. The Nanodrop was also utilised to determine the purity of 
the samples. A 260/280 ratio > 1.8 is indicative of low levels of contaminating protein. Similarly, a 
260/230 ratio > 2.0 is indicative of low levels of contaminating organic compounds such as those used 
in DNA extraction.  
2.3 Polymerase Chain Reaction 
2.3.1 Routine PCR 
Routine PCR was performed using HotStarTaq Polymerase (Qiagen, USA). PCR reactions were made 









Table 14: Components of routine PCR reactions 
Reagents Volume for 25 µl reaction (µl) 
10X PCR Buffer 2.5 
5x Q Solution 5 
10mM dNTP Mix 0.5 
10µM forward primer 1.25 
10µM reverse primer 1.25 
ddH2O 11.4 
HotStarTaq Polymerase 0.12 
 Total volume: 25µl 
 
PCR was carried out on a DYAD Peltier Thermal Cycler (Biorad, Hercules, USA) with the following 
cycling conditions (Table 15): 
Table 15: Cycling conditions for routine PCR 
Stage Step Temperature Time 
Holding Activation of 
polymerase 
95oC 5 minutes 
 
Cycling (35 cycles) 
Denaturation 95oC 30 seconds 
Annealing 63oC 1 minute 
Extension 72oC 1 minute 
Holding Final extension 72oC 7 minutes 
Holding Final hold 4oC ∞ 
 
2.3.2 High Fidelity PCR 
AmpliTaq Gold® 360 DNA Polymerase (ThermoFisher Scientific, USA) was used for amplifying 
fragments in which it was important that no incorrect bases were incorporated. Each 50µl PCR 









Table 16: Step 1 of making up AmpliTaq Gold® 360 reactions 
Reagents Volume required for 50µl reaction 
(µl) 
10X AmpliTaq Gold 360 Buffer 5µl 
25mM MgCl2 3µl 
10mM dNTPs (2.5mM each of dATP, dTTP, dGTP, 
dCTP) 
4µl 
AmpliTaq Gold 360 DNA Polymerase 0.25µl 
PCR-Grade Water 31.75µl 
 Total volume: 44µl 
 
The tubes were gently vortexed for 5 seconds to mix the components and centrifuged in an Orbital 
420 Centrifuge (Clements Medical Equipment, Australia) to eliminate air bubbles. Following this, 
DNA and primers were added as follows (Table 17): 
Table 17: Step 2 of making up AmpliTaq Gold® 360 reactions 
Reagents Volume required for 50µl reaction (µl) 
10µM Forward Primer 2µl 
10µM Reverse Primer 2µl 
50ng/µl cDNA 2µl 
 Total volume: 50µl 
 
The tubes underwent a quick spin in Orbital 420 Centrifuge before undergoing PCR in a DYAD 
Peltier Thermal Cycler with the following cycling conditions (Table 18): 
Table 18: Cycling conditions for AmpliTaq Gold® 360 PCR 
Stage Step Temperature Time 
Holding Activation of polymerase 95oC 5 minutes 
 
Cycling (30 cycles) 
Denaturation 95oC 15 seconds 
Annealing 60oC 30 seconds 
Extension 72oC 2.5 minutes 
Holding Final extension 72oC 7 minutes 





The amplified DNA products were run on a 1% agarose gel and examined using a Model UVT 400-M 
Ultraviolet Transilluminator (International Biotechnologies Inc., New Haven, USA) or a Chemidoc 
XRS+ imager (Biorad, Hercules, USA). 
2.3.3 Colony PCR 
Each colony PCR reaction was made up to 50µl using the HotStarTaq DNA Polymerase Kit. All 
reactions were carried out on ice as follows (Table 19): 
Table 19: Components of colony PCR reactions 
Reagents  Volume for 50µl reaction (µl) 
ddH2O  36 
10X PCR Buffer  5 
25mM MgCl2  3 
10mM dNTPs  1 
10µM forward primer   2 
10µM forward primer  2 
HotStarTaq Polymerase  1 
  Total volume: 50µl 
 
A small portion of bacterial colony was then added to each PCR reaction. PCR was carried out on a 
DYAD Peltier Thermal Cycler with the following cycling conditions (Table 20): 
Table 20: Cycling conditions for colony PCR 
Stage Step Temperature Time 
Holding Activation of polymerase 95oC 5 minutes 
 
Cycling (35 cycles) 
Denaturation 95oC 1 minute 
Annealing 54oC 1.5 minutes 
Extension 72oC 1 minute 
Holding Final extension 72oC 5 minutes 
Holding Final hold 4oC ∞ 
  
Following PCR, the samples were run on a gel alongside a 1kb+ ladder (ThermoFisher Scientific, 
USA) to screen for the desired DNA fragment. Gels were imaged using a ChemiDoc XRS+. If the 
desired fragments were present, the leftover XL2-Blue colony was inoculated into 2xYT broth for the 





2.4 Isolation of cDNA 
2.4.1 Reverse Transcription 
RNA was extracted from breast tissue before the commencement of this project using the RNEasy 
Mini Kit (Qiagen, USA) as per the manufacturer’s instructions. cDNA for utilisation in cloning was 
obtained from breast tissue RNA using the QuantiTect Reverse Transcription Kit (Qiagen, USA) 
according to the manufacturer’s instructions. Samples were incubated at 42oC for 2 minutes using the 
DYAD Peltier Thermal Cycler for the genomic digestion of DNA step. Samples were later incubated 
at 42oC for 15 minutes for the reverse transcription step and 95oC for 3 minutes to halt the reaction. 
The presence of cDNA was confirmed via PCR using AmpliTaq Gold® 360 DNA Polymerase.  
2.5 Cloning 
2.5.1 Production of XL2-Blue Competent Cells 
E.coli XLI-Blue cells were grown in 10ml of 2xYT broth containing 100µl of 5mg/ml of tetracycline 
for a final concentration of 50µg/ml. 5ml of this culture was inoculated into a conical flask containing 
500ml of 2xYT medium, lacking antibiotics. The culture was grown at 37oC for 3 – 4 hours on a 
Certomat® R Benchtop Shaker, shaking at 200rpm. The optical density was determined using an 
Ultraspec 10 Cell Density Meter (GE Healthcare Life Sciences, USA) at a wavelength of 600nm. 
Once the culture reached an optical density between 0.5 and 0.7, it was distributed between two 
500ml centrifuge bottles (Sigma-Alrdich, USA). The tubes were centrifuged at 4000rpm for 10 
minutes at 4oC. The supernatant was removed and each bacterial pellet was resuspended in 500ml ice-
cold 100mM MgCl2 then incubated on ice for 20 minutes. The cell suspension was centrifuged at 
4000rpm for 10 minutes at 4oC. The supernatant was removed and each bacterial pellet was 
resuspended in 50ml of ice-cold 100mM CaCl2. The solution was mixed and incubated on ice for 20 
minutes. The CaCl2 solution was centrifuged at 4000rpm for 10 minutes at 4oC, after which, the 
supernatant was removed. The bacterial pellets were added to 22ml ice-cold 14% glycerol/100mM 
CaCl2 and the cell suspension distributed as 650µl aliquots into Eppendorf tubes. These aliquots were 
frozen at -80oC for future use. 
2.5.2 Ligation of cDNA into pDrive and pcDNA3.1 Plasmids 
Two plasmids were used throughout this project: the pDrive TA Cloning Vector (Qiagen, USA) and 
pcDNA3.1(+) (ThermoFisher Scientific, USA). cDNA was ligated into pDrive using the PCR Cloning 
Kit according to the manufacturer’s instructions with the following exceptions: the ligation reactions 
were incubated at 15oC overnight instead of for 30 minutes. Additionally, a control containing ddH2O 




Prior to cloning into pcDNA3.1, the cDNA and the vector were digested with restriction enzymes 
XhoI and EcoRV (Promega, USA) as follows: a variable volume of DNA was added to 1µl XhoI, 1µl 
EcoRV, and 5µl Buffer D (Promega). ddH2O was then added to the reaction to make it up to 50µl. 
The reactions were incubated at 37oC for 1 – 5 hours depending on the amount of DNA used. The 
products were then run on a 1% agarose gel and the correct bands were excised using a scalpel. DNA 
was extracted using the Qiagen QIAEX II Agarose Gel Extraction Kit as per the manufacturer’s 
instructions. The extracted cDNA and vector then underwent ligation. The following equation was 
utilised to determine the amount of cDNA needed in the ligation reaction: 
 
The molar ratio used was 5. The ligation reaction was set up by adding the appropriate volume of 
cDNA and vector, along with 1µl T4 DNA Ligase and 1µl of T4 Buffer (New England Bio Labs). A 
control was produced using ddH2O instead of cDNA. Both the test and control were incubated at 15oC 
overnight. Following incubation, the ligatants were ready for transformation into XL2-Blue competent 
cells. 
2.5.3 Transformation 
XL2-Blue competent cells were thawed gently on ice. Once thawed, the DNA intending to be 
transformed was added to 200µl of XL2-Blue cells. For purified plasmid DNA, a 1 in 20 dilution was 
performed and 5µl was added to the competent cells. For ligatants, 5µl of neat DNA was added to the 
competent cells. Samples were incubated for 30 minutes on ice. They then underwent heatshock by 
being incubated at 42oC for 90 seconds. The samples were placed back on ice for 2 minutes and were 
then added to 800µl of 2xYT media. The samples then underwent incubation at 37oC for 1 hour on a 
B Braun Certomat® R Benchtop Shaker (B. Braun Melsungen, Germany) set at 200rpm. Following 
incubation, a volume up to 200µl of cells was spread onto a 2xYT plate containing ampicillin. If a 
volume of cells lower than 200µl was used, 2xYT media was added to make the volume up to 200µl. 
The plates were incubated at room temperature for 30 minutes before being inverted and incubated at 
37oC for 16 -  21 hours. The resulting bacterial cultures was then screened for the presence of 
transformed DNA via colony PCR or by inoculating the bacteria into a broth and extracting the DNA. 
2.5.4 DNA Extraction from Broth Cultures 
10ml 2xYT media was added to 50ml Greiner centrifuge tubes with 20µl 50 mg/ml ampicillin (final 
concentration 0.1 mg/ml). Single XL2-Blue colonies were dispersed into the tubes which were then 
incubated at 37oC for 16 – 21 hours on a Certomat® R Benchtop Shaker at 200rpm. DNA was then 
extracted from the 2xYT media using either the Wizard® Plus SV Minipreps DNA Purification 
System (Promega, USA) or the PureYield™ Plasmid Miniprep System (Promega, USA). The 




work. Following DNA extraction, the products were run on a 1% agarose gel alongside a 1kb+ ladder 
and viewed in either a Model UVT 400-M Ultraviolet Transilluminator or a ChemiDoc XRS+ to 
determine whether the correct DNA fragments were present. 
2.5.5 Sanger Sequencing 
Sanger Sequencing was performed to check that the cloned sequences were correct. 600 – 1500ng of 
DNA is required for Sanger sequencing along with 9pmol of primer. Therefore, Sanger sequencing 
reactions were made up by adding the required volume of DNA and primer to reach these 
requirements. Enough ddH2O was then added to the reaction to make it up to 12µl. Eppendorf tubes 
were sealed with Parafilm M wax (Bemis Company Inc., Neenah, USA) to prevent evaporation and 
leakage of the samples. The samples were then sent to the Australian Genome Research Facility 
(AGRF) – Perth to undergo Sanger sequencing.  
 
2.6 Cell Culture 
2.6.1 Thawing of Frozen Mammalian Cell Stocks 
The appropriate media was prewarmed in a 37oC water bath for ≥20 minutes before commencing cell 
thawing. The cryovial/s of cells were removed from liquid nitrogen and placed in the 37oC water bath 
until thawed. Cells were then added immediately to 10ml of prewarmed media. The cell suspension 
was spun in an Orbital 900 centrifuge (Clements, Australia) at 1200rpm for 2 minutes. The media was 
aspirated, leaving the cell pellet undisturbed. The cell pellet was then resuspended in fresh medium 
and distributed between 25cm2 and 75cm2 flasks depending on the cell density and the requirements 
of future experiments. 
2.6.2 Passaging of mammalian cell lines 
Media was aspirated from the flasks and the cells were washed using 1x phosphate buffered saline 
(PBS). The PBS was aspirated, and prewarmed 1x trypsin was added to the flasks. The flasks were 
incubated at 37oC with 5% CO2 for approximately 5 minutes until the cells began to lift sufficiently 
from the base of the flask. Media containing 10% foetal bovine serum (FBS) was then added to the 
flasks to inactivate the trypsin. The cell suspension was spun in an Orbital 900 centrifuge at 1200rpm 
for 2 minutes. The cell pellet was then resuspended in fresh medium and the cells added to 25cm2 
and/or 75cm2 flasks depending on the cell density and the requirements of future experiments.  
2.6.3 Maintenance of Mammalian Cell Lines 
Cells were grown in the appropriate media at 37oC with 5% CO2. Human embryonic kidney cells 
(HEK293) and human embryonic kidney cells containing the SV40 large T antigen (HEK293FT) 




lacking glutamine, supplemented with 2mM GlutaMAXTM (ThermoFisher Sciences, USA). All 
culture media were supplemented with 10% FBS and 1% penicillin and streptomycin. The media was 
changed every 3-4 days for all cell types and their growth was monitored with an inverted-phase-
contrast-microscope. 
2.6.4 Freezing Mammalian Cell Lines 
Cells were frozen down periodically to maintain the laboratory supply. Cells were washed with PBS 
and trypsinised before being centrifuged at 1200rpm for 2 minutes. The medium was then aspirated 
and cells were resuspended in ‘freeze down media’ containing 65% of the appropriate medium, 25% 
FBS, and 10% Dimethyl sulfoxide (DMSO). The cell suspension was added to cryovial tubes in 1ml 
aliquots. The cryovials were frozen slowly by being placed in a polystyrene container at -80oC for 
approximately 3 days before being stored in liquid nitrogen. 
2.6.5 Transfection of Mammalian Cells 
Transfections were carried out in 75cm2 flasks or 25cm2 flasks depending on the intended use of the 
transfected cells. Reactions containing one volume of Opti-MEM and varying amounts of DNA 
depending on the experiment were set up. Following this, reactions containing one volume of opti-
MEM and lipofectamine 2000 were produced and incubated at room temperature for 5 minutes. The 
amount of lipofectamine added to each reaction was always double the amount of DNA being used.  
The lipofectamine suspensions were then added to the corresponding DNA reactions and were 
incubated at room temperature for 20 minutes. In the meantime, cells were washed with PBS. After 
incubation, the lipofectamine-DNA mixtures were added to the corresponding flasks of cells along 
with the appropriate media containing 10% FBS (no antibiotics). Cells were incubated at 37oC with 
5% CO2 for 5 – 7 hours after which the media was aspirated and replaced with the appropriate media 
containing 10% FBS and 1% penicillin and streptomycin. The cells were then incubated at 37oC with 
5% CO2 for 40 – 48 hours. 
2.7 Functional Genomics 
2.7.1 Western Blot 
2.7.1.1 Cell Lysis 
Cells were washed with PBS and then put on ice to prevent protein degradation. RIPA buffer 
containing protease inhibitors was added to each flask to lyse the cells. Lysed cells were detached 
from the base of the flask using a cell scraper and transferred to pre-chilled 1.5ml Eppendorf tubes. A 
BD precision glide needle 25G (ThermoFisher Scientific, USA) attached to a 1mL tuberculin syringe 
(ThermoFisher Scientific, USA) was used to mix and improve cell lysis. The Eppendorf tubes were 




chilled Eppendorf tubes. The supernatant was either frozen for future use or underwent immediate 
preparation for blotting. 
2.7.1.2 Protein Quantitation 
Protein quantitation was performed using the Pierce™ BCA Protein Assay Kit (ThermoFisher 
Scientific, USA) as per the manufacturer’s instructions in a Sarstedt 96 well plate. Protein 
concentration was determined using a POLARstar Optima microplate reader (BMG LABTECH, 
Ortenberg, Germany).  
2.7.1.3 Gel Run and Blotting 
Following protein quantitation, the samples were combined with 6x SDS sample loading buffer and 
boiled for 5 minutes before being run on a 10x SDS-PAGE gel (70µg of protein in each well). A 
Precision Plus ProteinTM Dual Color Standards protein marker (Biorad, Hercules, USA) was run at the 
same time. A current of 80V was run through the gel for approximately 15 minutes until the samples 
migrated through the stacking gel. The current was then changed to 180V until the protein had 
migrated to the desired position in the gel. Following this, the gel was blotted onto a nitrocellulose 
membrane as described in Figure 5. Transfer was performed using a BioRad Mini Trans-blot 
electrophoretic at 32V overnight and then 70V for 1 hour the next morning. 
 
Figure 5: Set up of the western blotting apparatus. 
2.7.1.4 Ponceau Staining 
In order to visualise whether the blotting was successful, a Ponceau stain was carried out on the 
membrane. The membrane was washed with ddH2O and then placed in a container. Enough Ponceau 
stain was added to cover the membrane which was then incubated at room temperature for 5 minutes. 
The Ponceau stain was removed and the membrane was washed with ddH2O to remove any residual 





Figure 6: Nitrocellulose membrane post Ponceau staining with protein stained red. 
2.7.1.5 Immunodetection 
Once the presence of protein was confirmed via Ponceau staining, antibody probing could be carried 
out. The membrane was placed in a 50ml Falcon tube containing 10ml of blocking buffer consisting 
of Tris-buffered saline (TBS) with 3-5% skim milk powder. The samples were then incubated at room 
temperature with gentle agitation on a Ratek Instruments Roller Mixer for 1 hour. Following this, the 
blocking buffer was removed and 5ml of new blocking buffer, or 5ml of Tris-buffered-saline Tween 
(TBST) with 5% bovine serum albumin (BSA) was added depending on the antibody being used. 
Approximately 1ul of anti-FLAG M2 monoclonal antibody or anti-tubulin antibody was added to the 
5ml blocking buffer. 5µl rabbit polyclonal antibody to eEF2 or phosphorylated eEF2 (Thr56) antibody 
was added to 5ml TBST + 5% BSA. Anti-FLAG M2 monoclonal antibody and anti-tubulin antibodies 
were incubated for 1 – 1.5 hours at room temperature with gentle agitation. Rabbit polyclonal 
antibodies to eEF2 and phosphorylated eEF2 (Thr56) were incubated overnight at 4oC with gentle 
agitation on a Ratek Instruments Roller Mixer. The blocking buffer/TBST + 5% BSA was then 
removed and the membrane was washed with 15ml of TBS or TBST three times for 5 minutes. The 
TBS or TBST was replaced with 10ml blocking buffer with approximately 1ul of secondary antibody 
and incubated at room temperature for 1hr on a Ratek Instruments Roller Mixer. Anti-FLAG M2 
monoclonal antibody and anti-tubulin antibodies utilised a goat anti-mouse horseradish peroxidase 
conjugated antibody. The Rabbit polyclonal antibodies to eEF2 and phosphorylated eEF2 (Thr56) 
utilised a goat anti-rabbit horseradish peroxidase conjugated antibody. The membrane was once again 
washed with 15ml of TBS or TBS-tween for 5 minutes a total of 3 times. Following this, the 
membrane could be stored in TBS at 4oC or proceed directly with imaging.  
2.7.1.6 Membrane Imaging 
PerkinElmer Western Lightning® ECL Pro Enhanced Chemiluminescence substrate was prepared 
according to the manufacturer’s instructions. The prepared ECL substrate was then pipetted over the 
nitrocellulose membrane and incubated for 1 minute at room temperature. Imaging of the 





2.7.2.1 Preparation of Samples 
Cell lysis and protein quantitation were performed as explained previously (sections 5.1.1 and 5.1.2). 
The appropriate volume of lysate to yield 3 mg of protein was made upto a final volume of 1ml with 
RIPA buffer containing protease inhibitors.  
2.7.2.2 Washing Beads and Preclearing  
350µl of GammaBind G sepharose beads were added to two Eppendorf tubes along with 1ml of RIPA 
buffer for washing. The Eppendorf tubes were centrifuged for 1 minute at 14000rpm at 4oC and the 
supernatant was removed. This was repeated with 750µl RIPA buffer. The beads were then pooled in 
one Eppendorf tube with 500µl RIPA buffer and centrifuged for 1 minute at 14000rpm at 4oC. The 
supernatant was removed and a volume of RIPA buffer equal to the volume of beads was added. 80µl 
of this solution was distributed into Eppendorf tubes, giving ~40µl of beads in each tube.  The tubes 
were centrifuged for 1 minute at 14000rpm at 4oC and the supernatant removed. In order to preclear 
the lysates they were then added to the beads and mixed gently before being incubated at 4oC on a 
Ratek Instruments Roller Mixer for 2 hours.  Samples were centrifuged for 2 minutes at 14000rpm at 
4oC and the supernatant was added to new, pre-chilled Eppendorf tubes. 5µl of anti-FLAG M2 
monoclonal antibody was added to appropriate samples which were then incubated at 4oC overnight 
on a Ratek Instruments Roller Mixer. The next day, new beads were washed with RIPA buffer 
containing protease inhibitors and distributed into new pre-chilled Eppendorf tubes as previously 
outlined. Samples were then added to the new beads and incubated at 4oC with gentle agitation for 4 
hours. 
2.7.2.3 Washing and Elution of Beads 
Following the 4 hour incubation, the samples were centrifuged for 2 minutes at 2500rpm at 4oC. The 
supernatant was removed and 1ml RIPA buffer + protease inhibitors was added. The samples were 
mixed well and placed on a Ratek Instruments Roller Mixer for 1 minute at 4oC. Samples were then 
centrifuged for 1 minute at 2500rpm at 4oC. This was repeated 6 more times for a total of 7 washes.  
Post washing, all traces of supernatant were removed and 40µl of 2x sample elution buffer was added 
to each tube. The samples were mixed well and centrifuged at 14000rpm for 5 minutes at room 
temperature. All traces of supernatant was removed and added to fresh Eppendorf tubes. Samples 
were boiled for 5 minutes and loaded onto a 10% SDS -PAGE gel with a Precision Plus ProteinTM 
Dual Color Standards protein marker.  The gel was run at 80V for approximately 15 minutes and then 
at 180V until the protein had migrated sufficiently through the gel. Blotting, probing, and imaging 






3 IDENTIFICATION OF PUTATIVE CAUSAL 
MUTATIONS IN THE EXOME SEQUENCE 
OF INDIVIDUALS WITH PCOS. 
3.1 Introduction 
Whole-exome sequencing refers to the technique used to determine the DNA sequence of exonic 
regions of the genome. The exome makes up approximately 2% of the genome and is made up of 
genes which code for proteins (Schnekenberg and Nemeth 2014). Pathogenic mutations that alter 
protein structure and /or function are present in this region of the genome. Exome sequencing is more 
efficient and cost effective than whole genome sequencing because it eliminates the work needed to 
sequence the whole genome while still detecting the majority of pathogenic functional variants 
(Schnekenberg and Nemeth 2014). Therefore, exome sequencing is ideal for screening for functional 
missense variants and small insertion or deletion (INDEL) mutations. As there are likely to be many 
functional variants involved with the PCOS disease state (i.e. multiple genes are implicated and there 
are likely to be multiple mutations with each gene), exome sequencing is ideal for the genome-wide 
identification of functional variation, along with private mutations, that may implicated in PCOS 
aetiology.  
Whole-exome sequencing is also vastly more efficient and cost effective compared with time-
honoured approach of Sanger sequencing, as it requires less time to yield results and the analysis is 
conducted at scale rather than on the basis of a single exon being studied in each experiment 
(Singleton 2011). However, whole-exome sequencing can be more error-prone than Sanger 
sequencing, so findings need to be confirmed through additional means (Patel et al. 2014). The Sir 
Charles Gairdner Keogh Institute possessed exome sequencing data from 5 families with PCOS that 
had not yet undergone bioinformatic analysis. Therefore, it was an aim of this study to perform 
bioinformatic analysis on these samples and identify functional variant/s that may be involved in 
PCOS. Particularly, we aimed to identify a functional variant that would be ideal for functional 






3.2 Materials and Methods 
3.2.1 Sample Preparation and Exome Sequencing by Australian Genome 
Research Facility (AGRF)  
Eleven participants belonging to 5 families with familial PCOS were chosen to undergo exome 
sequencing. Three families consisted of affected mother daughter pairs, one family consisted of a pair 
of affected sisters, and the final family consisted of a mother and her two daughters who were all 
diagnosed with PCOS (Family 1: samples designated as Q1857 and Q1895; Family 2: Q1886 and 
Q1889; Family 3: Q1945 and Q1959; Family 4: Q1978, Q2023, and Q2025; Family 5: Q2030 and 
Q2048, respectively).  These individuals were recruited previously by the Keogh Institute of Medical 
Research, and their DNA samples were sent to AGRF for exome sequencing before the 
commencement of this project. Their diagnosis was confirmed by Professor Bronwyn Stuckey using 
the NIH PCOS diagnostic criteria (Zawadski and Dunaif 1992). In brief, whole blood was taken from 
each individual via venipuncture and DNA was extracted using the QIAamp Blood Midi Kit (Qiagen, 
USA) as per the manufacturer’s instructions. At the time, AGRF required DNA samples undergoing 
exome sequencing to be greater than 100 ng/µl. The DNA samples extracted from patients’ blood 
were quantified using the Qubit 2.0 Fluorometer (Invitrogen, USA) and their concentrations were 
determined to be in excess of 100ng/µl. DNA samples in excess of 200 ng/µl were diluted using 
sterile water to reach a final concentration of 100ng in 45µl. 4µl of each DNA sample with 2 µl of 5X 
loading dye underwent gel electrophoresis on a 2% agarose gel against a GelPilot 1kb Plus DNA 
Ladder (Qiagen, USA). A photographic image of the gel was taken using a Polaroid camera which 
was then uploaded to the AGRF website as a quality control measure. Genomic DNA samples that 
passed quality control measures were aliquoted (45µl) into 1.7ml Eppendorf tubes (Axygen, USA). 
Parafilm was used to seal the top of the Eppendorf tubes to prevent evaporation of the samples. The 
samples were sent to the AGRF Medical Research Facility (MRF) in Perth to undergo exome 
sequencing. Once at AGRF, the exomes underwent sequencing using the SureSelectXT Human All 
Exome v5 (Agilent, USA) capture protocol. Next generation sequencing (NGS) was performed using 
a HiSeq 2500 (Illumina Inc., USA). Reads were aligned to the hg19 reference sequence and data 
generated from all samples were returned as .FASTQ, .BAM, and .TXT file formats for analysis. 
These data files were available at the commencement of this research project.  
3.2.2 Bioinformatics analyses 
The C programming language and R statistical software were used for the bioinformatics analysis of 
the exome sequencing results that were supplied by AGRF. As the purpose of this project was to 
identify functional variants, the data from exome sequencing were first filtered to include only 
missense variants that were predicted to be pathogenic, along with INDEL mutations in the form of 




The pathogenicity of missense variants can be predicted using PolyPhen-2 and Sorting Tolerant from 
Intolerant (SIFT) scores. PolyPhen-2 and SIFT are free online programs that predict the pathogenicity 
of a missense mutation based on the possible effects of the mutation on protein stability and function, 
along with the degree of evolutionary conservation of the surrounding sequence. Both programs give 
the mutation a score between 0 and 1 denoting the possibility of the variant to be deleterious. 
PolyPhen-2 ranges from 0 (being benign) to 1 (being probably damaging) (Figure 7a). Conversely, 




Figure 7: Examples of the pathogenicity predictions for an example pathogenic single nucleotide 
variant (SNV) from (a) PolyPhen-2 and (b) SIFT. 
The exome data from AGRF includes PolyPhen-2 and SIFT scores for each mutation where these are 
available. An analysis pipeline was constructed, which included the ‘awk’, ‘cat’ and ‘grep’ command-
line utilities and scripts written to run under the R program (see Appendix section 8.3). Applying this 
pipeline to the exome data resulted in the generation of a spreadsheet of filtered results for each 
family that: 1) displayed all frameshift, stoploss, stopgain, and missense variants that had a PolyPhen-
2 score >0.95 and a SIFT score <0.5, and 2) were common between family members. The genes that 
contained the resulting predicted pathogenic variants were then assessed for a role in reproductive 
physiology.  This was done by entering the gene names into the Mouse Genome Informatics (MGI) 
online database. Through this method, we were able to determine whether dysfunction of these genes 
in mice caused physiological consequences that align with PCOS symptoms. The physiological 
consequences that were of most interest were reproductive phenotypes that involved impaired 
folliculogenesis, reduced fertility, and polycystic ovary morphology. Endocrine abnormalities 
involving androgens and insulin were also searched for. All pathogenic variants occurring in genes 
causing symptoms relevant to PCOS in mouse knock-outs reported by MGI, were selected for 
examination. These genes then underwent further research to determine which ones were most likely 
to result in a PCOS disease state in the event of a pathogenic mutation. Sequencing pileup data was 
visualised using the Integrative Genomics Viewer (IGV) software to make sure identified mutations 





Seven potentially pathogenic SNVs were identified in total (Table 21). These SNVs conformed to the 
following criteria: 1) were predicted to be pathogenic, 2) were present in all members of at least one 
family, 3) mutation of the corresponding gene in mice caused reproductive system symptoms that 
could be related to PCOS aetiology and 4) the corresponding gene was expressed in the ovary.  
Table 21: Details of potentially pathogenic variants were identified from 5 PCOS affected families 
through exome sequencing. 












rs71745629 1: 204159612 Stoploss KISS1 T/- Met/- N/A* N/A* 0.22 
rs34973695 1: 158612756 Missense SPTA1 G/A Leu/Phe 1 0.03 0.01 
rs143321413 16: 22295277 Missense EEF2K A/G Tyr/Cys 1 0 <0.01 
rs2228262 15: 39882178 Missense THBS1 A/G Asp/Ser 0.997 0.01 0.04 
rs6756629 2: 44065090 Missense ABCG5 G/A Arg/Cys 0.996 0.02 0.07 
rs34075341 9: 91616843 Missense S1PR3 G/A Arg/Glu 1 0.03 0.03 
rs34879202 7: 21882209 Missense DNAH11 G/A Arg/His 1 0.03 <0.01 
                         * Stoploss mutations are generally considered to be pathogenic, but are not modelled by Polyphen2 or SIFT.  
 
IGV software revealed between 8 to 83 high quality reads for all mutant alleles, meaning all mutations 
were genuine as opposed to being artefacts (Figure 8). 
 
Figure 8: Sequence data for rs71745629 in individual Q1959 visualised with IGV software. 13 reads 
of the mutant deletion and 11 reads of the wildtype T allele are evident, confirming the presence of 






The goal of the performed bioinformatics analysis was to identify pathogenic SNV likely to be 
involved in the aetiology of PCOS, which would be of interest for a functional genomics study. For 
this reason, the seven identified pathogenic SNV were subjected to further research. This allowed for 
prioritisation and determination of the SNV most likely to cause a PCOS phenotype in humans, 
thereby being be the best variant to investigate via functional genomics.  
3.4.1 SNVs that are least likely to play a role in PCOS 
Variants were discounted as being likely to have a role in PCOS based on a few criteria. Firstly, SNV 
occurring in genes that are not convincingly involved in ovarian function, steroidogenesis, or glucose 
metabolism are less likely to be involved with PCOS. Secondly, genes are very unlikely to be 
involved in PCOS if they contain pathogenic variants proven to cause disorders other than PCOS (or 
similar syndromes e.g. hypogonadotropic hypogonadism). Lastly, SNVs that do not have a minor 
allele frequency (MAF) below 0.05 are predictably not rare enough to be highly penetrant disease 
causing SNV. 
3.4.1.1 rs71745629 (KISS1) 
Rs71745629 is a stoploss present in the KISS1 gene which has a critical role in the reproductive 
system and the onset of puberty (Kuohung and Kaiser 2006). Knockout of Kiss1 in mice results in 
absent ovarian follicles, absent corpus luteum, decreased ovary weight, ovary cysts, abnormal vagina 
epithelium morphology, absent oestrus cycle, small uterus, anovulation, and female infertility 
(d'Anglemont de Tassigny et al. 2007, Lapatto et al. 2007). Ovary cysts, anovulation, and infertility in 
particular are highly characteristic of PCOS. Inactivating variants in the receptor for KISS1 (GPR54) 
cause hypogonadotropic hypogonadism in both sexes (de Roux et al. 2003, Seminara et al. 2003, 
Semple et al. 2005), and activating variants have been observed in patients with central precocious 
puberty (Teles et al. 2008). Variants within KISS1 itself have also been identified in patients with 
hypogonadotropic hypogonadism and central precocious puberty (Silveira et al. 2010). Rats treated 
with dihydrotestosterone (DHT) to induce a PCOS-like phenotype displayed decreased Kiss1 mRNA 
expression and decreased kisspeptin immunoreactivity in the hypothalamus (Brown et al. 2012). 
Kisspeptin is also more highly expressed in women with PCOS than in controls (Yilmaz et al. 2014). 
Due to the important role of KISS1 in reproduction and its differential expression in both DHT-treated 
rats and women, KISS1 would be an interesting gene to study in terms of PCOS aetiology. However, 
rs71745629 has a MAF of 0.2983 by ExAC and 0.2218 by 1000 Genomes, meaning that rs71745629 
is quite common and is therefore unlikely to be disease causing. Therefore, although variants in KISS1 





3.4.1.2 Rs34973695 (SPTA1) 
Rs34973695 was found in family 1 and is located in the SPTA1 gene. The only reproductive 
consequence caused by homozygous knockout of Spta1 in mice was infertility (Bernstein 1980). 
SPTA1 is significantly downregulated in pigs with extremely high fecundity compared with low 
fecundity pigs which could imply a role of SPTA1 in fertility (Zhang, Huang, et al. 2015). However, 
SPTA1 was one of 10 genes that differed significantly in expression between high fecundity pigs and 
low fecundity so a role in fertility cannot be proven (Zhang, Huang, et al. 2015). Additionally, 
homozygous knockout of Spta1 in mice has consequences in a range of other systems, most 
commonly in the haematopoietic, cardiovascular, biliary, and renal systems. Furthermore, variants in 
SPTA1 are known to cause blood disorders such as elliptocytosis (Baines 2008) and spherocytosis 
(Bogardus et al. 2014). As neither blood disorders nor disruptions in the haematopoetic, 
cardiovascular, biliary, and renal systems are characteristic of PCOS, variants in the SPTA1 gene are 
unlikely to play a role in PCOS aetiology.  
3.4.1.3 Rs34879202 (DNAH11) 
Rs34879202 is present in the DNAH11 gene. When Dnah11 is knocked out in mice, the reproductive 
consequences of reduced fertility and abnormal embryo implantation have been observed (Brown et 
al. 1989, McGrath et al. 2003). However, variants in the DNAH11 gene are well known to cause 
primary ciliary dyskinesia (PCD) and Kartagener syndrome (Bartoloni et al. 2002, Schwabe et al. 
2008). PCD is a disorder of ciliary dysfunction, leading to recurring upper respiratory tract infections 
and infertility in men due to decreased sperm motility. Situs inversus may also be present in which 
case the disorder is referred to as Kartagener syndrome (Bartoloni et al. 2002, Schwabe et al. 2008). 
As cilia dysfunction and situs inversus are not characteristic of PCOS, rs34879202 is unlikely to play 
a role in PCOS aetiology.  
3.4.2 Variants that may play a role in PCOS 
Two of the identified SNVs were located in genes that are currently subject to some promising 
research regarding a role in the reproductive system. However, research on these genes is new and in 
many cases inconclusive. In some cases, research hasn’t surpassed animal-only studies. Therefore, 
although these SNVs may be of interest regarding PCOS aetiology in the future, they were discounted 
for this project. It was concluded that, as this project is under time constraints, studying a SNV 
present in a gene known to have reproductive effects would increase the chances of producing time-
efficient, successful results. 
3.4.2.1 Rs2228262 (THBS1) 
Rs2228262 is located in the THBS1 gene which has been observed to cause decreased litter size and 
reduced fertility in homozygous knockout mouse models (Lawler et al. 1998). Apart from this 
reproductive phenotype, there are a plethora of other symptoms in multiple organ systems in Thbs1 




stomach epithelial hyperplasia, increased immune cell number, pancreas and lung inflammation, 
dilated gall bladder, kyphosis and lordosis, and abnormal dermal morphology (Lawler et al. 1998, 
Crawford et al. 1998). At first, the ubiquitous nature of THBS1 function makes it seem as if it is 
unlikely to play a role in PCOS. However, THBS1 plays many roles in the reproductive system and 
has actually been studied in regards to PCOS. Serum THBS1 is reduced in PCOS women but this 
expression can be increased with the use of metformin (Tan et al. 2009). THBS1 is also more highly 
expressed in PCOS women with IR compared to PCOS women without IR (Liu et al. 2015) which 
could imply a role of THBS1 in both the reproductive and metabolic symptoms of PCOS. 
Furthermore, THBS1 prevents follicular angiogenesis and induces apoptosis of granulosa cells 
(Garside et al. 2010). The decreased THBS1 expression seen in PCOS women could impact 
folliculogenesis as granulosa cells are essential for follicle development (Su, Sugiura, and Eppig 
2009). Additionally, hyperplasia of ovarian interstitium, increased ovarian blood flow, and decreased 
vascular resistance have been observed in women with PCOS (Pan et al. 2002, Li and Lin 2005). 
Given the role of THBS1 in follicular angiogenesis, these symptoms could be expected consequences 
of decreased THBS1 expression. As THBS1 is active in the reproductive system and may be 
implicated in PCOS, variants in THBS1 are good candidates for functional studies. Rs2228261, 
however, has a MAF of 0.0926 according to ExAC and a MAF of 0.0401 according to 1000 
Genomes. The MAF from ExAC implies that rs2228262 is not rare enough to be disease causing, 
whereas the MAF from 1000 genomes is only just rare enough to be disease causing. Therefore, 
although variants the THBS1 gene are promising for functional studies, it is debatable whether 
rs2228261 is disease causing and able to play a role in PCOS. 
3.4.2.2 Rs34075341 (S1PR3) 
Rs34075341 is located in the SP1R3 gene. Knockout and complex mutations of S1pr3 in mice lead to 
decreased litter size and lethality during organogenesis respectively (Ishii et al. 2001). S1PR3 is a 
receptor that recognises sphingosine-1-phosphate (S1P). S1P induces production of cyclooxygenase-2 
(COX-2) and prostaglandin E2 (PGE2) in human granulosa cells which are critical in ovulation 
regulation. The induction of COX-2 and PGE2 by S1P occurs though a S1P3/YAP signalling pathway 
which may implicate S1P3 in the regulation of ovulation but more research is needed (Cheng et al. 
2016). Furthermore, S1P protects human granulosa cells from H2O2 induced cell death which may 
implicate S1PR3 in granulosa cell apoptosis (Nakahara et al. 2012). If this is the case, dysfunction of 
S1PR3 could impact folliculogenesis as granulosa cells are essential for follicular development. 
However, this has not been tested. Preliminary evidence shows that SP1R3 mutations could yield 
reproductive consequences that align with PCOS but more research is needed to confirm this. 
Therefore, rs34075341 may have the potential to play a role in PCOS but it would be more ideal to 




3.4.3 Variants most likely to play a role in PCOS 
The ultimate goal of the bioinformatics analysis was to find a rare, functional variant located in a gene 
that is not only involved in the reproductive system, but is potentially implicated in multiple 
symptoms of PCOS (i.e. hyperandrogenism, anovulation, polycystic ovary morphology, and impaired 
glucose metabolism). Of the seven identified pathogenic SNVs, one (rs143321413 in the EEF2K 
gene) met these criteria. 
3.4.3.1 Rs143321413 (EEF2K) 
Rs143321413 is located in the EEF2K gene. Knockout of Eef2k in mice leads to an increase in 
primordial and primary follicles in young mice, increased secondary follicles in elders, abnormal 
fertility, abnormal ovarian folliculogenesis, abnormal superovulation, and decreased apoptotic ability 
(Chu et al. 2014). It is hypothesised by Chu et al. that the decrease in apoptotic ability in these mice 
leads to an accumulation of follicles and a reduced ability to select for a dominant follicle (Chu et al. 
2014). PCOS women display an increased amount of primordial and primary follicles (Webber et al. 
2003) which causes the polycystic ovary morphology symptom. Therefore, EEF2K dysfunction is a 
potential mechanism for the development of the polycystic ovary morphology phenotype. Aged Eef2k-
/- mice also exhibited the ability to become pregnant while age matched wildtype mice had undergone 
reproductive senescence (although the resulting pups were not viable). There is evidence that PCOS 
women may undergo menopause at a later age compared with controls (Dahlgren et al. 1992, Schmidt 
et al. 2011). Therefore, the delayed reproductive senescence of Eef2k-/- mice could further implicate 
EEF2K in PCOS aetiology. Furthermore, EEF2K is involved in the mTOR pathway which is 
regulated by insulin, and intermediates within the mTOR pathway can affect insulin sensitivity. For 
example, in adipose tissue, mTORC1 encourages insulin resistance by promoting serine 
phosphorylation of insulin receptor substrate 1 (IRS1). This decreases recruitment of PI3K, leading to 
a decrease in insulin activity (Werner et al. 2004, Um, D'Alessio, and Thomas 2006). Additionally, 
drugs that inhibit mTORC1 increase the risk of developing insulin resistance and new onset diabetes 
in transplant patients (Teutonico, Schena, and Di Paolo 2005). Therefore, EEF2K dysfunction may 
have the potential to contribute to the insulin resistance seen in many women with PCOS. 
Furthermore, the mTOR pathway engages in ‘crosstalk’ with the androgen receptor. Chronic 
inhibition of the mTOR pathway has been observed to cause increased expression of the androgen 
receptor (Qi, Morales, et al. 2015). Consequently, EEF2K has the potential to be involved in ovarian 
follicle accumulation, androgen metabolism, and insulin resistance which are all characteristic of 
PCOS. The rs143321413 variant has a MAF of 0.0011 by ExAC and 0.0004 by 1000 Genomes which 
means it is rare enough to be disease causing. Given its possible role in multiple PCOS phenotypes 
and its predicted pathogenicity, rs143321413 is the best candidate of those studied here to proceed 






Seven variants of interest were identified via bioinformatics of previously exome sequenced samples 
belonging to 5 families of PCOS women. These variants were predicted to be pathogenic and were 
known to be present in genes that were expressed in the ovaries, and had reproductive consequences 
when knocked in mouse models. In order to select a single SNV most likely to be involved with 
PCOS, SNVs were discounted based on a number of criteria. SNVs located in genes that did not cause 
reproductive consequences aligning with PCOS were discounted along with SNVs present in genes 
proven to be involved with other disorders. Genes that lacked enough reproductive research to draw a 
conclusion on their possible involvement in PCOS were also discounted. Furthermore, SNVs with a 
high minor allele frequency (MAF) should not be utilised as they unlikely to be disease causing and in 
any case numerous genome –wide association studies completed in individuals of European and 
Chinese decent should have identified relevant common genomic variants with a MAF greater than or 
equal to 5%; thus the focus here in on variant with MAF < 0.05. The 13 SNVs were successfully 
filtered down to one candidate (rs143321413 in the EEF2K gene). Rs143321413 is the most 
promising SNV of those available in terms of its probability of being involved with PCOS as it is 
potentially implicated in three symptoms of PCOS i.e. polycystic ovary morphology, 
hyperandrogenism, and insulin resistance. Given rs143321413’s possible role in PCOS, it was 

















4 EFFECT OF RS143321413 ON EEF2K 
AND EEF2 PROTEIN-PROTEIN 
INTERACTION  
4.1 Introduction 
Functional genomics refers to a multitude of techniques that seek to determine the relationship 
between genotype and phenotype. Genomic techniques such as exome/genome sequencing and 
genome wide association studies provide information about the genetic sequences present in 
individuals and populations. Functional studies use the information gleaned from these genomic 
techniques and aim to determine the resulting phenotypic effects. Typically, phenotypic effects are 
determined by investigating transcription, translation, regulation of gene expression, and protein-
protein interaction. As such, functional genomics can be used to investigate phenotypic differences 
caused by wildtype versus variant or mutated gene sequence.   
The rs143321413 variant was found within the EEF2K gene in a mother/daughter pair with PCOS via 
exome sequencing. EEF2K regulates protein synthesis via phosphorylation of eukaryotic elongation 
factor 2 (EEF2). EEF2 interacts with the ribosome and promotes GTP-dependent translocation, 
making it essential in protein synthesis. As a result of its regulation of protein synthesis, EEF2K can 
alter the cell’s probability of undergoing apoptosis (Chu et al. 2014). Furthermore, EEF2K is a 
member of the mTOR biochemical pathway which is regulated by insulin binding. Defects in the 
mTOR pathway have been observed to impact insulin sensitivity (Werner et al. 2004, Um et al. 2004, 
Teutonico, Schena, and Di Paolo 2005). Furthermore, the mTOR pathway engages in ‘crosstalk’ with 
the androgen receptor (Qi, Zhang, et al. 2015). Therefore, rs143321413 has the potential to impact 
insulin sensitivity, androgen signalling and the amount of growing follicles in the ovary through its 
effects on apoptosis. All of these possible phenotypic effects are relevant to the aetiology of PCOS. 
To determine whether rs143321413 has a pathogenic effect on cell function, we aimed to investigate 
the effect of the wildtype and mutant sequences on apoptosis, insulin signalling, androgen receptor 
signalling and protein-protein interaction of EEF2K with its substrate (EEF2) (Figure 9). However, 
due to time constraints, there was only time to complete one line of experimentation. The amino acid 
change caused by rs143321413 removes a tyrosine expected to be important for phosphorylation of 
EEF2 and replaces it with cysteine. Therefore, we aimed to perform a co-immunoprecipitation to 


























4.2 Materials and Methods 
4.2.1 Confirming the presence of rs143321413 in Q1857 and Q1895 
To confirm the presence of the rs143321413 variant in Q1857 and Q1895, primers were designed to 
amplify the region of the EEF2K gene containing the mutation. This fragment then underwent Sanger 
sequencing to visualise the presence of the mutation.  
The online tool Primer3 Version 0.4.0 (http://bioinfo.ut.ee/primer3-0.4.0/) was utilised to design 
primers. After inputting the sequence surrounding rs143321413, Primer3 generated a variety of 
primers that could potentially amplify this region of the genome. Optimal primers were selected based 
on the following criteria: 1) the annealing temperature was ~63; 2) the GC content was ~55%; 3) the 
primer length was ~20bp; 4) the primers did not bind anywhere in the genome apart from the target 
sequence. The selected primers (Table 22) matched all of these criteria and amplified a fragment of 
511bp. 















5’- TGTAGCTTGGTGGGGGATAG -3’ 
 




5’- GTAGCTGCCAAGGAGCAAAG -3’ 63.7  55% 20bp 
 
Routine PCR was performed on DNA isolated from Q1857 and Q1895 using the Ultraclean DNA 
Blood Isolation Non-Spin Kit (Mo Bio laboratories Inc. Carlsbad, USA) and PCR Kit (Mo Bio 
laboratories). PCR product was run on a 1% agarose gel alongside a GelPilot 1kb+ ladder (Qiagen, 
USA), which was viewed with a Model UVT 400-M Ultraviolet Transilluminator (International 
Biotechnologies Inc., New Haven, USA). The PCR product from both Q1857 and Q1895 was then 
prepared for Sanger sequencing using the rs143321413 forward primer. The reaction tubes were fitted 
with Parafilm M wax (Bemis Company Inc., Neenah, USA) to prevent evaporation of the samples and 




4.2.2 Cloning of the EEF2K ORF into the pcDNA3.1(+) mammalian 
expression vector 
In order to perform a co-immunoprecipitation experiment, expression of both wildtype and mutant 
EEF2K protein was required within a cell line. The aim of the following cloning experiments was to 
produce mammalian expression vectors capable of inducing expression of wildtype EEF2K and 
EEF2K containing the rs143321413 mutation.  
4.2.2.1 Primer Design 
Firstly, primers were designed to produce cDNA of the EEF2K ORF (Table 23 
). This was achieved by using the first 8 bases of the ORF in the forward primer and the reverse 
complement of the final 18 bases in the reverse primer. As well as amplifying the EEF2K ORF, the 
primers also needed to introduce restriction endonuclease sites for ligation into the pcDNA3.1(+) 
vector. The restriction sites chosen needed to be present only once in the pcDNA3.1(+) vector, 
preferably as close to each other as possible. Therefore, the EcoRV and XhoI restriction 
endonucleases were selected as they are present only once in the pcDNA3.1(+) vector, 21bp away 
from each other. XhoI and EcoRV possess the added bonus of being able to digest efficiently in the 
same buffer (Buffer D, Promega), meaning they can both be used at the same time in a restriction 
enzyme digestion reaction. This is more efficient than carrying out a different restriction digestion for 
each restriction enzyme. The sequence for an EcoRV restriction endonuclease site was added 5’ to the 
ORF sequence in the forward primer (Table 2). Likewise, the sequence for a XhoI site was added 5’ 
to the ORF sequence in the reverse primer. The sequence for a stop codon was present between the 
XhoI and ORF sequences within the reverse primer to prevent translation of the XhoI site. 
Additionally, a FLAG-tag needed to be present at the N terminus of the resulting EEF2K protein, in 
order to visualise expression. The N terminus was chosen for the addition of the FLAG tag because 
the EEF2K C terminus contains a domain essential for the recognition of EEF2 (Diggle et al. 1999). 
Therefore, the presence of a FLAG tag on the C-terminus would have the potential to impact EEF2Ks 
action on EEF2. To add a FLAG tag to the N-terminus of the resulting protein, the FLAG-tag 
sequence was placed 5’ to the EcoRV site on the forward primer. Lastly, a cytosine and a guanine 
were added to the 5’ end of the forward and reverse primer respectively to prevent degradation of the 















































4.2.2.2 Isolation of EEF2K cDNA and Cloning into the pDrive TA Cloning Vector 
Isolation of EEF2K cDNA from RNA extracted from breast tissue was attempted using the 
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, USA). However, EEF2K cDNA was 
ultimately purchased from SinoBiological Inc, USA. The purchased cDNA was present within the 
pGEM bacterial cloning vector and possessed one silent mutation (NM_013302.3:c.2105C>T). The 
EEF2K cDNA was amplified using AmpliTaq Gold® 360 DNA Polymerase (ThermoFisher 
Scientific). Once amplified, the cDNA underwent ligation into the pDrive TA cloning vector using the 
PCR Cloning Kit (Qiagen). The vectors were transformed into XL2-Blue cells and 6 of the resulting 
colonies were inoculated into 10ml of 2xYT broth containing 0.1mg/ml ampicillin. DNA was 
extracted from the broth cultures using the Wizard® Plus SV Minipreps DNA Purification System 
(Promega, Madison, USA). Once extracted, the DNA underwent restriction digestion with EcoRV and 
XhoI. The resulting fragments were subjected to electrophoresis on a 1% agarose gel and viewed 
under a Model UVT 400-M Ultraviolet Transilluminator to screen for EEF2K cDNA within the 
pDrive TA Cloning Vector. DNA that had the correct gel pattern was sent for Sanger sequencing to 
check for sequence fidelity.  
4.2.2.3 Sanger Sequencing 
In order to sequence the entire EEF2K cDNA, internal primers needed to be utilised. Three internal 
























































To sequence the EEF2K cDNA, four sequencing reactions were set up, one for each internal primer, 
and one using the EEF2K_ORF Forward Primer. Sanger sequencing with all four primers produced 
sequences that 1) overlapped and covered the entire EEF2K cDNA; 2) showed the presence of the 
FLAG tag and restriction endonuclease sites; 3) revealed the vector sequence on either side of the 
cDNA insert. This allowed for the confirmation of the correct insert sequence. 
4.2.2.4 Site-Directed Mutagenesis 
The rs143321413 mutation was introduced into the EEF2K cDNA within the pDrive TA Cloning 
Vector using the QuikChange Lightening Mutagenesis Kit (Agilent Technologies Inc., Santa Clara, 
USA). Mutagenesis primers were designed using 21 base pairs on either side of the rs143321413 






































69 60.5% 43bp 
*Primer sequences are shown with the rs143321413 variant highlighted red. 
Post mutagenesis, amplified DNA was transformed into XL10-Gold Ultracompetent Cells. Six of the 
resulting colonies were inoculated into 2xYT broth containing 0.1mg/ml ampicillin. After sufficient 
bacterial growth, DNA was extracted using the Wizard® Plus SV Minipreps DNA Purification 
System (Promega). DNA isolated from each colony was then sent for Sanger sequencing using the 
EEF2K Internal Forward 2 Primer (Table 2) for confirmation of the presence of rs143321413.  
4.2.2.5 Cloning of Wildtype and Mutant Inserts into pcDNA3.1(+) 
The pDrive TA Cloning Vector does not allow for expression within mammalian cell lines. Therefore, 
the EEF2K wildtype and mutant inserts needed to be transferred from pDrive into the pcDNA3.1(+) 
mammalian expression vector. pDrive TA Cloning Vectors containing the wildtype and mutant 
EEF2K inserts underwent restriction digestion with EcoRV and XhoI restriction enzymes. Likewise, 
empty pcDNA3.1(+) vector underwent restriction digestion with the same restriction endonucleases. 
The products were analysed by electrophoresis on a 1% agarose gel and bands corresponding to the 
EEF2K insert and linearised pcDNA3.1(+) vector were excised from the gel using a scalpel. DNA 
was extracted from the agarose gel using the QIAEX II Agarose Gel Extraction Kit (Qiagen). 
Wildtype and mutant EEF2K inserts then underwent ligation into pcDNA3.1(+) using T4 DNA ligase. 
Ligatants were grown in XL2-Blue competent cells and 6 colonies were inoculated into 2xYT broth 
containing 0.1mg/ml ampicillin. DNA was extracted using the Wizard Plus SV Minipreps DNA 
Purification System (Promega) and run on a 1% agarose gel. DNA containing the insert was sent for 
Sanger Sequencing using the EEF2K_ORF forward primer, and all three internal primers, to check the 
sequence and make sure insertion into pcDNA3.1(+) was successful. Recombinants containing 
wildtype and mutant EEF2K cDNA were transformed into XL2-Blue colonies to maintain a large 




Miniprep System (Promega) to produce transfection grade pcDNA3.1(+) vectors containing the 
wildtype and mutant inserts.  
4.2.3 Transfection optimisation of wildtype and mutant EEF2K  
4.2.3.1 Determination of the best cell line for transfection 
Three cell lines were available for functional genomics: COV434, HEK293 and HEK293FT. COV434 
was the most relevant cell line as they are human ovarian granulosa tumour cells. However, COV434 
cells are slow growing and, due to time constraints, could not be grown in a large enough quantities to 
be used in the experiments. Therefore, in order to achieve results within the given time frame, 
HEK293 and HEK293FT cell lines were transfected with equivalent amounts of wildtype, mutant, and 
empty pcDNA3.1(+) vector controls to identify which cells produced optimal expression of the 
resulting EEF2K proteins. Furthermore, varying amounts of mutant and wildtype DNA (5µg and 2µg) 
were transfected to identify the ideal amount of DNA for transfection. Transfections were carried out 
in ten 25cm2 flasks all up using Lipofectamine 2000 (ThermoFisher Scientific) transfection reagent at 
varying concentrations (Table 26).    




Transfected cells were lysed in RIPA buffer and 70µg of the resulting protein was analysed on a 10% 
SDS-PAGE gel. For western blot analysis, the gel was blotted onto an Amersham Protran 0.1  
nitrocellulose membrane (GE Healthcare Life Sciences, USA) and probed with 1µl anti-FLAG M2 
monoclonal primary antibody (Sigma-Aldrich, USA) followed by goat anti-mouse horseradish 
peroxidase conjugated secondary antibody (Sigma-Aldrich, USA). 
4.2.3.2 Identification of endogenous EEF2 
In order for a co-immunoprecipitation experiment to be carried out analysing the binding of wildtype 
and mutant EEF2K to EEF2, endogenous EEF2 needed to be present within the cells. Therefore, 70µg 
of protein from each lysate used for comparing expression between HEK293 and HEK293FT cells 
(section 2.3.1) was analysed on a 10% SDS-PAGE gel. The protein was blotted onto a Amersham 
Protran 0.1 nitrocellulose membrane which was detected with both 5µl rabbit polyclonal antibody to 
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eEF2 (Cell Signaling Technology) followed by 1µl goat anti-rabbit horseradish peroxidase conjugated 
antibody (Promega, USA). 
4.2.3.3 Determination of the amount of DNA needed for equivalent expression of wildtype and 
mutant 
In order to determine whether there is different binding of wild type and mutant EEF2K to EEF2 by 
means of co-immunoprecipitation reactions, the wildtype and mutant EEF2K need to be expressed 
equivalently. Therefore, transfection reactions were set up in HEK293FT cells to determine the 
amount wildtype and mutant plasmid DNA needed to produce an equal amount of protein expression. 
Three different comparisons were carried out using varying amounts of Lipofectamine 2000 
transfection reagent: 4µg of wildtype vs 6µg of mutant, 4µg of wildtype vs 5µg of mutant and 3µg of 
wildtype vs 5µg of mutant (Table 27). 
Table 27: Transfections for equivalent expression of wildtype and mutant in HEK293FT cells. 
 Comparison 1 Comparison 2 Comparison 3 
Wildtype/Mutant DNA 4µg wildtype  6µg mutant  
 




3µg wildtype  5µg mutant  
 
pcDNA3.1(+) 2µg N/A 1µg N/A 2µg N/A 
Lipofectamine 2000 12µl 12µl 10µl 10µl 10µl 10µl 
 
70µg of protein was then analysed on a 10% SDS-PAGE gel. Protein was then transferred onto a 
Amersham Protran 0.1 nitrocellulose membrane via western blotting. Protein was detected using 1µl 
anti-FLAG M2 monoclonal antibody and 1µl goat anti-mouse horseradish peroxidase conjugated 
antibody. 
4.2.4  Co-immunoprecipitation  
4.2.4.1 Transfection 
Six 75cm2 flasks of HEK293FT cells were grown to approximately 60-70% confluence in preparation 
for transfection. One flask was transfected with empty pcDNA3.1(+) using Lipofectamine 2000 
transfection reagent. Two flasks were transfected with wildtype EEF2K in pcDNA3.1(+), and another 
two flasks were transfected with mutant EEF2K in pcDNA3.1(+). This was to allow for a control 
lacking antibody to be carried out for both the wildtype and the mutant. One flask was transfected 
with Ras association domain-containing protein 1 in pcDNA3.1(+) containing a FLAG-tag 
(RASSF1). This was to be used as a control to test antibody binding (if antibodies are binding 
correctly, anti-FLAG M2 monoclonal antibody will bind to RASSF1, but rabbit polyclonal antibodies 


































pcDNA3.1(+) 12.5µg 3.5µg N/A 3.5µg N/A N/A 
Lipofectamine 
2000 
25µl 25µl 25µl 25µl 25µl 25µl 
 
4.2.4.2 Co-immunoprecipitation 
 A co-immunoprecipitation was carried out to analyse the effect of the rs143321413 variant on 
EEF2K’s interaction with EEF2. Two membranes were produced: one to analyse rs143321413’s 
effect on EEF2 binding, and one to analyse its effect on phosphorylation of EEF2. Cells were lysed 
using RIPA buffer and the resulting protein was quantified using a BCA assay. 3mg of each protein 
was used for co-immunoprecipitation, and the rest of the lysate was frozen at -80oC. Each protein was 
added to 40µl of GammaBind G sepharose beads (GE Healthcare Life Sciences, USA), which were 
pre-washed with RIPA buffer. Following this, the lysates were pre-cleared with GammaBind G 
sepharose beads to remove any non-specific binding protein. The lysates were then centrifuged in a 
benchtop microfuge and the supernatant was added to fresh Eppendorf tubes. 6µl anti-FLAG M2 
monoclonal antibody was added to all tubes with the exception of the wildtype and mutant no-
antibody controls. The samples were then incubated overnight at 4oC with gentle agitation by rotation. 
The next day, the antibody-protein complex was pulled down with 40µl of GammaBind G sepharose 
beads by mixing for 4 hours at 4oC. The beads were washed 7 times with RIPA buffer. Protein bound 
to the beads was eluted using an equal volume of 2x SDS sample loading buffer. Two 10% SDS-
PAGE gels containing half of each sample (~1.5mg of protein) were run and blotted onto Amersham 
Protran 0.1 nitrocellulose membrane s. One membrane (co-immunoprecipitation membrane 1) was 
probed with 5µl rabbit polyclonal antibody to eEF2. The other (co-immunoprecipitation membrane 2) 
was probed with 5µl rabbit polyclonal antibody to phosphorylated eEF2 (Thr56) (Cell Signaling 
Technology, USA). Protein was detected on each membrane with 1µl goat anti-rabbit horseradish 
peroxidase conjugated antibody. The membranes were then imaged with a ChemiDoc XRS+ (Biorad, 
Hercules, USA). Later, co-immunoprecipitation membrane 2 was stripped with a mild stripping buffer 
and probed with 1µl anti-FLAG M2 monoclonal antibody to determine the amount of EEF2K pulled 
down. The membrane was then probed with 1µl goat anti-mouse horseradish peroxidase conjugated 
antibody. Due to time constraints, co-immunoprecipitation membrane 1 was not probed with 1µl anti-




acceptable as the same amount of each protein was blotted onto both membranes. Therefore, both 
membranes should show the same result. 
4.2.4.3 Western blots of lysates 
Protein from the leftover frozen lysates (70µg), was run on two 10% SDS-PAGE gels and blotted 
onto Amersham Protran 0.1 nitrocellulose membranes. Lysate membrane 1 was probed with 5µl 
rabbit polyclonal antibody to eEF2 and lysate membrane 2 was probed with 5µl rabbit polyclonal 
antibody to phosphorylated eEF2 (Thr56). The bands produced on the co-immunoprecipitation 
membrane were faint and required a long exposure time. To avoid this problem with the lysate 
membranes, both were probed with 2µl goat anti-rabbit horseradish peroxidase conjugated antibody 
instead of 1 µl. Following imaging on a ChemiDoc XRS+, the membranes were stripped and probed 
with 1µl of both an anti-FLAG M2 monoclonal antibody and a mouse monoclonal anti-α-tubulin 






















4.3.1 Isolation of EEF2K cDNA 
Reverse transcription and amplification of EEF2K RNA resulted in an extremely faint band slightly 














Figure 10: 1% Agarose Gel showing the EEF2K cDNA band just before the 2kb marker.  
4.3.2 Presence of rs143321413 in Q1857 and Q1895 
Sanger sequencing of DNA isolated from Q1857 and Q1895 revealed that both individuals were 
heterozygous for an adenine and a guanine at NM_013302.3:c.2138 (Figure 11). 
         







Sanger sequencing of the pDrive TA cloning vector revealed the presence of EEF2K cDNA 
containing the FLAG-tag, EcoRV, and XhoI sequences (Figure 12). One incorrect base was 
incorporated (NM_013302.3:c.1139G>A) resulting in a silent mutation in the protein, which was 
















Figure 12: Chromatograms of EEF2K cDNA in pDrive showing the correctly incorporated a) FLAG-
tag sequence, b) EcoRV sequence, and c) XhoI sequence. 
 
Site directed mutagenesis resulted in the incorporation of a guanine at NM_013302.3:c.2138 in 5 of 














Figure 13: Chromatogram showing the rs143321413 mutation in one of the colonies resulting from 
site directed mutagenesis. 
Sanger sequencing of the wildtype and mutant inserts in pcDNA3.1(+) revealed the presence of the 
EEF2K cDNA within the vectors, along with the FLAG-tag and restriction endonuclease sites. 
4.3.4 Transfection optimisation of wildtype and mutant EEF2K in mammalian 
cell lines 
4.3.4.1 Transfection in HEK293 and HEK293FT cell lines 
When 5µg of wildtype or mutant was transfected, bands were observed at 82kDa, corresponding to 
the EEF2K protein (Figure 14). However, the intensity of the bands was drastically decreased in 
HEK293 cells compared with HEK293FT cells. The ‘Wildtype 5µg’ lane produced a darker band at 
82kDa than the ‘Mutant 5µg’ in both cell lines.  Additionally, all lanes produced a band at 50kDa 
corresponding to tubulin. The tubulin bands were slightly fainter in the HEK293 lanes, particularly for 












4.3.4.2 Presence of endogenous EEF2 
Probing with rabbit polyclonal antibody to eEF2 identified bands at 95kDa corresponding to EEF2 in 
all lanes (Figure 15). Probing with mouse monoclonal anti-α-tubulin antibody also resulted in bands at 










Figure 15: Expression of endogenous EEF2 in HEK293 and HEK293FT cells. 
 
4.3.4.3 Transfection optimisation for equivalent expression of wildtype and mutant EEF2K 
Transfection of variable amounts of wildtype and mutant resulted in bands at 82kDa corresponding to 
EEF2K protein in all lanes (Figure 16). ‘Comparison 3’ (Table 27; containing 3ug wildtype DNA and 
5ug mutant DNA) produced equally intense bands for wildtype and mutant EEF2K, suggesting that 
this is the optimal protocol. Conversely, comparisons 1 and 2 revealed a fainter wildtype EEF2K band 
compared with the mutant. Bands of similar intensity were observed at 50kDa corresponding to 









Figure 16: Comparisons of different ratios of wildtype and mutant for equivalent expression in 
HEK293FT cells. 









4.3.5.1 Co-immunoprecipitation  
The co-immunoprecipitation membrane 1 probed with 5µl rabbit polyclonal antibody to eEF2 
revealed one faint band at 95kDa corresponding to EEF2 in the ‘mutant + antibody’ lane (Figure 17). 
A significantly darker band was evident in the same position for the EEF2 control. The co-
immunoprecipitation membrane 2 probed with 5µl rabbit polyclonal antibody to phosphorylated eEF2 





















Figure 18: Co-immunoprecipitation membrane 2 probed with rabbit polyclonal antibody to 








Co-immunoprecipitation membrane 2 was stripped and probed with anti-FLAG M2 monoclonal 
antibody to visualise how much EEF2K was pulled down (Figure 19). The membrane revealed a band 
at 82kDa corresponding to EEF2K in the EEF2 control lane. Another very faint band was present at 
82kDa in the mutant + antibody lane. Bands were evident at ~50kDa corresponding to the anti-FLAG 
M2 monoclonal antibody in the ‘empty pcDNA3.1(+)’, ‘RASSF1’, ‘Wildtype + antibody’ and 










Figure 19:  Co-immunoprecipitation membrane 2 probed with anti-FLAG M2 monoclonal antibody to 
visualise pulled down EEF2K. 
4.3.5.2 Co-immunoprecipitation lysates 
Co-immunoprecipitation lysate membrane 1 was probed with rabbit polyclonal antibody to eEF2 
(Figure 20). This revealed bands of similar size at 95kDa in all cells transfected with EEF2K wildtype 
and mutant. This band corresponded to EEF2. A smaller band was present at the same position in the 
























Stripping lysate membrane 1 and probing with anti-FLAG M2 monoclonal antibody and mouse 
monoclonal anti-α-tubulin antibody revealed bands at 50kDa in all mutant and wildtype lanes (Figure 
21). These bands corresponded to tubulin. No bands were evident in the RASSF1 or pcDNA3.1(+) 
lanes at 50kDa. Unexpectedly, no bands were evident at 82kDa for EEF2K. However, white ‘ghost 
bands’ were present at 82kDa for both mutant lanes as well as the ‘wildtype no antibody’ lane (Figure 
22). These bands likely correspond to EEF2K but imaging was impacted due to an excessive 
concentration of horseradish peroxidase (see section 4.1.5). Faint probing was observed within the 














Figure 21: Co-immunoprecipitation lysate membrane 1 probed with anti-FLAG M2 monoclonal 






Figure 22: white ‘ghost bands’ with partial probing at 82kDa on lysate membrane 1. 
 
Lysate membrane 2 was probed with rabbit polyclonal antibody to phosphorylated eEF2 (Thr56) and 
showed bands at 95kDa in all lanes (Figure 23). Unexpectedly, bands were also present in all lanes at 



















Figure 23: Co-immunoprecipitation lysate membrane 2 probed with rabbit polyclonal antibody to 
phosphorylated eEF2 (Thr56). 
 
Co-immunoprecipitation lysate membrane 2 was stripped and probed with anti-FLAG M2 monoclonal 
antibody and mouse monoclonal anti-α-tubulin antibody. This revealed bands at 82kDa corresponding 
to EEF2K in all wildtype and mutant lanes. Bands were fainter in both wildtype lanes compared with 














Figure 24: Co-immunoprecipitation lysate membrane 2 probed with anti-FLAG M2 monoclonal 














4.4.1 Isolation of EEF2K cDNA 
EEF2K cDNA was successfully isolated from RNA extracted from breast tissue. However, the 
concentration of cDNA obtained was too low to use in cloning experiments. One explanation for the 
low DNA yield may be that the RNA used for cDNA isolation was not fresh and had been stored at    
-80oC for two years. This could have resulted in degradation of nucleic acids. Additionally, although 
EEF2K is expressed in breast tissue, it’s expressed much more in skin. Therefore, a higher yield of 
cDNA would be expected from RNA extracted from a cell line isolated from skin e.g. the HaCat 
human keratinocyte cell line. Unfortunately, due to time constraints, there was not enough time to 
order, cultivate, and extract RNA from keratinocytes, nor for optimisation of reverse transcription and 
amplification reactions. Therefore, EEF2K cDNA was purchased from Sinobiological Inc, USA. 
4.4.2 Cloning 
Ligation of EEF2K cDNA containing a flag tag and EcoRV and XhoI restriction endonuclease sites 
into the pDrive TA cloning vector was successful. However, one incorrect base was incorporated into 
the cDNA sequence (NM_013302.3:c.1139G>A). This was unexpected as Amplitaq Gold 360o is a 
high fidelity DNA polymerase with decreased chance of introducing sequence errors. The introduced 
base led to a silent mutation in the EEF2K protein. Silent mutations refer to point mutations in the 
DNA that do not change the resulting amino acid in the protein. Therefore, it was deemed acceptable 
to continue to use this vector as the silent mutation would not affect the protein sequence. 
Site-directed mutagenesis was successful at inducing the rs143321413 mutation in 5 of the 6 tested 
colonies.  
Ligation of both wildtype and mutant EEF2K sequences into pcDNA3.1(+) was successful. Both 
wildtype and mutant cDNA within the vectors possessed an intact flag tag, as well as restriction 
endonuclease sites. 
4.4.3 Determination of optimal cell line for co-immunoprecipitation 
Transfection of EEF2K wildtype and mutant expression vectors in both HEK293 and HEK293FT cell 
lines revealed that expression of both proteins was highest when 5ug was transfected (Figure 6). 
However, expression of both wildtype and mutant was noticeably higher in HEK293FT cells 
compared with HEK293 cells.  
Tubulin bands were slightly fainter in the HEK293 lanes. Tubulin can be used to test how well gel 
loading was performed as this protein is ubiquitously expressed in most cell lines (Eisenberg and 
Levanon 2003). It is critical in quantitative experiments to load the same amount of protein in each 
well to obtain accurate results. If the intensity of tubulin probing is equal in all lanes of a blotted 




tubulin probing appears slightly fainter in HEK293 lanes signified that less protein was loaded into 
these wells. This had the potential to make it seem as if FLAG expression was lower in HEK293 cells 
than it actually was. However, the difference in tubulin intensity was so slight that it was unlikely to 
account for the significant difference in FLAG expression between the cell lines. Therefore, it was 
concluded that expression of EEF2K protein was most efficient in HEK293FT cells. As such, the 
HEK293FT cell line was designated as the optimal cell line to use for co-immunoprecipitation.     
Transfection of 5µg of DNA resulted in lower expression of mutant compared with wildtype. 
Expression of wildtype and mutant needs to be equivalent in order to proceed with a co-
immunoprecipitation. Therefore, a second transfection optimisation was necessary to determine the 
ratio of wildtype to mutant needed to produce equal levels of expression.  
4.4.4 Presence of endogenous EEF2 
Endogenous EEF2 was present in both HEK293 and HEK293FT cells. Therefore, commencement 
with co-immunoprecipitation was possible. 
4.4.5 Transfection for equivalent expression 
The combination of 3µg of wildtype and 5µg of mutant plasmids resulted in equivalent expression in 
HEK293FT cells. Unexpectedly, the combination of 4µg of wildtype with 5µg or 6µg of mutant 
plasmid revealed lower expression of wildtype than mutant. This result may be questionable as 3µg of 
wildtype would not be expected to express better than 4µg of transfected plasmid. Certainly, tubulin 
bands were a similar intensity in all lanes meaning that the differing expression was not due to a gel 
loading error. One possible explanation is that many cells lifted from the surface of the ‘4µg wildtype’ 
flasks during transfection and were possibly lost during wash steps. To combat cell lifting in future 
experiments, flasks should be coated with Poly-L-Lysine before cell seeding. Another possibility is 
that there is some mechanism in the cells which regulates EEF2K expression via a feedback loop; 
consequently, more plasmid transfected may not equal greater protein expression.  Regardless of the 
unexpected result with the ‘4µg wildtype’ transfections, it was evident that the ratio of 3µg wildtype 
to 5µg mutant produced equivalent expression, and this ratio could be used in a co-
immunoprecipitation experiment. 
4.4.6 Co-immunoprecipitation 
Co-immunoprecipitation of mutated EEF2K has been carried out by Pigott et al. (2012). In this line of 
experimentation, EEF2K possessing a tyrosine to alanine mutation at codon 713 displayed decreased 
activity against EEF2 (Pigott et al. 2012). Rs143321413 is a similar mutation, causing a change from 
tyrosine to cysteine at codon 713. Therefore, it was expected that the rs143321413 mutation would 
also cause a decrease in EEF2K activity on EEF2. However, this was not known for certain as alanine 
and cysteine are amino acids with differing properties which could have the potential to affect the 




polyclonal antibody to eEF2 resulted in one EEF2 band in the ‘mutant + antibody’ lane as well as the 
EEF2 control lane (Figure 17). This result implies that mutant EEF2K bound to EEF2 but wildtype 
EEF2K did. This was unexpected as it was hypothesised that wildtype EEF2K would bind to EEF2 
better than mutant EEF2K, however it is possible that the mutation results in an increased affinity for 
binding to EEF2. Another explanation could be that wildtype EEF2K did not express as well as the 
mutant, and therefore there was not enough protein available to bind to EEF2.  
Unfortunately, the co-immunoprecipitation membrane 2 that was probed with rabbit polyclonal 
antibody to phosphorylated eEF2 (Thr56), did not show any bands corresponding to phosphorylated 
EEF2 apart from the EEF2 control lane (Figure 18). This either means that no EEF2 was 
phosphorylated by EEF2K, or phosphorylation occurred at undetectable levels. This was unexpected 
given that probing with EEF2 antibody revealed binding of mutant EEF2K to EEF2. Therefore, at the 
very least, the mutant EEF2K in this experiment should have been exerting its kinase action by 
phosphorylating EEF2. A possible explanation is that transfection did not produce enough EEF2K 
protein to phosphorylate a detectable amount of phosphorylated EEF2. There were multiple bands in 
the EEF2 control lane which was likely a result of protein degradation.   
Stripping of co-immunoprecipitation membrane 2 and probing with anti-FLAG M2 monoclonal 
antibody revealed the amount of EEF2K pulled down (Figure 19). A very faint band corresponding to 
EEF2K was present in the ‘mutant + antibody’ lane. No other EEF2K bands were present apart from 
in the EEF2 control lane. This signified that mutant EEF2K was pulled down but in very low 
amounts. The ‘wildtype + antibody’ lane did not possess an EEF2K band, meaning that either no 
wildtype EEF2K was pulled down, or it was pulled down at levels that were too low to detect. This 
discrepancy in the amount of wildtype and mutant being pulled down explains why only mutant 
EEF2K was detected binding to EEF2 on co-immunoprecipitation membrane 1 (Figure 17). As little 
to no wildtype EEF2K was pulled down, binding to EEF2 could not occur.  
Probing of the co-immunoprecipitation lysates with rabbit polyclonal antibody to eEF2 
displayed very strong bands at 95kDa, meaning that large amounts of EEF2 were present in the cells 
(Figure 20). The membrane was stripped and probed with anti-FLAG M2 monoclonal antibody and 
mouse monoclonal anti-α-tubulin antibody. Strong, equivalent tubulin bands were present in all 
wildtype and mutant lanes, meaning that an equal amount of protein was loaded in these lanes (Figure 
21). Unexpectedly, no EEF2K bands were present. Instead, white ‘ghost bands’ where observable 
where the expected EEF2K bands should have been (Figure 22). It is impossible for EEF2K to be 
missing because otherwise no binding would have occurred between mutant EEF2K and EEF2 on the 
co-immunoprecipitation membrane 1 (Figure 17). The most likely explanation for the presence of the 
‘ghost bands’ is an overabundance of horseradish peroxidase (HRP). The bands on the co-




imaging. This induced concern that there may have been protein present that was not visible. To avoid 
this problem on the lysate membranes (Figures 9 – 13), the amount of anti-mouse horseradish 
peroxidase conjugated antibody used was doubled. However, the subsequent probing was 
unexpectedly stronger than the previous co-immunoprecipitation membranes, resulting in a high 
concentration of HRP on the membranes. A high concentration of HRP causes a rapid depletion of the 
ECL chemiluminescent substrate. Once the chemiluminescence reaction is complete, the protein can 
no longer be imaged, resulting in a white band. This problem can be avoided in future experiments by 
utilising a smaller amount of secondary antibody.  
A second membrane was blotted with the co-immunoprecipitation lysates and probed with phospho-
eEF2 antibody (Figure 23). Bands were evident at 95kDa in all lanes meaning that phosphorylated 
EEF2 was present in all cells. However, the bands were quite faint even after exposing the membrane 
to UV light for extended periods of time. This lends weight to the hypothesis that EEF2K was 
successfully phosphorylating EEF2 in all cells, but that it was not occurring at levels high enough to 
be detectable in the co-immunoprecipitation experiment. The membrane was stripped and probed with 
anti-FLAG M2 monoclonal antibody and mouse monoclonal anti-α-tubulin antibody antibodies 
(Figure 24). As both lysate membranes were loaded with the same amount of wildtype and mutant 
EEF2K protein, both membranes would be expected to produce the same result when probed with 
these antibodies. As expected, tubulin bands were equivalent in all wildtype and mutant lanes. Bands 
corresponding to EEF2K were evident on this membrane, which confirmed the hypothesis that a fault 
occurred in the previous lysate membrane and interfered with imaging of EEF2K. The second lysate 
membrane revealed that expression of mutant EEF2K was higher than wildtype (Figure 4). This 
accounts for the discrepancy in the amount of wildtype and mutant EEF2K that was pulled down. 
Evidently, the ratio of 3µg of wildtype to 5µg of mutant did not result in precisely equivalent 
expression in these experiments. The transfection optimisation to determine the ideal ratio of wildtype 
to mutant should be repeated using Poly-L-Lysine coated flasks to reconfirm how much wildtype and 
mutant should be transfected for another co-immunoprecipitation experiment.  
Although the technical aspects of co-immunoprecipitation were successful, less progress was made in 
characterising the effect of mutant versus wildtype sequence than expected. The suite of experiments 
provided a number of important insights for future research. The binding of mutant EEF2K to EEF2 
revealed that it is indeed possible to observe EEF2K activity in HEK293FT cells and that future co-
immunoprecipitations will be a valuable tool in analysing the rs143321413 variant. The low levels of 
phosphorylated EEF2 in the lysates implies that co-immunoprecipitation using rabbit polyclonal 
antibody to phosphorylated eEF2 (Thr56) should be possible, but a lot more protein needs to be 
blotted. It is now clear that for better results, a different ratio of wildtype to mutant needs to be 
transfected in Poly-L-Lysine coated flasks to prevent cell lifting, and more protein needs to be utilised 




HRP should not be used during membrane probing. If these strategies are adopted, future co-
immunoprecipitation experiments should be successful.   
4.5 Conclusion 
The aim of this line of experimentation was to analyse the pathogenicity of the rs143321413 variant 
by observing its effect on protein interaction with EEF2. The production of mammalian expression 
vectors containing wildtype and mutant EEF2K cDNA sequences was successfully carried out. 
Furthermore, wildtype and mutant EEF2K were successfully transfected into HEK293 and 
HEK293FT cells. Unfortunately, the co-immunoprecipitation was unable to reveal any effects of 
rs143321413 on EEF2K interaction with EEF2; due to limitations with the technique. However, the 
co-immunoprecipitation did provide valuable information on how to proceed with further 
experiments. The production of EEF2K wildtype and mutant in pcDNA3.l(+) vectors, and the results 
gleaned from the co-immunoprecipitation, will benefit future research into rs143321413, and by 
extension functional variants involved with PCOS. With the construction of wildtype and mutant 
EEF2K plasmids successfully achieved and transfection protocol optimised, future research could also 
focus on other approaches to demonstrate differential function of the mutant protein including 










5 CLINICAL RECRUITMENT AND 
IDENTIFICATION OF PUTATIVE EXONIC 
CAUSAL MUTATIONS IN WESTERN 
AUSTRALIAN WOMEN WITH PCOS  
5.1 Introduction 
The Keogh Institute at Sir Charles Gairdner Hospital is the home of the Western Australian Database 
of PCOS women. Founded in 2004, the database was put together by Professor Bronwyn Stuckey and 
Associate Professor Scott Wilson with the help of researchers Michelle Jones and Lisa Italiano. Since 
then, over 450 individuals with PCOS have supplied blood samples to the Keogh Institute for use in 
molecular genetic applications. It was one of the aims of this study to add to the number of samples 
possessed by the Keogh Institute by recruiting approximately 6 mother/daughter or sibling/sibling 
pairs with PCOS. Additionally, we aimed to identify familial functional variants in the recruited 
individuals so the Keogh Institute could continue to undertake functional genomics experiments after 
the completion of this project.  
5.2 Materials and Methods 
5.2.1 Clinical recruitment 
The Human Ethics Committee of Sir Charles Gairdner Hospital gave their approval for this study to 
Professor Bronwyn Stuckey, Keogh Institute of Medical Research. 
Women with PCOS were recruited through word of mouth and the use of the ‘PCOS Research 
Western Australia’ Facebook page. When an individual expressed interest in being a part of the study, 
an email was sent to them containing a patient information sheet, a consent form, and a questionnaire 
regarding their symptoms (see Appendix section 8.2). Once filled out, the consent form and 
questionnaire were sent back to the Keogh Institute by the participant. Utilising the questionnaire, 
Professor Bronwyn Stuckey confirmed the PCOS diagnosis of the recruited women using the NIH 
diagnostic criteria based on menstrual cyclicity and clinical hyperandrogenism (Zawadski and Dunaif 
1992).  
The recruited individuals were also provided with a list of PathWest Collection Centre locations. 
Participants went to their local PathWest Collection Centre in their own time where their blood was 
taken via venipuncture. Two EDTA 10 mL vacuum blood collection tubes and one clot activator tube 




to Sir Charles Gairdner Hospital. Once the blood was received by the laboratory, each individual was 
given a unique laboratory number. Whole blood was from each participant was aliquoted into four 
5ml sterile tubes. The blood in the CAT was spun in a centrifuge at 3500rpm for three minutes to 
obtain serum which was aliquoted into one 5ml sterile tube. Each of the five tubes were labelled with 
the individuals’ laboratory number, their date of birth, and the date when the blood was received. 
The phenotypic data available for the recruited individuals was age, height, weight, body mass index 
(BMI), menstrual cycle patterns, age of menarche, and degree of hirsutism. The number of first degree 
relatives with PCOS was also supplied by participants. Unfortunately, clinical information such as 
homeostasis model assessment (HOMA) and circulating hormone levels e.g. FSH, LH, testosterone, 
and DHEAS were difficult to obtain due to the nature of recruitment (lacking a clinician), and time 
constraints associated with this project.  
5.2.2 Exome sequencing 
One of the aims of this project was to perform exome sequencing on the DNA of approximately 6 
mother/daughter or sibling/sibling pairs PCOS pairs. 6 subjects in all were recruited but unfortunately 
only three of them could undergo exome sequencing (family 1). Therefore, samples from two sisters 
that were already present in the Western Australian Database of PCOS women were prepared for 
exome sequencing as well (family 2). Subjects were designated as - Family 1: Q2254, Q2256, Q2261; 
and Family 2: Q2107 and Q2108. DNA was extracted from whole blood of the five individuals using 
the UltraClean® Blood DNA Isolation Kit (Non-Spin) (Mo Bio Laboratories, USA). The resulting 
DNA was quantitated using a Nanodrop One (ThermoFisher, Scientific, USA). Samples undergoing 
exome sequencing at the Australian Genome Research Facility (AGRF) are required to contain 5µg of 
DNA. The appropriate volumes of DNA were added to 1.7mL Eppendorf tubes (Axygen, USA) which 
were labelled and sealed with Parafilm M wax (Bemis Company Inc., Neenah, USA) to prevent 
evaporation of the samples. The samples were then sent to the AGRF medical research facility in 
Perth where exome sequencing was performed using the Agilent SureSelectXT Human All Exon 
V5+UTR system. Reads were aligned to the hg19 reference sequence and data generated from all 
samples were returned as .FASTQ, .BAM, and .TXT file formats for analysis. 
5.2.3 Bioinformatic Analysis 
The C programming language and the R statistical software were utilised to produce a pipeline for 
filtering the sequencing results supplied by AGRF (see Appendix section 8.3). This resulted in one 
spreadsheet for each family consisting of mutations predicted to be pathogenic that were present in all 
relatives. The genes possessing these mutations were then analysed for a role in reproductive biology, 
along with androgen and glucose metabolism. This was achieved by entering the gene names into the 
Mouse Genome Informatics (MGI) and PubMed online databases. The Integrative Genomics Viewer 




     
5.3 Results 
5.3.1 Clinical Recruitment and exome sequencing 
Six women were successfully recruited, and samples of their blood were added to the Western 
Australian Database of PCOS women. Four of the women were a family consisting of three sisters 
and their mother. However, although the mother claimed to have PCOS, a diagnosis could not be 
confirmed. Therefore, DNA from the mother could not undergo exome sequencing. Furthermore, as 
the aim of this line of experimentation was to identify familial functional variants implicated in 
PCOS, the unrelated individuals could not be utilised either. Instead, DNA from two previously 
recruited sisters yet to undergo exome sequencing was used. Exome sequencing of both families was 
successful and sequencing data was received from AGRF, ready for bioinformatic analysis. 
5.3.2 Identified mutations 
Approximately 74,000 variants were called for all individuals. The amount of coding variants 
identified in each individual are shown in table 29. 
Table 29: Number of coding variants identified via exome sequencing in each individual. 















Q2107 74,142 27,269 598 364 296 229 64 32,245 
Q2108 73,899 27,459 588 379 312 244 62 32,177 
Q2254 73,586 26,988 598 316 315 210 66 32,075 
Q2256 73,409 26,894 576 351 347 214 70 32,084 
Q2261 73,662 27,044 612 327 311 245 69 31,842 
 
Three mutations were identified that met the followin criteria: 1) were predicted to be pathogenic, 2) 
were likely to be involved in PCOS phenotypes i.e. ovulatory dysfunction, steroidogenesis, and 
insulin resistance, 3) were present in all members of either family, 4) the corresponding gene was 
expressed in the ovary (Table 29).  
Table 30: Details of potentially pathogenic variants were identified from 2 PCOS affected families 
through exome sequencing. 





















Missense PTPRN2 C/A Gln/His 1 0 0.002 




The IGV software revealed that rs80127039 and rs61757813 generated over 36 high quality reads, 
confirming that they are present in the individuals. Unfortunately, an error occurred in the files which 
prevented visualisation of reads corresponding to rs143321413. Due to time constraints, this error 



























Three mutations were discovered in the newly exome individuals that were deemed likely to play a 




exome sequencing (NRG1 and PTPRN2). Conversely, the third identified mutation was rs143321413 
in the EEF2K gene. 
5.4.1 Neuregulin 1 (NRG1) 
Neuregulin 1 is a member of the EGF-like factor family. It is involved in development and 
differentiation of a number of organ systems via its action on the ErbB-mediated Erk signaling 
pathway. NRG1 plays a role in oocyte maturation and fertility by maintaining the rate of progression 
from the meiosis MI to MII phase  (Kawashima et al. 2014). Targeted disruption of NRG1 in mice 
decreases fertility due to an increased rate of progression from the meiotic MI phase to the MII phase. 
Additionally, NRG1 has the potential to impact ovulation and steroidogenesis due to its involvement 
in the ErbB-mediated Erk signaling pathway, as injection of the ErbB selective inhibitor AH1478 into 
rat ovarian bursa blocks ovulation and inhibits progesterone production. (Jamnongjit, Gill, and 
Hammes 2005, Ashkenazi et al. 2005). However, targeted disruption of NRG1 in mice failed to 
negatively impact ovulation or progesterone production (Kawashima et al. 2014). Therefore, 
malfunction of NRG1 on its own may not be enough to play a role in the PCOS phenotypes of 
anovulation and impaired androgen metabolism/action. Yet, in tandem with other mutations, NRG1 
may contribute to the overall PCOS phenotype due to its role in fertility and ErbB signalling.  
5.4.2 Protein Tyrosine Phosphatase, Receptor Type N2 (PTPRN2) 
Protein Tyrosine Phosphatase, Receptor Type N2 is an enzymatically inactive member of the protein 
tyrosine phosphatase family. It exists as a transmembrane protein of dense core vesicles which are 
involved with secretion of hormones and neurotransmitters (Kubosaki et al. 2006). Double knockout 
of Ptprn2 with Ptprn in mice results in infertility and anovulation which are characteristic of PCOS. 
However, the anovulation phenotype in knockout mice was caused by a decrease in dense core 
vesicles, resulting in a reduced ability to secrete LH from the pituitary (Kubosaki et al. 2006). PCOS 
women typically display elevated or unchanged LH levels, not a deficit (Banaszewska et al. 2003). 
Therefore, a SNV that decreases the activity of PTPRN2 may be unlikely to induce a PCOS 
phenotype. Conversely, an activating mutation in PTPRN2 has the potential to increase the amount of 
dense core vesicles, thereby elevating circulating LH levels. Elevated LH levels likely to contribute to 
hyperandrogenaemia via LH-induced steroidogenesis (Nelson-Degrave et al. 2005). Successful 
conception is also reduced in PCOS women with high LH concentrations, and they have an increased 
chance of experiencing pregnancy complications (Tarlatzis et al. 1995, Kousta, White, and Franks 
1997). Therefore, activating mutations in PTPRN2 could play a role in hyperandrogenism and 
infertility which are PCOS symptoms.    
 
Along with LH, PTPRN2 also impacts insulin secretion. Autoimmune responses against PTPRN2 
cause Type 1 Diabetes as they lead to an inability to secrete insulin. Conversely, overexpression of 




PTPRN2 may have the potential to cause hyperinsulinaemia, and impact insulin sensitivity as a result. 
Overall, an activating mutation in PTPRN2 could contribute to the development of HA, infertility, and 
impaired insulin metabolism which are all common symptoms of PCOS. Functional genomic 
experiments to determine whether rs61757813 is an activating mutation would be valuable in the 
future study of PCOS. 
5.4.3 Eukaryotic Elongation Factor 2 (EEF2K) 
The rs143321413 variant identified in chapter 3 and analysed using functional genomics in chapter 4 
was also found in this round of exome sequencing. For a detailed description of rs143321413’s 
potential role in PCOS see Chapter 3, section 4.3.1. However, as we were unable to view the reads 
corresponding to rs143321413 on IGV, there is a chance that it was just an artefact and is not actually 
present in this cohort. Rs143321413 is rare in the general population, with a MAF of 0.0004. 
Therefore, if the presence of rs143321413 in this second cohort is genuine, this may imply that 
rs143321413 is present and plays a causative role in PCOS in many PCOS patients, rather than only 
playing a role in Family 1 from chapter 3. If rs143321413 does indeed induce a PCOS phenotype in 
multiple individuals, it has the potential to become a valuable clinical tool. For example, tests that 
screen for the rs143321413 mutation in PCOS patients could be developed and utilised to produce 
patient specific treatments. However, the presence of rs143321413 will need to be confirmed in more 
PCOS individuals, and proven to segregate with disease before any clinical measures will be able to 
be taken. 
5.5 Conclusion 
Six individuals were successfully recruited from the Western Australian population, and samples of 
their blood were added to the Western Australian Database of PCOS women. Unfortunately, not all of 
these patients were able to undergo exome sequencing as two of them were unrelated and we were 
interested in finding mutations that segregated within families. Another patient also had to be 
excluded as their PCOS diagnosis could not be confirmed. Therefore, samples from two previously 
recruited sisters were submitted for exome sequencing along with the newly recruited family of three 
sisters. Following bioinformatic analysis on the exome sequencing data, three mutations were 
identified that have the potential to play a role in PCOS aetiology and will therefore be valuable in 
future PCOS research. Two of these were not present in the previous round of exome sequencing. 
However, the third identified mutation was rs143321413. The presence of rs143321413 in a second 
PCOS family is an exciting result that could be an indication that rs143321413 is plays a causative 
role in PCOS in a number of PCOS patients. However, exome sequencing on more PCOS families 
will need to be carried out to confirm this. Additionally, healthy controls should undergo exome 






















6 GENERAL DISCUSSION AND 
CONCLUSION 
6.1 Bioinformatic analysis of old exome sequencing data files 
The hypothesis that exome sequencing of families affected by PCOS could be used to identify 
mutations that may play a role in PCOS was indeed proven correct. The rs143321413 mutation within 
the EEF2K gene is predicted to be pathogenic, segregates with family members, and is rare in the 
general population (MAF = 0.0004), thereby increasing its chances of being disease-causing. 
Rs143321413 has the potential to be involved in three common symptoms of PCOS: overabundance 




the insulin-stimulated mTOR pathway, and androgen signalling as the mTOR pathway engages in 
‘crosstalk’ with the androgen receptor.  
6.2 Functional genomics on the rs143321413 mutation 
Mammalian expression vectors containing wildtype and mutant cDNA sequences were successfully 
created via cloning experiments. These expression vectors will be invaluable in future research of 
rs143321413. The expression vectors were successfully used to induce wildtype and mutant 
expression within HEK293 and HEK293FT cells via transfection using Lipofectamine 2000 reagent. 
Transfection optimisation revealed that HEK293FT cells express both wildtype and mutant EEF2K 
better than HEK293 cells, and that protein is expressed better after transfection with 5µg of 
expression vector as opposed to 2µg. Therefore, it was confirmed that the designed expression vectors 
were functioning properly to induce expression of EEF2K within mammalian cell lines. Additionally, 
the transfection optimisation will reduce the work that needs to be carried out in future cell culture 
experiments involving rs143321413. Although it could not be proven that rs143321413 impacts 
binding of EEF2K to EEF2, the performed co-immunoprecipitation revealed a number of valuable 
insights for success in future experiments (see section 6.4).  
6.3 Exome sequencing of newly recruited PCOS patients 
Six women with were successfully recruited and their blood samples were added to the Western 
Australian Database of PCOS women. Three newly recruited sisters, along with two previously 
recruited sisters had DNA sent for exome sequencing. Once again, the hypothesis that exome 
sequencing of PCOS families can be used to identity possibly causative mutations for PCOS was 
successful. Two new mutations that may be involved in PCOS were identified in these families: 
rs80127039 in NRG1 and rs61757813 in PTPRN2. Rs80127039 may work in tandem with other 
mutations to impact ovulation and steroidogenesis due to its role in fertility and ErbB signalling. If 
rs61757813 is an activating mutation, it has the potential to encourage HA, infertility, and insulin 
resistance due to increased LH and insulin secretion due to an increase in dense core vesicles. Lastly, 
the EEF2K rs143321413 mutation was identified in the sequencing data files received by AGRF. 
Unfortunately, it could not be confirmed that rs143321413 was genuinely present in the newly exome 
sequenced individuals as there was an error in the files utilised by the IGV software. However, if 
rs143321413 is indeed present in these individuals, it could be tentatively hypothesised that 
rs143321413 is a causative factor of PCOS in many patients, rather than in the family it was initially 
identified only. If this is true, it could lead to the development of clinical screening tests for the 




6.4 Future directions 
Bioinformatic analysis of exome sequenced DNA from PCOS affected families identified the 
rs143321413 as having a likely role in the aetiology of PCOS. The developed mammalian expression 
vectors containing wildtype and mutant EEF2K cDNA should therefore be used to perform further 
cell culture experiments. Another co-immunoprecipitation should be performed after confirming the 
correct ratio of wildtype to mutant required during transfection for equivalent expression. 
Transfections should be carried out in Poly-L-Lysine coated plates to prevent cells from lifting from 
the flask surface. Additionally, a lot more protein should be utilised in the co-immunoprecipitation.  
Another line of experimentation that should be carried out is the effect of rs143321413 on 
downstream signalling in insulin and androgen pathways. This is because EEF2K is in the mTOR 
pathway, and it therefore has the potential to alter expression of intermediates in insulin and androgen 
signalling pathways. A further experimental design would be to compare the effect of rs143321413 on 
downstream insulin signalling with and without the presence of metformin. This line of 
experimentation could help determine whether rs143321413 does indeed impact the PCOS symptoms 
of HA and IR, and if so, whether metformin could be a useful treatment strategy for individuals 
possessing this mutation. 
It will also be useful to carry out these experiments in a number of different cell lines originating from 
different ovarian cells (i.e. granulosa cells, theca cells, and epithelial cells) and compare the results. 
As these cell types all have different roles in the ovary, the rs143321413 may have different effects in 
each cell line that are all relevant to PCOS.  
Lastly, similar functional genomic experiments should be performed on rs80127039 and rs61757813 
to determine whether they play a role in PCOS. It would also be prudent to perform these experiments 
on other functional variants within the EEF2K gene to see if they produce similar phenotypic effects 
to rs143321413. 
6.5 General conclusion 
PCOS is a complex, heterogeneous genetic disorder that likely results from several genetic lesions 
working in tandem to produce a PCOS phenotype. The aetiology of PCOS is largely unknown. 
Therefore, the elucidation of genetic factors at play in PCOS has the potential to improve 
understanding of the mechanisms of the syndrome, and broaden future treatment options. Whole 
exome sequencing is a method by which functional variants can be identified in individuals suffering 
from genetic syndromes. This thesis intended to identify variants that likely play a role in PCOS, and 




1. Perform bioinformatics on new and previously exome sequenced PCOS families to identify 
variant/s that could be involved in PCOS which would be ideal for functional genomics 
investigation. 
2. Produce wildtype and mutant sequences in mammalian expression vectors and investigate the 
effects of the selected variant on substrate binding, as well as expression of intermediates in 
relevant biochemical pathways. 
3. Recruit approximately 6 PCOS women in familial pairs to add to the WA PCOS cohort and 
submit genomic DNA samples from those individuals for exome sequencing in order to 
identify new possibly pathogenic variants for future functional genomic work. 
 
The main finding of this thesis was the identification of the rs143321413 within the EEF2K gene in a 
family affected by PCOS. Rs143321413 is potentially involved in three common symptoms of PCOS: 
overaccumulation of preovulatory follicles, HA, and IR.  
Expression vectors containing wildtype and mutant sequences were created, and successfully induced 
expression of EEF2K after transfection of HEK293FT using Lipofectamine 2000 reagent. However, a 
co-immunoprecipitation to determine the ability of mutant EEF2K to bind EEF2 was unsuccessful. 
Despite not being able to glean the effect of rs143321413 on EEF2K activity, the co-
immunoprecipitation revealed that detection of EEF2K binding to EEF2 is indeed possible and 
therefore, further coimmunoprecipitation reactions will be valuable in understanding the function of 
the rs143321413 mutant. Additionally, the production of mammalian expression vectors and 
optimisation of transfection reactions will aide in the future functional genomic experiments 
concerning rs143321413. 
An additional finding of this thesis was the identification of the rs80127039 and rs61757813 
mutations within the NRG1 and PTPRN2 genes respectively. Functional genomic experiments into the 
phenotypic effects of these mutations will help improve understanding of the genetics of PCOS. 
In conclusion, the functional variant rs143321413 is likely to have a causative role on the 
development of a number of the symptoms defined by PCOS including overabundance of 
preovulatory follicles, androgen metabolism, and insulin resistance; and has the potential to advance 
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Phosphate Buffered Saline (PBS) 
Reagent Amount for 1L 




Potassium Chloride (KCl) 0.2g 
Di-Sodium Hydrogen Orthophosphate, 
Anhydrous (Na2HPO4) 
1.44g 




• Add ~900mL ddH2O. 
• pH to 7.4 with HCl. 
• Make up to 1L with ddH2O. 
Dulbecco’s Modified Eagle Medium 
Reagent Amount for 1L 
Dulbecco’s Modified Eagle Medium (DMEM), 
Powder, High Glucose, Pyruvate 
1 sachet 
HEPES 4.77g 
Sodium Bicarbonate (NaHCO2) 3.7g 
 
• Add ~950mL ddH2O. 
• pH to 7.4. 
• Let mix for ~20 minutes. 
• Make up to 1L with ddH2O. 
• Filter using a 50mL Rapid-Flow Bottle Top Filter 
2x YT Medium +/- AGAR 
Reagent Amount for 500mL 
BactoTM Tryptone Pancreatic Digest of Casein  8g 
BactoTM Yeast Extract 5g 
NaCl 2.5g 
OPTIONAL: BactoTM Agar 7.5g 
 
• Add ~450mL ddH2O. 
• pH to 7.0 with NaOH. 
• Make up to 500mL with ddH2O. 





• Store at ambient temperature. 
Tris-Buffered Saline (TBS) 
Reagent Amount for 2L 
Trizma® base 4.84g 
NaCl 58.44g 
 
• Add 1.8L of ddH2O. 
• pH to 7.5. 
• Make up to 2L with ddH2O. 
• Store at 4oC. 
Tris Buffered Saline-Tween (0.1%) (TBST) 
Reagent Amount for 1L 
TBS 1L 
Tween® 20 1mL 
 
• Store at 4oC 
Tris Buffered Saline-Tween (0.2%) (TBST) 
Reagent Amount for 1L 
TBS 1L 
Tween® 20 2mL 
 
• Store at 4oC 
 
 
1x TAE Buffer 
Reagent Amount for 8L 
50x TAE 160mL 
 
• Make up to 8L with ddH2O 
1mg/mL Ethidium Bromide 





Ethidium Bromide (EtBr) 1mg 
 
1% Agarose Gel 
Reagent Amount for 50mL 




• Add 0.5g agarose to 50mL TAE. 
• Microwave until completely dissolved. 
• Add 2.0µl EtBr. 
• Allow to set. 
Transfer Solution 
Reagent Amount for 2.5L 
Trizma® base 7.54g 
Glycine, Electrophoresis Grade 36g 
Methanol 500mL 
  
• Make up to 2.5L with ddH2O. 
• Store at 4oC. 
0.5M Tris Cl 
Reagent Amount for 100mL 
Trizma® Base 12.114g 
 
• Add ~50mL ddH2O. 
• pH to 8.0 using HCl. 
• Make up to 100mL with ddH2O. 
• Store at 4oC. 
20% SDS 
Reagent Amount for 100mL 
Sodium dodecyl sulfate, Ultra Pure (SDS) 20g 
 
• Make up to 100mL with ddH2O. 





Reagent Amount for 200mL  
0.5M Tris Cl 20mL  
Triton X-100 2mL  
20% SDS 1mL  
Sodium deoxycholate 1g  
 
• Make up to 200mL with ddH2O. 
• Store at 4oC. 
6x Loading Buffer 
Reagent Amount for 52µl 
6x SDS Buffer 29.7µl 
2-Mercaptoethanol  15.0µl 
0.1% bromothymol blue 7.3µl 
 
2x Sample Elution Buffer 
Reagent Amount for 440µl 
2x SDS Buffer 340µl 
2-Mercaptoethanol 40µl 
0.1% bromothymol blue 60µl 
 
10% SDS-PAGE Separating Gel 
Reagent Amount for 7.5mL 
ddH2O 3.2mL 
4x Separating Buffer 1.87mL 
30% Acrylamide/Bis Solution 29:1 2.4mL 
10% Ammonium persulphate solution 25µl 
Tetramethylethylenediamine (TEMED) 7.5µl 
 
10% SDS-PAGE Stacking Gel 
Reagent Amount for 6.6mL 
ddH2O 4mL 
4x Stacking Buffer 1.7mL 




10% Ammonium persulphate solution 66µl 
TEMED 6.6µl 
 
Mild Stripping Buffer 
Reagent Amount for 500mL 
Glycine 7.5g 
SDS 0.5g 
Tween® 20 5mL 
 
• Add ~200mL 
• Adjust to pH 2.2 with HCl. 











8.2 Clinical Recruitment Forms 
Participant Information Sheet and Consent Form 
 
Study Title: Genetic variation in genes regulating steroid biosynthesis and insulin metabolism, and 
their association with polycystic ovary syndrome 
Introduction 
You are being invited to take part in a research study involving the analyses of genes (DNA) 




research study, it is important for you to understand why the research is being done and what it will 
involve. 
Please take time to read the following information carefully and ask us if there is anything that is not 
clear or if you would like more information. 
Purpose of the study 
Polycystic ovarian syndrome (PCOS) is the most common form of endocrine (gland and hormone) 
disorder in premenopausal women. This common clinical syndrome starts soon after beginning of 
menstrual function and features consist of irregular periods, hirsutism (hairiness) and obesity often in 
association with enlarged ovaries. 
The aim is to study the genetic basis of PCOS. We will examine whether gene variations predispose 
to developing PCOS. We will examine whether particular genetic code (DNA) variations are 
associated with a particular form of PCOS. 
We are requesting your consent to a sample of your blood, as well as your permission to obtain related 
health information about you for the purposes of medical research. This information sheet provides 
information relating to this consent. 
Why have I been chosen? 
You have been chosen to take part because you have PCOS. We will be recruiting 400 women with 
this condition to take part in the study, which is being conducted at the Keogh Institute. 
If you do not have PCOS and have normal menstrual cycles, you will be selected as controls (your 
clinical details will be matched with women who have PCOS). Equal numbers of controls will be age-
matched with equal number of PCOS. 
Study description 
You will need to sign the consent form before you can take part. If you are under 18 years of age, 
your parent or guardian will also need to sign. 
Why am I being asked to provide this sample? 
You are being asked to provide a sample of blood (approximately 30 mLs) for the analysis of your 
blood biochemistry and you genetic code or DNA. Information about you will be used for research on 
PCOS. 
Does the decision to participate affect my care in any way? 
The choice to take part in this genetic research is entirely up to you and your medical care will not be 
affected by your decision not to take part. 
 
What will be done with my blood sample? 
Medical researchers for genetic studies of polycystic ovarian syndrome will use your stored DNA for 
this study. The study has been approved by the Human Research Ethics Committee of Sir Charles 
Gairdner Hospital. It will be conducted according to the principles set out in the National Health and 
Medical Research Council of Australia’s National Statement on Ethical Conduct in Human Research 
and the guidelines on the Privacy Act.  
Researchers working on this study are required to demonstrate that they meet the appropriate 
Australian standards of ethics and privacy as detailed above 
Your DNA sample will be stored under strict security at Sir Charles Gairdner Hospital until it used up 
or you contact the Medical Director at the Keogh Institute for Medical Research to request its 




carefully, but cannot guarantee against inadvertent loss or damage that is beyond the Institute’s 
control. In all cases you have an over-riding right to revoke your consent at any time. 
The aim of our research is to increase scientific and medical knowledge in the management of women 
with PCOS. However sometimes research on your DNA may lead to findings that result in the 
development of a commercial test or treatment. There will be no financial reward or remuneration to 
you in this event. 
Access to medical records: protecting your privacy 
Your DNA sample made available to researchers will be identified by a code only and it will not be 
possible for them to link it in any way to your personal information. However, the discovery of factors 
important in understanding PCOS may also require the knowledge of other relevant information about 
you. This information may come from hospital notes, specialists and GP records or may be 
information kept about you by the Department of Health as part of its regular function. 
You are asked to give your consent to the researchers to access medical information kept about you 
relevant to medical research. Your details will be held in strict confidence at all times. The 
appropriate guidelines and statues required with Australia abide access to your health information. 
Your consent is for ongoing and continued access to your health information and you may 
withdraw this consent at any time by writing to the Medical Director at the Keogh Institute 
(name and telephone number at the end of this document). 
What will be done with my DNA sample? 
Your sample will be used solely for genetic analyses looking at gene types and gene variations 
associated with PCOS. Your sample will expressly not be used for research that involves reproductive 
cloning. No researchers will be permitted to derive a genetic profile of you as an individual. No 
sample or health information will be released to any 3rd party. 
Future implications of donating my DNA 
Whilst your donated samples are not intended to be used in your diagnoses or treatment, it is possible 
that future DNA testing may result in new information about diseases or potential diseases that you 
carry. Such information will require extensive testing and validation before it can be determined to be 
useful but some of this information may have health implications for you or your family and through 
approved medical channels to ensure proper care is available to you. At that time you may be 
approached by a medical practitioner associated with the study. You may choose what further 
information or investigations you would like to proceed with. 
 
 
Findings from this research will be presented at scientific meetings and published in scientific 
journals but any publications will not contain any specific details of your identity. If you have any 
concern you may contact the medical director at the Keogh Institute at any time.  
 
What bad effects can happen to me by donating this sample? 
A needle will be used to draw blood from a vein in your arm. Most people experience slight pain at 
the site of the needle insertion and some may develop a bruise or very rarely an infection of the 
puncture site. 
Informed consent 
We ask that you give careful consideration to the information set out in this brochure before providing 




• Advising your family members, or the Executor of your will, of the existence of your DNA 
sample; perhaps even provide them with a copy of this Information Sheet and your signed 
Consent Form 
• Advising your family members of the purpose for which you have provided your DNA 
sample 
 
What if I change my mind? 
You maintain the right to withdraw your DNA sample at any time. If you wish to have your sample 
withdrawn from the DNA bank or stop access to your health information, please notify the Medical 
Director in writing. A letter confirming removal of your DNA sample or health information will be 
sent to you. 
 
Further information 
For independent advice or for any complaints you can contact the Human Research Ethics Committee 
at Sir Charles Gairdner Hospital. Their telephone number is written on the bottom of this participant 
information and consent from that you be will be given a copy to keep. 
Do you have further questions? 
If you have any concerns or questions about the genetic study or storage of your DNA sample, please 
contact the Medical Director, Dr Bronwyn Stuckey of the Keogh Institute on (08) 9346 2008 or Dr 







Consent for blood taking and DNA banking for clinical research 
 
I, __________________________________ of 
__________________________________________________ have read the Information sheet 
entitled ‘Genetic variation in genes regulating steroid biosynthesis and insulin metabolism and their 
association with polycystic ovary syndrome’. 
 
 I have had explained to me and I understand the consequences involved in my voluntary donation of 
my DNA. 
 
I have had an opportunity to discuss my participation with my family members, ask questions and am 
satisfied with the answers given 
 
In making my donation, I understand and agree that: 
 
1) The blood (which in this consent form, includes its constituents and any cell lines derived 
from the blood) will be used in relation to genetic research study associated with polycystic 
ovarian syndrome 
2) A sample of my DNA or derived cell line/s held in a bank will be discarded upon my written 
request to the Medical Directory of the Keogh Institute for Medical Research 
3) I will be approached by a medical professional in regard to potentially important health 
information that arises from this research that may impact on me or my family. At that time I 
may choose what further information or investigations I would like to proceed with  
4) I can request to know more specific details of any studies that used my samples at any time by 
contacting the Medical Director of the Keogh Institute for Medical Research 
5) Research results and the fact that I have made this donation will not be revealed to any 3rd 
party not directly part of medical research without my written consent, except under subpoena 
6) The Keogh Institute for Medical Research will not be liable for any loss of or damage to DNA 
used in accordance with this form 
7) I will not benefit financially if this research leads to development of a new treatment or 
medical test 
8) Storage of and access to my DNA sample will be managed by The Keogh Institute for 
Medical Research and only released where the research proposal has been approved by the 
Human Research Ethics Committee and with consent 
9) I understand that international research collaboration using my DNA will only take place 
where researchers abide by equal or more stringent regulations of privacy and ethics as those 
in Australia, as assessed by the Human Research Ethics Committee 
10) I give permission to access health information about me related to the research area defined in 
point 1 above, such as is kept in a medical record or by the WA Department of Health, to 
assist medical research only where the research proposal has been approved by a Human 














                                     I do                    I do not  
 





















The Sir Charles Gairdner Group Human Research Ethics Committee has given ethics approval for the 
conduct of this project. If you have any ethical concerns regarding the study you can contact the 
SCGG HREC office on telephone number (08) 9346 2999. 
 
All study participants will be provided with a copy of the Information Sheet and Consent Form 




PCOS Questionnaire:  
 
Given name  
Family name  
Date of birth  
Weight  
Height  
Date of admission  
Admission diagnosis  
Admission blood pressure  
  
How did you hear about the study? Please 
circle your response. 
 
a) Social Media  
b)Pamphlets   
c)University  
d)Keogh Institute   
  
PCOS history:  
Have you ever been diagnosed with PCOS?  
At what age did you get your first period?  
In the absence of hormonal contraceptive use, 
are/were your periods: Please circle only one 
response 
Always regular 
 Regular then irregular 
 Always irregular 
If your periods were ever irregular, what was 
the longest time between periods? Please circle 
only one response 
Less than 6 months 
 More than 6 months 
  
Between which ages did you use the 
contraceptive pill? 
 
What were your main reasons for oral 




 Regulate periods 
 Other (please specify) 
Have you ever used any other form of hormonal 
contraception? (Contraceptive patch, NuvaRing, 
intrauterine device, Depo Provera or Noristerat 




In your premenopausal years, did you 
experience hirsutism (excess body hair)? Please 
circle the pictures which best apply to you on 
the next page. 
 
As an adult, what was your lowest weight?  





Fertility history:  
How many children have you had?  
Did it ever take you longer than 12 months to 
conceive (from when you first started trying)? 
 
Did you ever require assisted reproductive 
technology?  
 
Was male infertility a contributing factor?  
Did you ever have gestational diabetes?  




How many of your first degree relatives have 
PCOS? Tick the boxes 
Mother 
 Sisters (how many?)  _______ 






















#Open .CSV in excel. Replace all spaces with an underscore and replace all commas with a 
blackslash.  
#Rename column 73 "Chromsome", rename column 76 "Reference", rename column 77 
"Alternative". 
#Make a folder called Commas_Spaces_Removed. 
#Save in a Commas_Spaces_Removed folder as: 2107_CSR.csv, 2108_CSR.csv, 2254_CSR.csv, 
2256_CSR.csv, and 2261_CSR.csv (CSR for commas and spaces replaced) 
 
#Step 2: 
#Make a folder in the Commas_Spaces_Removed folder called "First_Column" 
#Open Lenux and open a terminal. 
#Make a new csv file with one column containing Chromosome, Start, End, Reference, and 
Alernative columns put together in one column separated by a colon. 
awk -F"," '{print $73 ":" $2 ":" $3 ":" $76 ":" $77}' 2107_CSR.csv |perl -pe 's/"//g' > 
First_Column/2107_FC.csv 
awk -F"," '{print $73 ":" $2 ":" $3 ":" $76 ":" $77}' 2108_CSR.csv |perl -pe 's/"//g' > 
First_Column/2108_FC.csv 
awk -F"," '{print $73 ":" $2 ":" $3 ":" $76 ":" $77}' 2254_CSR.csv |perl -pe 's/"//g' > 
First_Column/2254_FC.csv 
awk -F"," '{print $73 ":" $2 ":" $3 ":" $76 ":" $77}' 2256_CSR.csv |perl -pe 's/"//g' > 
First_Column/2256_FC.csv 




#Copy Column made up of Chromosome, Start, End, Reference, and Alternative columns put together 
into the first column of the Name_CSR files. 
#Save in a new folder in the "First_Column" folder called "First_Column_Added" as 
Q1857_FCA.csv, Q1895_FCA.csv, Q1978_FCA.csv, Q2023_FCA.csv, and Q2025_FCA.csv  
 
#Step 4: 




#Only stacks the files with the ONE COLUMN of 'Chromosome:Start:End:Referance:Alternative' 
ontop of each other. 
#Put files for EVERY FAMILY in same masterlist. 
#Pipe into sorting command. 
#Save in nre folder called Sorted_Masterlist as 2107+2108+2254+2256+2261_Masterlist.csv 




#Make a new folder in the "Removed_Duplicates" folder called "Merged_Families" 
#Make sure you're in the First_Column_Added folder as the directory. 
#Open R and read in the masterlist with removed duplicates: 
#NOTE: merging wasn't working so I changed the name of the first column from 






#Read in Family 1 and merge. 
#NOTE: cannot have denoted name of csv start with a number. Therefore changed to Q2107 and 
Q2108. 
Q2107 <- read.csv("2107_FCA.csv",header=T) 
Q2108 <- read.csv("Q2108_FCA.csv",header=T) 
m1 <- merge(ml,Q2107,by="Masterlist",all.x=TRUE) 




#Read in Family 2 and merge 
Q2254 <- read.csv("2254_FCA.csv",header=T) 
Q2256 <- read.csv("2256_FCA.csv",header=T) 
Q2261 <- read.csv("2261_FCA.csv",header=T) 




m2 <- merge(m1,Q2256,by="Masterlist",all.x=TRUE) 




grep -v "NA" 2107+2108_Merged.csv | perl -pe 's/"//g' > Removed_NAs/2107+2108_NA.csv 
grep -v "NA" 2254+2256+2261_Merged.csv > Removed_NAs/2254+2256+2261_NA.csv 
 
#Step 10: 
awk -F"," '$11 == "frameshift_deletion" || $11 == "fameshift_insertion" || $11 == 
"nonsynonymous_snv" || $11 == "stoploss" || $11 == "stopgain"' Removed NAs/2107+2108_NA.csv 
> Mutant/2107+2108_Mutant.csv 
awk -F"," '$11 == "frameshift_deletion" || $11 == "fameshift_insertion" || $11 == 
"nonsynonymous_snv" || $11 == "stoploss" || $11 == "stopgain"' Removed 
NAs/2254+3356+2261_NA.csv > Mutant/2254+2256+2261_Mutant.csv 
 
#Step 11: 
awk -F"," '$47 < 0.06 && $49 > 0.994 || $47 == "." && $49 == "."' 2107+2108_Mutant.csv > 
Pathogenic/2107+2108_Pathogenic.csv 
awk -F"," '$47 < 0.06 && $49 > 0.994 || $47 == "." && $49 == "."' 2254+2256+2261_Mutant.csv > 
Pathogenic/2254+2256+2261_Pathogenic.csv 
 
 
